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ABSTRACT 
Metalloproteins play important roles in biological systems since metal-binding sites are 
found in ~ 1/3 of structurally characterized proteins and in ~ 1/2 of all proteins. Despite progress, 
the role of many metal-binding sites remains poorly understood. Furthermore, their detailed 
geometric and electronic structure has yet to be fully elucidated. Site-directed mutagenesis using 
natural amino acids has continued to be the primary method of probing of metal-binding sites. 
However, it has become increasingly evident that site-directed mutagenesis, though powerful, 
cannot address the precise role of the metal ligands without changing multiple factors because of 
limited number of natural amino acids that allows isostructural substitutions. The relative paucity 
of functional group availability within the proteinogenic amino acids also limits ability to fine 
tune and expand protein’s activity. To address the need to precisely determine specific metal 
binding ligand functionalities, and further efforts to engineer new function into proteins, 
expressed protein ligation (EPL) has been used to introduce non-proteinogenic amino acids to 
metalloproteins, such as the Type 1 (T1) copper site of azurin and the CuA site found in 
engineered CuA Azurin to aid the understanding of the roles of each ligand in this electron 
transfer protein.  
This thesis covers the replacement of two copper-binding ligands in azurin, Cys112 and 
Met121, with nonproteinogenic amino acid analogues. Investigating the Cys112(S)-Cu Ligand-
to-Metal Charge Transfer (LMCT) that gives azurin its intense blue color and its signature 
absorbance at 625 nm in the visible spectrum using two different analogues has been performed. 
Incorporating selenocysteine for Cys112 resulted in a new variant that maintained type 1 
geometry , making it possible to elucidate the electron density of the site with more precision in 
the future. To further expand this concept, EPL was used to incorporate homocysteine (Hcy) to 
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investigate the rack hypothesis for the type 1 copper center. Insertion of a Cys derivative with an 
additional methylene group demonstrated that the type 1 site in azurin was capable of adjusting 
sufficiently through protein folding to maintain type 1 geometry and function. Together, these 
mutations provide insight into the unique relationship between the site’s geometric features and 
its electronic features by minimally perturbing the site and selectively altering each feature 
individually. 
Secondly, while conversion of blue copper sites with a weak axial ligand to green copper 
sites containing a medium strength axial ligand has been demonstrated in cupredoxins, 
converting blue copper sites to a red copper site with a strong axial ligand has not been reported. 
By replacing the weak Met121 thioether from azurin with a strong thiolate ligand from Hcy, a 
variant was created which had spectra (RL= 1.5, and A||  = 180 x 10-4 cm-1) and a Cu-S(Cys) 
distance (2.22 Å) very similar to that of the red copper protein nitrosocyanin. The results 
strongly support the “coupled distortion” model, which helps explain axial ligand tuning of 
spectroscopic properties in cupredoxins, and demonstrate the power of using unnatural amino 
acids to address critical chemical biological questions.  
Lastly, the unique Cu coordination of a backbone carbonyl in CuA azurin site was 
investigated using backbone carbonyl analogues of Glu. By replacing the carbonyl of the natural 
peptide linkage with an ester moiety, we have shown that the basicity of the coordinating 
carbonyl seems not to play a major role in either the spectroscopic or reduction potential features 
of the CuA site. These studies have provided a unique methodology for investigating metal ligand 
interactions beyond the standard side chain interactions.  
In summary, a means to investigate the specific function of individual metal ligand 
residues in azurin and CuA azurin by using EPL to incorporate nonproteinogenic amino acid 
! "#!
analogues has been demonstrated. This work has resulted in new insights into the role of the 
metal ligands and has shaped future metalloprotein engineering efforts. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 TRANSITION METALS IN BIOLOGY 
 The distribution of transition metals found in the human body is very different 
compared to the relative abundance of metals found in nature (Figure 1.1).1,2 The 
distribution of metal ions found in the human body more closely resembles that of 
seawater than of earth.3,4 Moreover, of all the metals found in nature, only nine (iron, 
zinc, copper, molybdenum, vanadium, manganese, chromium, nickel, and cobalt) are 
biologically relevant.5 These biologically relevant metals, when used enzymatically, are 
bound by a large series of proteins containing unique ligand sets creating functions 
without which life would not exist. These proteins, termed metalloproteins, constitute 
greater than half of all the proteins found in life.5 With functions ranging from oxygen 
transport to electron transfer and redox chemistry, metalloproteins are intimately 
involved in a host of cellular processes absolutely necessary for life.  
 
 
Figure 1.1: Comparison of metal distribution in the human body compared to the earth and seawater. A) 
Relative logarithmic abundance. B) Relative concentrations of ions found in seawater compared to humans. 
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 Proteins with standard natural functional groups and no metal cofactors are 
limited when performing reactions requiring electron equivalents. Metalloproteins 
however, possess the distinct advantage of efficiently shuttling or storing electrons 
needed for chemical processes by using metal cofactors. Without metalloproteins’ 
capability to shuttle and store reducing and oxidizing equivalents, key cellular processes 
such as the generation of ATP would be dismantled. 
  How do metalloproteins manage to create such a diverse set of functions with 
such a limited supply of metals and metal ligands?  One method to expand metalloprotein 
functionality is utilization of identical ligand sets with slightly different geometries in 
different protein scaffolds. Having a different scaffold with the same ligand set retains the 
overall protein function while the minor changes in geometry and bond length of the site 
can allow fine-tuning to accommodate new physiological function. Additionally, 
substitution of metal ligands with other natural amino acids with different functional 
groups can expand metalloprotein function, imparting new protein function.  
 Arguably, nature uses different metals to accomplish identical functions. For 
example, three different metal containing families (heme iron, non-heme iron, and copper 
proteins) are shown in Table 1.1. This small sample set demonstrates that using 
considerably different metals and metal ligand sets retains similar chemistry. Using this 
rationale, it is clear that cells can adapt to conditions of their environment by substituting 
available metals for metals that are limited to maintain necessary cellular functions. 
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Table 1.1: Functional diversity in Fe and Cu proteins. 
 
1.2 COPPER PROTEINS 
 Copper is one of nine biologically relevant metals and a trace metal essential for 
all living organisms.6 Copper metalloproteins function in oxidation, and dioxygen 
transport and participate in fast electron transfer. These different functions are achieved 
by modifying the Cu ligand set in their respective protein scaffolds (Table 1.1). The 
diverse range of activities of Cu proteins resulted in development of a classification 
scheme dividing Cu metalloproteins into six major divisions based primarily on the 
number of Cu ions bound by the protein (Table 1.2).7 Each of the divisions is further 
subdivided by their biological function. The mononuclear copper proteins function in 
electron transfer and catalysis. The binuclear copper proteins function in electron transfer 
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and O2 activation and transport (Table 1.2). Trinuclear and tetranuclear copper proteins 
are involved in catalytic reactions and are newer members and therefore less 
characterized.  
 While copper proteins involved in reactions other than electron transfer are 
interesting and have been reviewed many times,8-14 this thesis focuses solely on the 
copper sites involved in electron transfer; the type 1 copper or blue copper proteins and 
the CuA or purple copper proteins. The low Cu+ to Cu2+ redox potential (~150 mV) 
combined with the abundance of Cu found in human serum (Figure 1.1b) results in a 
series of proteins with high Cu binding affinity and extremely fast electron transfer rates.  
 
Table 1.2: Copper protein classification based on active site. The basic structure representation for each 
copper site is shown below the table. 
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1.3 TYPE 1 COPPER PROTEINS 
General Protein and Metal Binding Site Structure 
 Copper proteins that function solely in electron transfer are known as 
cupredoxins. Cupredoxins are Cu proteins that contain the type 1 copper site or the CuA 
site. Type 1 copper proteins contain a uniquely conserved Greek-key !-barrel fold (eight 
!-strands that form two !-sheets folded around a center "-helix) (Figure 1.2 A). The 
mononuclear Cu binding site is located within the C-terminal !-strands. The mononuclear 
site binds Cu with three conserved ligands in a trigonal plane.15 The trigonal plane 
consists of two equatorial histidine residues and a single equatorial cysteine. The Cu ion 
is also coordinated by at least one additional axial ligand (Figure 1.2 B) and these 
proteins share a conserved short Cys(S)-Cu(II) bond (2.1-2.5 Å) resulting in strong 
covalent character and a very intense absorbance at ~600 nm. 
 
 
Figure 1.2: The general type 1 Cu protein fold and metal binding site. A) The Greek-key !-barrel fold of 
cupredoxins. B) The general type 1 Cu site. See text for details. 
 
 6 
 Though all type 1 copper proteins contain identical equatorial ligand sets, the 
amino acid in the axial ligand position differs. The axial ligand currently is considered to 
play a significant role in the magnitude of the redox potential of each type 1 copper 
protein.16,17 Though the axial ligands typically only result in minor structural differences, 
they can significantly alter the electrostatics of the site. Because of these differences, the 
type 1 copper proteins have been subdivided into three classes; Class 1, Class 2, and 
Class 3 (Figure 1.3), based on the identity of the axial ligand present. The class 1 
proteins, such as amicyanin, have a methionine residue in the axial position. Class 2 
proteins, such as stellacyanin, have a non-methionine residue such as glutamine 
(stellacyanin) or leucine (laccase) in the axial position. Class 3 proteins, while also 
containing a methionine in one axial position contain an additional axial interaction with 
a backbone carbonyl. Azurin, the prototypical Class 3 type 1 copper protein, has a fifth 
coordination with the backbone carbonyl of Gly45. The importance of the differing axial 
position functional groups will be addressed further in Chapter 4. 
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Figure 1.3: Type 1 Cu protein classes - A) Class 1 - amicyanin (PDB Code: 1AAC). The metal site has a 
Met as the axial ligand. B) Class 2 - stellacyanin (PDB Code: 1JER). The metal site has a Gln as the axial 
ligand. C) Class 3 - azurin (PDB Code: 4AZU). The metal site has a Met in one axial position as well as a 
Gly backbone carbonyl as a secondary axial ligand. 
 
1.4 AZURIN FROM PSEUDOMONAS AERUGINOSA 
 Pseudomonas aeruginosa azurin is a well studied, prototypical type 1 Cu protein 
scaffold that has advanced the understanding of cupredoxin function. Azurin is a class 3 
blue copper protein and therefore has five ligands to coordinate the Cu ion. Within the 
conserved trigonal plane lie two histidine residues (His 46, His117) and a single cysteine 
(Cys112). Methionine (Met121) is one of the axial ligands and serves as a weak axial 
ligand. Opposite to Met121 is a second weak axial interaction with the backbone 
carbonyl of Gly45 (Figure 1.4).7,18,19  
The type 1 copper proteins contain an unusually short Cys(S)-Cu(II) bond 
distance of approximately 2 Å. The Cys(S)-Cu(II) bond distance in azurin is 2.1 Å and 
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confers strong covalent character giving an intense ligand-to-metal charge transfer 
(LMCT) band stemming from the S#(Cys112) 3p$ % Cu(II) dx2-dy2 charge transfer (CT) 
transition.7 The LMCT imparts azurin with its blue color and strong absorption at 625 nm 
(Figure 1.5 A). The LMCT is also responsible for the unique EPR spectrum seen for 
azurin (Figure 1.5 B). Characterized by 4 lines of equal intensity with narrow parallel 
hyperfine splittings (A|| = 60 Hz), the EPR spectrum differs greatly from “normal” copper 
coordination compounds (Figure 1.5 B). Typical synthetic copper compounds have much 
larger hyperfine splittings (A|| > 160 Hz) and do not always mimic the type 1 copper site 
features well (Figure 1.5).7 
 
 
Figure 1.4: Pseudomonas aeruginosa azurin. A) The full-length holo-azurin protein (PDB Code: 4AZU). 
B) Type 1 Cu site of azurin. C) Schematic diagram of the type 1 site found in azurin. 
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Figure 1.5: Pseudomonas aeruginosa azurin spectroscopic characterization. A) UV-vis spectroscopy 
shows the LMCT band at 625 nm. B) X-band EPR shows narrow parallel hyperfine splittings 
 
The Role of Cys112 in Azurin 
 The equatorial Cys112 and the axial Met121 ligands in azurin are suggested to be 
responsible for the large increase in redox potential and more efficient ET properties over 
“normal” copper complexes. The type 1 copper site in azurin has been exhaustively 
modified using site-directed mutagenesis and its variants have been extensively studied 
using a broad range of spectroscopic20-30 and crystallographic techniques.31-35 These 
thorough investigations have shown that Cys112 is essential for protein function.   
Early studies established the loss of the azurin spectral properties when Cys112 
was substituted with other natural amino acids differing greatly in size and electronics. In 
contrast, substitution of the remaining three ligands, His46, His117, and Met121 
primarily yields proteins dominated by the strong LMCT and blue color.22,36-39 However, 
the presence of the Cys112 thiol is not a requisite for copper binding. A single Cys112 
mutant, Cys112Asp, retained the ability to bind copper,40 though all the spectral features 
including the distinct LMCT band at 625 nm disappeared, and the ET properties of azurin 
were greatly reduced.40,41 Additional spectroscopic studies established the original type 1 
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copper site had been transformed into a type 2 “normal” copper site with the Cu bound by 
a bidentate Asp112.40,42 Thus while maintaining the ability to bind Cu within the 
mononuclear site, the protein was no longer capable of performing typical azurin 
functions. 
The Cys(S)-Cu(II) bond length in azurin is exceptionally short at ~2.1 Å. At such 
a short distance, it can be expected that the bond between the Cys thiolate and the Cu(II) 
metal would be a covalent interaction. Resonance Raman (rR) and X-ray absorption 
spectroscopy (XAS) were very useful in confirming the covalent nature of the S-Cu 
bond.43-47 The high Cu-S stretching frequency in rR combined with the XAS data and 
DFT calculations has verified the S-Cu as highly covalent and has shown the amount of S 
character (a direct measure of covalent interaction) to be ~38%.48,49 Though these studies 
have provided support for a covalent interaction between Cys112 and Cu, the relative 
contributions of electron density of the metal-ligands and the metal remain debated. By 
analyzing the two protons attached to C! of Cys112 using ENDOR spectroscopy some 
light has been shed onto this predicament.50 Using ENDOR, the spin density of the 
sulfur-centered orbitals was determined to be approximately 30-40%.48-50 The remaining 
electron density resides on the Cu and and is spread weakly over the other ligands in the 
trigonal plane. 
 
The Role of Methionine 121 in Azurin 
Methionine 121 was thought to be the ligand responsible for tuning the redox 
behavior of azurin and has undergone extensive study by site-directed mutagenesis and 
substitution with nonproteinogenic amino acids.16,17,36,51,52 Initial crystal structures of 
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azurin placed the Met121-Cu bond at a distance greater than 3 Å, suggesting little 
interaction of the axial ligand with the Cu ion.33,53,54 However, more recent structures and 
computational calculations placed the bond length closer to ~2.5 Å, supporting the idea 
that the Met121 thioether can interact with the Cu.23,55,56 An extensive list of mutants was 
created to better probe the axial ligand interaction with Cu.26,39,52,57-59 While the majority 
of these mutants display very similar spectroscopic signatures as WT azurin, a 
tremendous range of reduction potentials was observed with azurin Met121 variants and 
has substantiated the role of Met121 in determining the redox behavior of azurin.  
The Met121 variants provided evidence for control of the redox couple in azurin 
and have provided evidence to support that the axial ligand may also play multiple other 
roles in azurin. One of the proposed roles of Met121 is protecting the site from 
exogenous small molecule interactions. Some azurin Met121 mutations have transformed 
the azurin type 1 site into mimics of similar type 1 copper proteins such as nitrite 
reductase or laccase,21,60-64 supporting the idea that the axial ligand may play a role in 
protecting the copper ion from exogenous ligands and water.65-67 Such development adds 
an additional method to modulate the redox behavior of azurin and its type 1 copper 
cousins.29,51 Moreover, it has been proposed that the axial ligand may function in 
maintaining correct active site geometry.68-71   
 
1.5 CUA AZURIN 
General Protein and Metal Site Structure 
 The CuA site is found in terminal oxidases such as cytochrome c oxidase (CcO) 
and nitrous oxide reductase and is intricately involved in electron transfer and the proton 
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shuttle for the generation of ATP. While the type 1 copper proteins have high structural 
homology, proteins containing the CuA copper site do not share a common protein fold. 
The CuA site geometry however is well conserved with only minor axial ligand changes.  
 The CuA site is currently the only electron transfer site known to contain binuclear 
Cu and represents the only known Cu-Cu bond within a protein. It displays entirely 
different geometry than its electron transfer cousins, the type 1 copper proteins.72 The 
CuA site displays geometry more similar to dinuclear non-heme iron proteins and Fe-
only/FeNi hydrogenases (though they do not share common ligand sets) than to other Cu 
electron transfer sites. The 2 Cu ions sit in a rigid diamond core consisting of µ2 bridging 
thiolates from two cysteine residues that hold the Cu ions in a diamond shape (Figure 1.6, 
C/D). The diamond core helps limit rearrangement during the redox event and contributes 
to exceptionally fast electron transfer kinetics and abnormally small reorganization 
energy.54,73-77 The small reorganization energy is imparted by the site’s mixed valence of 
Cu(1.5) • Cu(1.5). The oxidation to the Cu(II) • Cu(II) state is not favorable, thus limiting 
the range of reduction potentials allowed by the site.73-75 The wide range of reduction 
potentials found in type 1 Cu proteins are not found in CuA proteins since the CuA site 
function is more strictly conserved than type 1 sites.   
 Two additional equatorial histidine residues complete the geometries of the CuA 
site diamond core. Similar to the type 1 copper site, each copper ion also has additional 
axial ligands such as methionine thioether or backbone carbonyl interactions from nearby 
residues (Figure 1.6). These equatorial ligands have been shown not to be the major 
determinant of the redox potential of CuA sites.78 
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 The study of the CuA site in its native scaffold is challenging since native proteins 
containing CuA sites are either membrane bound or very large (e.g. bovine CcO is >200 
kDa). Moreover, these proteins contain multiple other metal-binding sites giving rise to 
cross signals that interfere with data collection and make interpretation difficult. Thus 
typical spectroscopic techniques that are used to characterize metalloprotein active sites 
cannot be used in many CuA scaffolds. While model structures using synthetic chemistry 
were successful in providing insight into the structure of the CuA site,79,80 the structures 
were unsuccessful in providing insight into CuA site functionality because study inside a 
protein scaffold is needed to fully understand the site’s delicate nature.  
 
Figure 1.6: Structural comparison of Cytochrome c Oxidase and nitrous oxide reductase. A) Crystal 
structure of bovine heart CcO (PDB ID: 2DYR).81 B) Structure of nitrous oxide reductase from P. 
denitrificans (PDB ID: 1FWX).82 C) Cu site in CcO. D) CuA Site in nitrous oxide reductase. 
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The CuA Azurin Protein Model 
 Using protein scaffolds other than native structure is a powerful tool to understand 
metalloprotein active site dynamics. Since most CuA scaffolds have unwanted, interfering 
cross signals from other metal sites, development of a new scaffold that retained only the 
CuA signal would be extremely useful for characterization of the CuA site. Though the 
scaffolds of type I and CuA proteins differ dramatically, the sites reside in similar 
cupredoxin folds. Thus a new model system was proposed that would eliminate the 
unwanted cross signals of other metal sites in the native scaffold while maintaining native 
CuA signals.81 However, finding a model system that mimics not only the active site but 
also maintains the native spectroscopic signatures is difficult. The primary sequences of 
the azurin type 1 Cu binding loop and the CuA Cu binding loop found in P. denitrificans 
CcO were compared and had sequence similarities.83  
 
Figure 1.7: Sequence overlay of azurin and CuA azurin. The red box highlights the differences in the active 
site sequence. 
 
Engineering a CuA site into the azurin scaffold required extensive mutation. 
Creating a CuA site in azurin was accomplished by substituting residues in the type 1 
copper binding loop in wild type (WT) P. aeruginosa azurin with the residues in the CuA 
binding loop of P. denitrificans CcO (Figure 1.7).83 This new methodology, termed loop-
mutagenesis, created a new, engineered protein (CuA Az) (Figure 1.8).83-85 The native 
Cys112 Cu ligand was not replaced to maintain continuity within the azurin scaffold 
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while attempting to limit protein misfolding. To maintain the conserved CxxxC motif 
found in many CuA proteins a second Cys residue was introduced at position 116. 
 
 
Figure 1.8: Engineered CuA azurin. A) Full length CuA Az (PDB: 1AAC). B) The di-nuclear CuA Az site. 
Residues are numbered in bold. C) Schematic representation of the CuA Az site. The residues highlighted in 
blue represent the ligands found naturally in the type 1 copper site in azurin. The residues in purple were 
engineered to fulfill the CuA site. 
 
 Spectroscopic characterization of CuA Az revealed the engineered protein would 
provide an excellent model for the CuA site.85 The LMCT bands at 480 nm and 520 nm 
with a d-d transition at 750 nm are well in line with spectra seen in other CuA sites 
(Figure 1.9 A). Furthermore, the characteristic 7 line EPR spectra of CuA sites were also 
seen in the engineered scaffold (Figure 1.9 B).85 While allowing for simpler spectral 
characterization of the CuA site in an easy to express scaffold, new difficulties in 
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characterizing the CuA Az chimera were encountered. Specifically new pH dependencies 
not found in native CuA scaffolds resulting in some type I copper signal were observed. 
However, these complications are seen at pH extremes and before Cu binding is 
complete. Inspection of the engineered site shows how some type 1 characteristics could 
remain when the engineered CuA site is overlaid with the original type 1 site in azurin 
(Figure 1.8 C). If the site were imaginarily divided, one of the bound Cu ions would 
retain most of the type 1 ligand set (Figure 1.8C, blue) and the second bound Cu would 
contain a new ligand set differing from azurin (Figure 1.8C, purple).  Thus when titrating 
with Cu, it is conceivable that the original type I site may momentarily form before the 
second reduced Cu ion binds, temporarily displaying type I characteristics. 
 
 
Figure 1.9: Spectroscopic Characterization of CuA azurin. A) UV-vis spectrum. B) X-band EPR spectrum. 
 
 A study that substituted the bridging Cys residues in CuA Az with Ser revealed a 
separation of spectral features, neither of which gave the engineered CuA signals.86 
Rather, substitution of Cys116 resulted in a protein with type 2 characteristics and a 
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yellow color while substitution of Cys112 resulted in a protein with type 1 characteristics 
and blue color. This separation of spectral features is not found in Cys-to-Ser mutations 
of the natural P. denitricans CcO site. Therefore, while the engineered protein acts as a 
good mimic of a WT CuA site, the CuA Az scaffold is not without its own limitations of 
study. 
 
1.6 METHODS OF NONPROTEINOGENIC AMINO ACID INCORPORATION 
While site-directed mutagenesis provided substantial information towards 
understanding both the type 1 Cu and CuA electron transfer sites, studying the role of 
each residue of these sites is difficult since the paucity of functional groups in the 20 
naturally occurring amino acids (of which only seven are available for metal binding) 
severely limits the coordination chemistry. The selective incorporation of 
nonproteinogenic amino acids that contain functional groups not available in 
proteinogenic amino acids into the type 1 Cu and CuA sites could fine tune 
metalloprotein function. Moreover, the roles of the individual Cu metal binding ligands 
could be better elucidated by substitution with isosteric nonproteinogenic amino acid 
analogues. Incorporation of nonproteinogenic amino acids, however, cannot be done with 
standard mRNA translation. 
Natural mRNA translation uses a specific three-nucleotide codon for the 
recruitment of aminoacylated tRNA factors for correct proteinogenic amino acid 
incorporation. However, these codons are specific for their cognate tRNA synthetases, 
eliminating the ability to use the current genetic code to incorporate nonproteinogenic 
amino acids. Many tRNA synthetases are so intimately designed to accept their cognate 
amino acid that they reject similar natural isosteric analogues through a molecular 
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“double sieve” mechanism.87,88 These specificity filters limit misacylation of tRNAs and 
create another barrier to using cellular machinery for the incorporation of 
nonproteinogenic analogues. Though difficult and much more involved than standard 
proteinogenic amino acid incorporation, natural biosynthetic methodologies exist for 
incorporation of nonproteinogenic amino acids.  
 
1.7 BIOSYNTHETIC ROUTES FOR NONPROTEINOGENIC AMINO ACID INCORPORATION 
Translational Recoding 
The twenty known proteinogenic amino acids were long thought to be the only set 
of building blocks used for protein biosynthesis. However, the discovery that selenium 
was essential for the function of two proteins, glycine reductase and glutathione 
peroxidase, began a search for the function of Se in a cellular environment, leading to the 
discovery of selenocysteine (Sec, U), the 21st amino acid.89,90 The revelation that Se was 
directly incorporated into these proteins as the novel amino acid, selenocysteine, was a 
profound discovery.91 Other recently discovered naturally incorporated novel amino acids 
have questioned the limitation of the genetic code and have shown that amino acids 
outside the standard twenty proteinogenic amino acids are readily available in some 
species.92-94 
To date, the incorporation of extra proteinogenic amino acids has relied on the 
ability to recode known stop codons, a technique known as translational recoding or 
codon suppression. The incorporation of Sec is currently the best-understood route and 
though the route uses available cellular machinery, the incorporation of Sec is far from 
simple. Sec incorporation is done through a translational recoding event at a UGA opal 
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stop codon and requires four gene products, selA, selB, selC, and selD.95 Improper read-
through of the stop codon results in truncated variants of the desired translated protein.  
 A series of cis and trans factors are required to correctly read-through the UGA 
codon for Sec insertion. Some parallels in how Sec and the standard 20 amino acids are 
incorporated do exist. Both methods have dedicated tRNAs (selC for Sec) and EF-Tu-like 
factors (selB for Sec) for ribosome recruitment. However, key differences exist. The Sec-
tRNA[Ser]Sec used for translational incorporation is different from other standard tRNAs in 
two ways. First, the tRNASec acceptor arm is longer than traditional proteinogenic tRNAs. 
Secondly, Sec-tRNASec is also unlike the other bacterial and eukaryotic tRNAs that are 
acylated with the correct amino acid and require no further chemistry. Sec-tRNASec is 
charged with a serine residue (Ser-tRNASec) that is converted through a series of steps to 
selenocysteine using the gene products of selA (a selenocysteine synthase) and selD (a 
selenophosphate synthetase).96-98 While this type of acylation chemistry to synthesize the 
desired amino acid on tRNA occurs in certain methanogens it is not a common 
methodology for tRNA acylation.99  
As shown in Figure 1.10, Seryl-tRNA synthetase initiates the process for the 
incorporation of Sec by charging tRNASec with Ser. Once acylated, the synthesis of Sec 
from Ser begins through the generation of selenomonophosphate (SePi) by 
selenophosphate synthetase (SelD).95-98,100 Once generated, selenocysteine synthase 
(SelA) uses the SePi to begin converting the Ser residue to selenocysteine.101,102 When the 
ribosome reaches the UGA codon used for Sec incorporation, a downstream RNA hairpin 
termed the SECIS element (Selenocysteine Insertion Sequence) signals for the 
recruitment of a trans acting protein, SelB required for incorporation of Sec. SelB is an 
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EF-Tu homolog containing a SECIS binding loop region in its C-terminus. SelB interacts 
with the SECIS element and the ribosome causing the ribosome to momentarily pause on 
the UGA stop codon. 
Once paused on the UGA codon, the ribosome’s interaction with SelB causes it to 
refrain from initiating a translational abort. This pause also provides time for the EF-Tu 
homologous domain of SelB to recruit the correctly acylated Sec-tRNASec where it then 
undergoes GTP hydrolysis, incorporating Sec at the UGA codon.100,101 The efficiency and 
success of Sec incorporation is highly dependent on the availability of all of the required 
cis (SECIS) and trans (selA/B/C/D) elements. Missing a single component greatly 
decreases incorporation efficiency.  
While selective recombinant expression of selenoproteins was accomplished, 
expression is limited due to the translation recoding needed for UGA and differences in 
SECIS element recognition. Differences in both the location of and the distance between 
the SECIS loop and the UGA codon within prokaryotic and eukaryotic systems greatly 
complicate expression system development.  
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Figure 1.10: General Scheme for incorporation of selenocysteine using SECIS elements. Amino-acylation 
of tRNA with serine (shown in blue) is the first step of synthesis followed by the installation of the selenol 
shown in red. A specific tRNA is used for the recruitment to the ribosome. See text for more details. 
 
In prokaryotic systems, the SECIS loop is located in the coding region at a 
distance of ~20 nucleotides from the UGA codon. The amino acids following the UGA 
codon are encoded and translated into the complete protein product.102 In contrast, the 
eukaryotic and archea SECIS loops have variable distances from the UGA codon, are 
found exclusively in the 3`-untranslated region of the gene, and are consequently not 
translated into the protein product.103 This difference in proximity of the SECIS elements 
has limited the ability to translationally encode selenoproteins in E. coli recombinant 
expression systems. However, Hilvert and coworkers have recently used a redesigned 
SECIS element to recombinantly incorporate Sec into cytochrome P450cam to 
investigate heme axial ligand interaction with Cys.104 This report currently represents the 
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only fully engineered SECIS element for expression of a eukaryotic selenoprotein 
product in a recombinant expression system.  
Another potential limitation using SECIS elements is the inability to incorporate 
multiple Sec residues per protein. Incorporation of multiple Sec residues in an engineered 
protein sequence may be required to gain function or to study the specific roles of 
residues in the metal ligand set. 
 
Nonsense Suppression 
Nonsense suppression techniques are a comparable technique to natural Sec 
incorporation. Similar to translational recoding of the opal stop codon for Sec 
incorporation, some E. coli strains are known to naturally recode the amber stop codon 
(UAG). The amber stop codon is the least used stop codon by E. coli. Recoding the UAG 
stop codon provides an efficient methodology for expressing proteins containing specific 
nonproteinogenic amino acid substitutions.105,106 
 The incorporation of nonproteinogenic amino acids using nonsense suppression 
requires many aspects to be effective.107 A unique codon must be available or created that 
can only be recognized by an exogenously expressed aminoacyl-tRNA synthetase, 
ensuring correct and efficient translation and subsequent incorporation of a 
nonproteinogenic amino acid. However, to be efficient at incorporation, the engineered 
synthetase cannot acylate endogenous tRNAs. Therefore, for a nonsense suppression 
system to work, an exogenously expressed, non-host synthetase/tRNA pair must 
efficiently interact with the host ribosome while not interfering with the host’s natural 
translational machinery. Discovering an aminoacyl-tRNA synthetase/tRNA pair that 
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suites the above requirements requires a tremendous amount of selection.105 Adding to 
the difficulty, the desired nonproteinogenic amino acid must easily cross the membrane 
to be incorporated if it cannot be made in vivo, and the analogue must not serve as a 
substrate for any endogenous host synthetases.105-106  
 Though a complicated and difficult challenge to overcome, Schultz and 
coworkers have developed a toolkit to produce orthogonal-tRNA:aminoacyl-tRNA-
synthetase pairs capable of incorporating a broad range of nonproteinogenic amino 
acids.107-111 By exposing the tRNA/tRNA-synthetase pairs from Methanococcus jannashii 
to rounds of positive and negative selection, the successful incorporation of 
nonproteinogenic analogues was achieved site-specifically into a range of recombinantly 
expressed proteins in E. coli. While greater than 30 different types of probes have been 
incorporated into proteins using nonsense suppression techniques, the successful 
generation of a tRNA/tRNA-synthetase pair remains a limitation of the technique.  
 
Auxotrophic Substitution 
Using auxotropic bacteria is an older method for incorporating nonproteinogenic 
amino acid analogues. An auxotrophic bacterium is an engineered strain that has lost the 
ability to produce a particular amino acid, requiring external addition of the amino acid 
for incorporation into any growing polypeptide chain. The incorporation of seleno-amino 
acid analogues such as selenomethionine using E. coli auxotrophs has long been 
performed to solve phasing problems in protein crystallography.  This methodology has 
also been applied to the use of cysteine auxotrophic bacteria to substitute cysteine 
residues with selenocysteine for similar purposes.112,113 However, using bacterial 
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auxotrophs for proteinogenic amino acid replacement with nonproteinogenic amino acids 
is not without its limitations.  
Using auxotrophs for replacement of amino acids with their isosteric analogues 
suffers from two key limitations. First, the method replaces all proteinogenic amino acids 
found in the protein with the analogue and therefore typically alters more than one single 
site of interest. Secondly, though deficient in the synthesis of a particular amino acid, 
cells do find alternative routes to make amino acids and recycle those already in the cell. 
Consequently, complete controlled replacement with analogues using this technique has 
yet to be accomplished, with typical replacement percentages between 60-80%.114,115 
Incomplete replacement results in multiple different protein isoforms, complicating 
characterization and ultimately reducing the technique’s usefulness to directly probe the 
individual functionalities of residues. 
 
1.8 SYNTHETIC AND SEMI-SYNTHETIC ROUTES FOR NONPROTEINOGENIC AMINO ACID 
INCORPORATION 
 While biosynthetic routes for the incorporation of nonproteinogenic amino acids 
represent one method for direct substitution of amino acid residues, a chemical approach 
can alternatively create a regimented methodology that can be repeated for a multitude of 
different nonproteinogenic amino acids, with potentially limitless possibilities for 
selective location of incorporation. 
 
 
 
 25 
Standard Solid Phase Peptide Synthesis 
 Using Solid Phase Peptide Synthesis (SPPS) to directly synthesize full-length 
proteins containing nonproteinogenic amino acids was one of the first chemical 
methodologies applied to studying protein function with nonproteinogenic amino acids. 
Using PEG or PS resins containing different linkers, peptides and full-length proteins of 
interest can be synthesized step-by-step using a purely chemical methodology. While 
seeming to be the perfect means for the incorporation of nonproteinogenic amino acids, 
since virtually any functional group can be incorporated into the synthesized peptide 
chain, SPPS suffers from major limitations.  
 The number of residues that are consecutively coupled to the peptide chain limits 
solid phase peptide synthesis. To achieve high yields each coupling step of the synthesis 
requires high efficiency (>99%). However, as the peptide chain elongates, secondary 
structure can form and the peptide can fold upon itself making additional couplings to the 
free amine more difficult. This ultimately decreases the coupling efficiency, lowering the 
final yield. Over the span of a long peptide sequence, these relatively small decreases in 
coupling efficiency result in decreased peptide yields and increased peptide impurities. 
Peptide sequences made by SPPS therefore typically do not exceed 70 amino acids in 
length, limiting the technique’s usefulness in the synthesis of full-length proteins, as very 
few protein sequence are less than 100 amino acids in length.  
 
Native Chemical Ligation 
 Native Chemical Ligation (NCL) was developed to use the advantages of SPPS 
but enable synthesis of longer peptides.116 NCL uses thioester-mediated ligation of two 
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peptide sequences to make longer peptides that are inaccessible by standard SPPS 
techniques. Two peptides of interest, in which one or both contain a single or multiple 
nonproteinogenic amino acids, are synthesized separately by standard SPPS and purified 
to homogeneity. The proposed mechanism of NCL is shown in Figure 1.11. NCL begins 
when the free N-terminal cysteine thiol of Peptide 2 attacks the C-terminal thioester of 
Peptide 1 via a chemoselective transthioesterification (Figure 1.11, Step 1) forming a 
transient thioester intermediate (Figure 1.11). The intermediate undergoes a spontaneous 
S-N acyl rearrangement (Figure 1.11, Step 2), forming the native peptide bond with a Cys 
at the linkage site. 
 
 
Figure 1.11: Native chemical ligation. In step 1, a transthioesterification of the two peptides yields the 
intermediate product 2. A spontaneous N-S acyl rearrangement yields the final product 3 containing a 
peptide bond. 
 
NCL can provide peptide sequences of significantly longer length than those 
available by standard SPPS. Preparation of synthetic peptide-alkyl esters to facilitate 
transthioesterification has been achieved by alkylation of peptide thiocarboxylates and by 
direct synthesis.116-118 Though many of these thioester derivatives are stable, their 
reactivity at pH 7 is extremely low resulting in long reaction times and increased side-
reactions. To promote faster transthioesterification, external thiol catalysts such as benzyl 
mercaptan, thiophenol, and 2-mercaptoethanesulfonate (MES) have been added.119,120 
Though these external catalysts can decrease reaction times, they suffer in the presence of 
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hindered thioesters. Recent work by Kent and coworkers examined the proposed 
mechanism of NCL by investigating a wide range of thiol catalysts to attain faster 
reaction kinetics and minimize side-reactions commonly seen in NCL.121 It was 
subsequently determined that aryl-thiols capable of rapid thiol-exchange yet retaining 
high reactivity with Cys for transthioesterification, provided the highest protein yields.  
 The requirement of a Cys residue at the junction site is a potential limitation of 
NCL. To perform NCL the native protein sequence must contain an easily accessible Cys 
residue to carry out the ligation or a Cys residue must be engineered into the sequence at 
a position to make a suitable length peptide by SPPS. Techniques exist to reduce Cys 
residues to Ala using Raney nickel reduction.122 Moreover, different chemistries such as 
using auxiliaries to facilitate ligation rather than a Cys residue have been developed to 
avoid the obligate need for a Cys residues in NCL by.123  
 
Expressed Protein Ligation 
 Expressed Protein Ligation (EPL) is a recombinant extension to NCL.116,118,124,125 
In NCL, synthetic installation of a C-terminal thioester moiety is required to facilitate the 
transthioesterification needed to afford the full-length (FL) polypeptide. As this step can 
be relatively difficult to accomplish, suffers from low yields, and is limited by the length 
of peptide that can be synthesized using SPPS, an alternative methodology to create a C-
terminal thioester moiety would be advantageous. As an alternative to NCL, EPL uses a 
modified version of protein splicing to generate protein-thioesters (Figure 1.12). 
 RNA splicing is a natural process used to increase the number of gene products 
from a single gene sequence. Similarly, protein splicing is a natural process used to 
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increase the number of protein products from a single mRNA sequence. Protein splicing 
gives rise to two protein products, a spliced variant usually an enzymatic protein and an 
intein that can be a homing endonuclease to limit protein translation. Protein splicing is 
similar to RNA gene splicing. However, protein splicing is found in prokaryotes, 
eukaryotes, and archea whereas gene splicing is not found in prokaryotes. The 
comparison between the splicing methods is depicted in Figure 1.12. Genes in eukaryotes 
are divided into two separate elements, introns and exons and by removing the introns 
and linking the exons, different mRNA variants are translated leading to different protein 
products.  Likewise, mRNA that will be transcribed for protein splicing contains two 
separate elements, inteins and exteins. The inteins catalyze their excision from the protein 
sequence and link the exteins together to create fully functional proteins. 
 
 
Figure 1.12: Comparison of protein and RNA splicing pathways. A) Protein splicing follows standard 
DNA transcription and mRNA translation to create a precursor protein that is then spliced using a self-
excising intein to create the final protein. B) RNA splicing follows standard DNA transcription to make a 
mRNA precursor from which the exons are spliced, the introns removed, and standard mRNA translation 
then results in the final protein. 
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 Following translation the exteins are joined by inteins that catalyze their ipso 
excision.126-129 The splicing event at the intein/extein junction is catalyzed using internal 
Cys or Ser residues (Figure 1.13). Protein splicing begins when the intein undergoes a N-
S/O acyl rearrangement, creating a transient ester at the C-terminal of the first extein 
(Figure 1.12, Step 1).128,129 Attack of this ester via a transesterification by a Cys or Ser 
residue at the N-terminal of the second extein causes the splicing of the adjacent exteins 
by an intermediate ester linkage, but the intein remains attached to the N-terminus of 
extein 2 (Figure 1.12, Step 2.)  
 Cyclization of an Asn residue via attack of the amide by the amine side chain 
mediates excision of the intein. The intein-maleimide is then released from the ligated 
exteins (Figure 1.13, Step 3). The final FL polypeptide is afforded following a 
spontaneous S/O-N rearrangement, to create the amide bond between the adjacent 
exteins. Typically the extein is a protein needed for enzymatic reactions whereas the 
intein-malemide is hydrolyzed to the acid and used as an endonuclease to regulate protein 
expression. 
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Figure 1.13: Protein splicing using inteins. (R= O, S) Step 1: The Initial N-R acyl rearrangement enables 
the transesterification in Step 2, splicing the two exteins. Step 3: Intramolecular cyclization of the C-
terminal Asn residue of the intein causes its release. The spliced protein then undergoes a spontaneous R-N 
acyl rearrangement to give the final peptide sequence. 
  
Intein-chemistry was later seen as an easy route to make C-terminal thioesters by 
using recombinant techniques instead of synthetic techniques.121 However, isolation of C-
terminal thioesters from inteins is difficult since they are quickly captured by flanking 
exteins. Limiting the Mxe intein’s ability to capture the C-terminal thioester was 
performed. By eliminating the intein’s C-terminal activity through mutation, the intein 
was arrested with the thioester in place for capture using an external thiol catalyst via 
transthioesterifcation.126 
 This procedure was quickly marketed by New England Biolabs (NEB) as the 
Intein Mediated Purification with an Affinity Chitin-binding Tag (IMPACT) system and 
initially used as a procedure for protein purification.126 When the protein of interest was 
fused to the modified intein and a chitin-binding domain (CBD) and passed down a 
column of chitin resin, the protein-intein-CBD fusion could be isolated. The addition of 
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an external thiol catalyst then forces transthioesterification, releasing the protein-
thioester. Subsequent hydrolysis of the thioester to make the free acid is performed to 
obtain the purified protein of interest. This new type of affinity chromatography quickly 
demonstrated superiority for the isolation of protein-thioesters over chemical synthesis 
while also allowing for longer protein-thioester sequences than those obtained using 
NCL. Moreover, the technique serves as a method for protein purification. The protein-
thioester or the protein-acid could be attained from the same protein expression by 
altering the external thiol used in the transthioesterification.   
 Extending the principles of intein splicing past protein purification to perform 
EPL was the next logical step.120,124 EPL is a modified version of NCL that uses 
recombinant expression to obtain the thioester instead of using the synthetic 
methodologies found in NCL. In EPL, formation of the thioester is achieved by using a 
modified Mxe intein in the presence of an external thiol to facilitate transthioesterification 
(Figure 1.14). Similar to in vivo protein splicing, the process begins with the shift of 
equilibrium causing an initial N-S acyl rearrangement, making a transient thioester 
between the fusion protein and the intein (Figure 1.14, Step 1). An external thiol catalyst 
is added to mediate the transthioesterification with the protein of interest, creating a 
protein-thioester and leaving the intein bound to the column. However, choice of the 
correct external thiol catalyst is essential. Thiols such as dithiothreitol (DTT) can cause 
cyclization and the formation of protein-acids through rapid hydrolysis of the thioester. 
Attractive thiols for EPL are those that are sufficiently nucleophilic for the initial 
transthioesterification event, but are also labile enough to be displaced by a second 
 32 
transthioesterification with a synthetic peptide containing an N-terminal Cys, not by 
water to form the protein-acid.121  
 Following elution from the column, the protein-thioester is isolated in high yields. 
When a peptide containing the desired nonproteinogenic amino acid(s) and an N-terminal 
Cys residue is added to the protein-thioester, another transthioesterification is mediated 
creating a new transient protein-thioester resulting in the FL protein (Figure 1.14, Step 3). 
A spontaneous S-N acyl rearrangement produces the FL protein with a native peptide 
bond (Figure 1.14, Step 4). 
 
 
Figure 1.14: General scheme for expressed protein ligation (EPL). Step 1: Equilibrium between the fusion 
protein Cys and thioester results N-S acyl rearrangement. Step 2: Addition of an external thiol causes 
transthioesterification between the protein and the thiol giving a protein thioester free from the chitin resin 
bound remainder of the fusion protein. Step 3: Addition of a synthetic peptide with a N-terminal Cys causes 
a second transthioesterification followed by a spontaneous S-N acyl rearrangement (Step 4) to give the final 
FL protein with a peptide bond. 
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 Though EPL can make the isolation of the thioester easier and can greatly 
increase protein-thioester yields compared to many of the synthetic methodologies 
currently available, EPL, like NCL, requires the obligate need of a Cys residue at the 
ligation site. The length of peptide containing the nonproteinogenic amino acid(s) is 
limited to the lengths available when using SPPS.  
 
1.9 INCORPORATING NONPROTEINOGENIC AMINO ACIDS INTO AZURIN AND CUA 
AZURIN 
 While the biosynthetic methodologies for incorporation of nonproteinogenic 
amino acids are appealing, we decided to pursue the incorporation of nonproteinogenic 
amino acids into the azurin scaffold by using synthetic routes. Azurin and CuA azurin 
(because it is built from the azurin scaffold) are well suited for the use of EPL to 
incorporate nonproteinogenic amino acids (Figure 1.15). At a length of only 128 residues 
for azurin (130 residues for CuA Az), the protein is small. The convenient accessibility of 
three of the five copper binding ligands in the C-terminal 17 amino acids of azurin 
(Cys112, His117, and Met121), and six of the eight copper binding ligands in the C-
terminal 19 amino acids in CuA azurin (Cys112, Glu114, Cys112, His120, and Met123), 
provides numerous site-specific locations for incorporating nonproteinogenic amino acids 
to investigate the specific functionality of the copper ligands. Additionally, the necessary 
synthesized peptides contain Cys112 at the N-terminus that participates in 
transthioesterification, affording an effective route to semi-synthesize azurin and CuA 
azurin variants containing nonproteinogenic amino acids by EPL. 
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Figure 1.15: Expressed protein ligation of azurin. The first 111 amino acids of azurin are expressed in-
frame to the Mxe intein and the chitin-binding domain (CBD) using the pTXB1 vector. After purification 
by affinity chromatography with chitin beads, the formation of azurin(1-111)-SR is mediated by the intein 
with the addition of an external thiol. Capture of the azurin-SR is done with the C-terminal 17 amino acid 
synthetic peptide which after a S-N acyl rearrangement gives FL WT azurin. 
 
 To semi-synthesize azurin using EPL, the N-terminal 111 amino acid protein-
thioester needed for transthioesterification was made recombinantly using an intein-
fusion. Cloning work done by Berry, et al. resulted in an azurin1-111-intein-CBD fusion 
protein using the NEB pTXB1 vector containing the modified Mxe intein.16 In initial 
studies, intein-mediated protein cleavage to attain the azurin-SR (protein-thioester) was 
successful though the azurin-SR readily hydrolyzed in buffer. In an attempt to limit 
hydrolysis and optimize the azurin-SR stability, ligations at a range of pH were 
completed but no improvement in yield was observed. Instead of azurin-SR isolation, 
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attempts to capture the azurin-SR with the synthesized peptide using an on-column 
cleavage-capture were tried. Though protein yields increased using this methodology, 
hydrolysis of the thioester remained problematic at pH ranges from 5-8.5. While the 
yields are far from theoretical yields due to hydrolysis, significant protein yields are 
obtainable (~5 mg/L growth).  
 
1.10 SUMMARY 
 While site-directed mutagenesis has remained the primary means for probing 
ligand functionality in metalloproteins, a new area of investigation has recently began 
using nonproteinogenic amino acids to more narrowly define ligand function and fine 
tune metalloproteins. The two metalloproteins that we have chosen to probe using 
nonproteinogenic amino acid substitution are azurin and CuA azurin, two cupredoxins 
involved in electron transfer. Both proteins exhibit characteristic LMCT bands that 
produce deep colors (blue in azurin and purple in CuA azurin) and distinctive EPR 
signals. Both proteins are also well studied and changes to either the CT bands or EPR 
signals reliably show perturbations of electronic and geometric components of the site.  
 Though many routes for the incorporation of nonproteinogenic amino acids exist, 
both biosynthetically and synthetically, expressed protein ligation serves as the most 
straightforward methodology to study both the type 1 copper site in azurin and the CuA 
site in CuA azurin by nonproteinogenic amino acid substitution. Since the azurin-thioester 
protein is readily accessible through recombinant expression and the synthesis of a 17-
mer peptide (19-mer peptide for CuA Az) containing an N-terminal Cys residue can be 
achieved, using EPL to incorporate nonproteinogenic amino acids into both scaffolds can 
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be accomplished. Herein will be described the efforts at probing the type 1 copper site 
with the nonproteinogenic amino acids selenocysteine (Chapter 2) and homocysteine 
(Chapters 3 and 4). Furthermore, efforts at understanding the unique bridging thiolates 
used to bind Cu in CuA azurin (Chapter 5) as well as the unique binding properties of the 
backbone carbonyl from Glu114 in CuA azurin (Chapter 6) with nonproteinogenic amino 
acids will be described. 
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CHAPTER 2 
INVESTIGATING THE RACK HYPOTHESIS: CYS112HCY AZURIN 
 
2.1 INTRODUCTION 
Introducing functional groups that are unavailable in the 20 proteinogenic amino 
acids by incorporating nonproteinogenic amino acids can fine tune function and define 
metal ligand functionality.1-5 Moreover, unique functional groups can act as an initial step 
in metalloprotein engineering.5-7 Pseudomonas aeurginosa blue copper azurin has been 
found to be a very good metalloprotein model system for the incorporation of 
nonproteinogenic amino acids.1-5 The blue copper or type 1 copper site in azurin has 
trigonal-bipyramidal geometry with the His2Cys equatorial plane consisting of His46, 
His117, and Cys112. The unique bipyramidal geometry is created in azurin by the 
presence of two axial ligands interactions. Typical of many type 1 copper sites, a Met 
residue (Met121) acts as an axial ligand. In addition, the azurin type 1 copper site has an 
anionic interaction with the backbone carbonyl oxygen from Gly45 (See Figure 1.4). 
The type 1 copper proteins display unique spectroscopic properties (strong ligand-
to-copper charge transfer bands and small parallel hyperfine splitting in EPR) and 
increased redox potentials (300-600 mV) that are not found in most copper complexes 
outside the blue copper scaffold (See Figure 1.5). These unique characteristics have been 
attributed to the so-called “rack hypothesis” which states that the unique properties 
inferred to the blue copper proteins (including azurin) are a direct function of the entatic 
geometry enforced by the azurin protein scaffold.8-12 The constrained geometry reduces 
the Jahn-Teller effect normally seen in copper complexes and thus reduces the 
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reorganization energy required during electron transfer, making blue copper proteins 
efficient electron transfer agents.13-15 The rack hypothesis has been supported by 
extensive investigation by spectroscopic and crystallographic methods.8-12,16,17 These 
studies also defined the roles of the metal ligands in azurin. Consequently, Cys112 and 
Met121 are responsible for the spectroscopic properties and reduction potential of azurin 
respectively.1-6,8-12,18,19  
Site-directed mutagenesis (SDM) of Cys112 to any other proteinogenic amino 
acid results in species that lack the spectral characteristics associated with blue copper 
proteins.20-23 Only a single mutation, Cys112Asp, retains any spectroscopic 
characteristics.22 However, instead of wild-type (WT) blue copper type I character, it 
displays spectroscopic signatures of type 2 copper-binding proteins.22 Recently the Gray 
laboratory has developed a “new” copper protein from the C112D azurin mutant.24 By 
adding an additional mutation, M121L, a new protein termed Type 0 Cu was created.24 
The variant was capable of binding copper while maintaining a high redox potential and 
similar geometry to WT azurin all without having a thiolate within the metal binding 
center.24 The spectral similarities are attributed to increased interaction of the other 
ligands to the Cu, especially the Gly45 backbone carbonyl. While the protein displays 
similar overall geometry and high redox potentials, features not seen in the Cys112Asp 
mutant alone, the LMCT band is completely absent.24  
In contrast to Cys112 mutations, mutation of the equatorial His residues or Met121 
yields proteins dominated by the Cys112 LMCT and retaining blue color.13,20-22 These 
SDM studies firmly suggest that Cys112 is essential for blue copper properties. Previous 
reports from our laboratory using expressed protein ligation (EPL) to incorporate the non-
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standard amino acid selenocysteine (Sec) at position 112 have thus far remained the only 
reported mutations of Cys112 that retain WT type 1 copper site characteristics.1,3,4 The 
Cys112Sec variant firmly established EPL as a new and interesting method to probe the 
type 1 copper site in ways that cannot be accomplished using site-directed mutagenesis.  
While the Cys112Sec mutation was able to show electronic contributions of 
Cys112 to the function of azurin, it was unable to establish any additional information 
supporting the rack hypothesis.1,3,4 Thus to investigate how the azurin scaffold reacts to 
mutations affecting proper site formation, a longer derivative of Cys, homocysteine 
(Hcy), was incorporated at position 112. Because homocysteine contains a thiolate like 
Cys, there should be no electronic differences. However, the additional methylene group 
of homocysteine will push the thiolate closer to the Cu, affecting the geometry and 
forcing the site to adopt alternative conformations. By analyzing the changes in 
spectroscopy and reduction potential of the Cys112Hcy azurin variant new insights into 
the rack hypothesis are possible that cannot be accomplished through standard SDM.13-15 
  
2.2 CONSTRUCTION OF CYS112HCY AZURIN USING EPL 
Ligation with homocysteine at the ligation junction, though retaining a free 
thiolate for transthioesterification, is not identical to performing EPL with Cys at the 
ligation junction. The elongated aliphatic chain of homocysteine participates in the 
ligation, resulting in an intermediate six-membered ring rather than the five-membered 
ring found in standard ligations using Cys.25 The different rates of forming six-membered 
rings compared to the five-membered ring found in Cys ligation could pose difficulties 
during both steps of EPL. Nonetheless, native chemical ligation (NCL) has been 
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performed using homocysteine in place of Cys at the ligation point and has shown to 
proceed smoothly.25,26  
Though homocysteine was used at the ligation point in NCL, its incorporation 
into proteins to study protein characteristics has yet to be explored.26 Using homocysteine 
at the ligation point in NCL was performed to remove the residual thiolate at the ligation 
junction by creating Met residues through subsequent methylation of the free thiolate 
with methyl-iodide.25 While useful by creating another potential break point other than 
Cys for NCL, the Cys112Met mutation fails to maintain blue copper properties. Thus no 
reports incorporating homocysteine to study thiol interactions exist. A single report using 
homocysteine at the ligation junction (without subsequent methylation) was completed to 
study the constraining effects of disulfide bonds on cyclic peptides.25 Consequently, the 
effects homocysteine may have on metal binding in a metalloprotein has yet to be 
explored.  
Incorporating homocysteine to study metalloprotein geometry could support 
conclusions of the rack hypothesis that cannot be tested using other techniques. If 
metalloproteins do use scaffold folding to impose entatic structure to their metal binding 
sites, an additional methylene unit on Cys112 in azurin should impose difficulties for the 
protein to correctly adopt the type 1 geometry.9,15 Thus either the protein will be unable 
to accommodate the elongated homocysteine side chain and the azurin properties will be 
perturbed, or the azurin scaffold will adjust to accommodate the elongated side chain and 
minimize modification to the site’s properties. 
Using methodology similar to other reported nonproteinogenic amino acid 
incorporation studies into azurin, a peptide consisting of the last 17 amino acids of azurin 
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containing a Cys112Hcy mutation (H2N-HcyTFPGHSALKMGTLTLK-OH) was 
prepared using standard solid phase peptide synthesis.1-5 Truncated azurin (residues 1-
111) was ligated in-frame to the modified Mxe-intein, and a CBD (NEB – PtxB1 vector) 
and expressed in an E. coli expression system. The fusion protein was then isolated using 
chitin resin and EPL completed in the presence of mercaptophenyl acetic acid (MPAA) 
as the transthioesterification mediator to obtain the desired full-length Cys112Hcy azurin 
variant. The Cys112Hcy Az-apo protein was analyzed using matrix-assisted laser 
desorpotion ionization mass spectrometry (apo-Cys112Hcy Az: calcd Mw, 13945; obsd 
Mw, 13948; holo-C112Hcy Az: calcd Mw, 14023; obsd Mw, 14027).  
 
2.3 SPECTROSCOPIC CHARACTERIZATION OF CYS112HCY AZURIN 
Addition of Cu(II) to the apo-Cys112Hcy protein resulted in a blue color change 
and absorption at 618 nm by visible spectroscopic analysis; a 7 nm blue shifted peak 
from the WT absorption at 625 nm (Figure 2.1). As previously noted, a strong 
S(Cys112)3p!-Cu(II)-3dx2-y2 charge transfer results in an intense absorption at 625 nm in 
WT azurin.9,27 It is likely that the absorption at 618 nm by the Cys112Hcy Az variant is a 
blue-shifted S(Hcy112)!Cu(II) charge transfer band. This shift likely represents a 
perturbation of the site geometry rather than any changes in the Cu(II)-Hcy covalent 
interaction. 
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Figure 2.1: Visible spectroscopy of Cys112Hcy azurin: The SHcy112-Cu(II) charge transfer is at 618 nm. 
The WT azurin charge transfer is at 625 nm. The peaks are normalized to better display changes in 
absorbance. 
 
The X-band EPR spectrum (Figure 2.2) of the mutant has a larger parallel 
hyperfine splitting (58 x 10-4 cm-1) than WT azurin (26 x 10-4 cm-1) suggesting a reduced 
covalency between the homocysteine ligand and the Cu(II). Simulation of the spectrum 
gave g-values of 2.24, 2.045, 2.076 (compared with 2.26, 2.056, and 2.039 for WT 
azurin).3,4,9,27 The site therefore seems to maintain its overall axial character suggesting 
little difference between the homocysteine and WT type 1 copper site geometries.  
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Figure 2.2: X-band EPR spectrum for Cys112Hcy azurin overlaid with WT azurin. EPR Conditions: Field 
Center = 3000 G, Field Sweep = 2000 G, Modulation Amplification = 3 G, Frequency = 9.049 GHz, Power 
= 0.2 mW, Temperature = 30 K.  
 
2.4 ELECTROCHEMICAL ANALYSIS 
An observed reduction potential increase of 35 mV (360 mV Cys112Hcy, 325 
mV WT Az vs NHE) is also suggestive of decreased covalent character between the 
S(Hcy112)-Cu(II) in correlation with the EPR data presented (Figure 2.3). The increased 
potential may be a result of geometric compensation and may be allowing more Met-
Cu(II) interaction and thus an increased potential. 
 57 
 
Figure 2.3: Cyclic voltammetry overlay of WT azurin and Cys112Hcy azurin. The potential for the mutant 
is 35 mV higher than WT under identical conditions (NH4OAc, pH 5.0, 0.1 M NaCl.). WT Azurin E1/2 = 
325 mV. C112Hcy Az E1/2 = 360 mV. Values are corrected to NHE. 
 
 
2.5 MOLECULAR MODELING 
To further validate geometric changes in the Cys112Hcy mutant, molecular 
modeling using VMD software was undertaken with the help of Nicholas Marshall from 
the Lu group. Figure 2.4 clearly shows that the overall site distortion is minimal when 
compared to the WT overlay, supporting the claim that the site has undergone geometric 
rearrangement in order to maintain type 1 copper characteristics. As modeled, the Cu 
appears to be at a greater distance to Met121 (4.4 Å) than the corresponding interaction in 
WT azurin (3.18 Å). Though demonstrating very little perturbation of the active site 
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residues, VMD is currently not capable of fully simulating M2+-ligand charge interactions 
and thus models solely on electrostatics, altering the actual Met121 and Gly45 distances. 
As such, it is highly likely that the Cu positioning is very similar in both the variant and 
WT azurin, explaining the minor 7 nm blue shifted spectra and expanded hyperfine 
splittings seen in the X-band EPR spectrum. 
 
 
Figure 2.4: Molecular model structural overlay of Cys112Hcy azurin with WT azurin. Cys112Hcy is in 
light gray, WT azurin is in dark gray. The approximated bond lengths to the modeled Cu are listed in the 
provided table. 
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2.6 CONCLUSIONS 
An azurin variant containing a Cys112Hcy mutation has been obtained through 
EPL. The mutant displays typical type 1 copper site features but with an apparent 
decrease in the covalent interaction between the S(Hcy112)-Cu(II) when compared with 
the WT S(Cys112)-Cu(II) interaction. While not conclusive, incorporation of 
homocysteine in azurin lends support to the “rack hypothesis.” The Cys112Hcy variant 
maintained its blue color suggesting little perturbation of the site. Additionally, while the 
hyperfine splittings of the variant were wider than those of WT azurin, suggesting weaker 
thiolate-Cu interaction, they were still of the same magnitude and maintained similar g 
values and axial geometry. Thus the EPR data further support that little geometric 
variation is induced in the Cys112Hcy azurin variant, suggesting that the scaffold was 
able to adapt its structure to maintain WT properties.  
Molecular modeling, while limited due to current computer programming 
capabilities, further supports that the azurin scaffold was capable of rearranging to 
maintain type 1 geometry and the cupredoxin fold. It appears that the protein 
compensates for the additional methylene group on homocysteine by pushing the ligand 
side chain deeper into the protein cavity, and thus maintaining a similar S-Cu(II) distance 
to WT azurin. 
Because determining electron transfer kinetics is a difficult set of experiments to 
do and requires a substantial amount of protein, the electron transfer kinetics of the 
variant were not measured. Instead, to gauge any changes to WT properties, the redox 
behavior of the variant was compared to WT azurin. While the reduction potential is 35 
mV higher than tthat of he WT, it is certainly not suggestive of large changes to the site.  
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2.7 FUTURE DIRECTIONS 
Validation of Site Geometry. The spectroscopic studies thus completed while 
suggestive of little perturbation of site geometry, are not conclusive. Studies are needed 
to verify site geometry to ensure that the Cys112Hcy variant molecular modeling data is 
reliable. Verifying the molecular modeling will provide more evidence supporting the 
rack hypothesis. EPL derived metalloproteins are notoriously difficult to crystallize 
because of misfolded protein species and the low protein yield following the ligation. 
While challenging, obtaining a crystal structure would definitively assign bond lengths 
and angles supporting any changes to the site’s geometry. Additionally, our laboratory 
has previously established collaborative efforts using ENDOR spectroscopy to establish 
bond lengths. These collaborative efforts could provide additional means to determine 
perturbations present in the variant scaffold. 
Lastly, while difficult to perform, determining the electron transfer kinetics of the 
site in order to obtain approximate reorganization energy values would provide evidence 
supporting the rack hypothesis. While all of the current spectroscopic evidence supports 
that the azurin scaffold successfully accommodated the elongated side chain of 
homocysteine, without verification of electron transfer kinetics the true changes to the 
site will remain unknown. Key to the rack hypothesis is that the reorganization energy of 
blue copper proteins remains relatively static because of the entatic forces imposed by the 
scaffold. Only kinetic studies can provide that information. 
 
 
 
 61 
2.8 EXPERIMENTAL 
General. All chemicals used were obtained from Aldrich. All amino acids were 
purchased from Novabiochem, Advanced Chemtech, or Chem-Impex Internation. 
Protecting groups used for Fmoc-SPPS were Cys(Trt), Ser(OtBu), Glu(OtBu), 
Cys(StBu), Asn(Trt), His(Trt), Lys(Boc), Thr(OtBu). Methylene chloride (DCM) was 
distilled from calcium hydride. Tetrahydrofuran (THF) was distilled from sodium and 
benzophenone. Dimethylformamide (DMF) was dried over 2 Å sieves before use. All 
aqueous buffers were degassed under Ar or N2 as specified immediately prior to use. UV-
Visible, MS, and EPR Spectroscopy: UV-Vis spectra were taken on a Cary 5000 
spectrometer. X-band EPR spectra were collected on a Varian E-122 spectrometer at the 
Illinois EPR Reseach Center (IERC). The samples were run at ~30 K using liquid He and 
an Air Products Helitran cryostat without glassing agents. The magnetic field was 
calibrated using a Metrolab PT 2025 NMR Gaussmeter, and the microwave frequency 
was measured with an EIP model 578 frequency counter equipped with a high-frequency 
option.  
Mass spectral data was collected at the Mass Spectrometry Laboratory, School of 
Chemical Sciences, University of Illinois by either Electrospray Ionization (ESI MS), or 
matrix assisted laser desorption ionization (MALDI) techniques as indicated. Mass 
spectral data reported as – mass, peak (percent).  
Preparative RP-HPLC was done with a Waters Delta 600 system. Solution A was 
0.1 % TFA in H2O, and solution B was 80 % MeCN/20 % H2O with 0.1 % TFA. Unless 
otherwise stated, a linear gradient of 20% to 70% B over 23 min was used for all runs. 
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Solid phase peptide synthesis (SPPS) was performed on a Rainin PS3 automated peptide 
synthesizer or manually using medium fritted funnels. 
 
H2N-HcyTFPHGSALMKGTLTLK-COOH 
Synthesis of C112Hcy 17-mer Peptide, (3.1), Lab Book 7, page 21. 
Solid Phase Peptide Synthesis. The peptide was synthesized on a 0.2 mmol scale 
with a Rainin model PS3 peptide synthesizer (Woburn, MA) using standard Fmoc-based 
chemistry. Wang resin preloaded with Fmoc-Lys(Boc) was pre-swelled in DMF (6 x 10 
min, 6 mL). All Fmoc-deprotections were accomplished using 20% piperidine/DMF (v/v) 
(3 x 3 min, 6 mL). Synthesis of the peptide from Lys128 through Thr113 was completed 
using a five-fold excess of amino acids pre-activated in 0.4 M N-methylmorpholine 
(NMM) (6 mL) and O-(1H-6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HCTU) (4 equiv.) for 3 min and coupled to the resin for 45 min 
under N2 sparging. Amino acids were double coupled when necessary and completion of 
the couplings were monitored by qualitative Kaiser test. Fmoc-Hcy(Trt)OH (3 equiv.) 
was coupled without pre-activation using 1-hydroxybenzotriazole hydrate (HOBt) (6 
equiv.) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (6 
equiv.) in DMF at 25 °C for 2-4 h until full coupling could be observed by qualitative 
Kaiser tests.  
Cleavage. The resin carrying the fully protected peptide was washed with ethanol 
(3 x 15 mL) and dried under reduced pressure. Peptide cleavage from the resin was 
achieved by treating the resin with a cocktail of 5% triisopropylsilane 
(TIPS)/H2O/thioanisole in neat trifluoroacetic acid (TFA) (10 mL) at 25 °C for 2 h. The 
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mixture was filtered and the eluent concentrated using rotary evaporation to obtain a 
yellow oil. The peptide was precipitated from the yellow oil by trituration with cold 
diethyl ether and isolated by centrifugation at 3000 x g at 10 ˚C. The crude peptide was 
dissolved in 1:1 dH2O/acetonitrile (MeCN) (~10-15 mL) and lyophilized prior to 
purification. The crude lyophilized product was purified by preparative RP-HPLC and 
lyophilized directly after purification to afford a white solid. (Yield: 65 mg). MALDI-
MS. Expected: 1819.14, Observed: 1819.5. 
 
Expressed Protein Ligation, Lab Book 7, page 48. 
Cultures of E. coli BL21 (DE3) cells containing the NEB pTXB1 plasmid to 
express the azurin(1-111)-Intein-CBD fusion protein were grown in LB media for 8 h at 
37 ºC and used to inoculate eight 2 L flasks of LB media containing 100 mg/mL 
ampicillin. The cells were grown at 37 ºC for 16 h with shaking at 210 rpm and harvested 
at 9000 x g. The cell stock was then frozen stored at -80 ºC until needed.  
The frozen cell stock was re-suspended in a lysis buffer containing 20 mM 
HEPES, pH 8.0, 250 mM NaCl, 1 mM EDTA, 1 mM PMSF, 0.1% Triton-X-100 and 1 M 
urea (100 mL). The suspension was then lysed using sonication (Misonix Sonicator 4000, 
0.5 inch diameter probe) for a work time of 6 min (6 sec. on, 10 sec. rest). Additional 
urea was added to bring the final concentration to 1.5 M and the lysate was subjected to a 
second round of sonication for 3 min work time (6 on, 10 off). The crude lysate was 
centrifuged at 13,500 x g for 30 min. The supernatant was carefully decanted and the 
fusion protein bound by batch absorption to 70 mL of chitin resin pre-equilibrated with 
20 mM HEPES, pH 7.2, 250 mM NaCl, and 1 mM EDTA (buffer 1) for 1-2 h at 4 º C. 
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The chitin resin was then poured into a column and the column headspace was purged 
with Ar. The column was then washed with 5 column volumes of buffer 1 by cannulation 
under Ar pressure. 
Ligations were initiated by the addition of the 17-mer peptide (1.02 mM, 60 mg) 
and 2 equiv tris-(2-carboxyethyl)phosphine (TCEP) (3 mM, 30 mg) in 40 mL of degassed 
buffer 1 (35 mL) containing ~50 mM mercaptophenyl acetic acid (MPAA) (50 mM, 350 
mg) to the column under Ar pressure via cannulation. The chitin resin was re-suspended 
in the column and the entire column was agitated gently at 4 ºC for 64 h. After ligation, 
the column was eluted under Ar pressure and washed with 1 column volume of buffer 1. 
The eluent was centrifuged at 13500 x g for 30 min and the supernatant was concentrated 
using 10,000 MWCO Centricon concentration spin tubes at 3000 x g to a final volume of 
~10 mL. The concentrated protein was then exchanged into 50 mM Universal buffer (50 
mM NaOAc, 40 mM each MES/MOPS/TRIS/CAPS) pH 7 via PD10 (G25 Sephadex) 
columns. The desalted sample was titrated with incremental additions of freshly made 20 
mM CuSO4 solution in H2O. The titrated sample was purified using a Pharmacia SP 
HiTrap column (5 mL) that was washed with 10 column volumes of 1 M NaCl in H2O 
and equilibrated with 10 column volumes of 25 mM MOPS, pH 6.5. Following 
purification, the protein was concentrated and analyzed using MALDI-TOF-MS and ESI-
MS. (Apo-calculated: 13930. Observed: 13932. Holo-calculated: 13994. Observed: 
13996). 
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Electrochemical Measurements, Lab Book 6, page 44. 
The reduction potential of each mutant was determined by cyclic voltammetry 
after verifying the WT azurin reduction potential using a CH Instruments 617A 
potentiostat equipped with a picoamp booster and a Faraday cage. A pyrolytic graphite 
edge (PGE) electrode was polished and 2-3 mL protein solution was applied directly to 
the electrode following previously described methods. After a short incubation time, the 
electrode was immersed in either 20 mM NaOAc, pH 4.0 with 100 mM NaCl, 20 mM 
NH4OAc, pH 5.0 with 100 mM NaCl, or 25 mM KH2PO3, 100 mM KCl before data 
collection.  Each protein was then sampled at varying scan rates between 10 mV and 500 
mV. The reduction potentials were measured against Ag/AgCl and converted to NHE. 
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CHAPTER 3 
INCORPORATING 77SE-SEC INTO AZURIN: C112U AZURINi 
 
3.1 INTRODUCTION 
Protein design and engineering has contributed greatly to our understanding of 
protein structure and function. A common practice when designing and engineering new 
function into protein scaffolds is to use site-directed mutagenesis (SDM) to replace a 
specific amino acid in proteins with other natural amino acids. While quite powerful, it 
has become increasingly evident that SDM cannot address the precise role of a specific 
amino acid because, with limitation of 20 natural amino acids, it is often difficult to 
change only a single factor. Thus when a residue is altered, both the electronics and 
sterics of the site are perturbed, limiting the ability to precisely determine function. This 
limitation is even more evident in metalloprotein design and engineering, as even a 
smaller number of natural amino acids are capable of coordinating to metal ions.1,2  
More importantly, metal-binding sites are intricately designed to accept a specific 
metal ion among large numbers of other metal ions for binding and activity. Since 
geometry and ligand donor sets of metal-binding sites are much more varied than those of 
metal-free active sites, a subtle change of one factor can have a profound effect on 
structure and activity. Therefore the need for introducing isostructural unnatural amino 
acids into metalloproteins is even greater. Such an endeavor not only defines the role of 
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amino acids more precisely, but also produces novel metalloproteins with both predicted 
and unprecedented properties.3,4  
The type I site is defined by an unusually short copper to cysteine bond (2.1 Å) 
and this shortened bond, together with its unique metal-binding site geometry, is 
responsible for an intense ligand to metal charge transfer (LMCT) band resulting from 
the S!(Cys112) 3p! ! Cu(II) dx2-y2 charge transfer transition giving azurin its strong 
visible absorption at 625 nm and thus its intense blue color.5-7 The highly covalent nature 
of the LMCT between the copper and Cys ligand is also responsible for the narrow 
hyperfine splittings in the parallel region of the EPR spectra (A" ~ 60 X 10-4 cm-1), 
smaller than those of “normal” copper coordination compounds ((A" ~ 160 X 10-4 cm-1) 
(See Figures 1.4, 1.5).7 
 
3.2 INCORPORATING SEC INTO AZURIN: BACKGROUND 
Precisely studying the role of a single residue requires incorporating 
nonproteinogenic amino acid analogues. Selenocysteine (Sec or U), an isosteric analogue 
of Cys, has been used to study the type I site of azurin.8-10 Since Se and S share similar 
atomic radii, electronegativity, and oxidation states, the replacement by Sec is much more 
conserved than replacement of Cys with other naturally occurring amino acids (Figure 
3.1). The similarity also yields comparable oxidized analogues (e.g. disulfides and 
diselenides) and allows for mixed S-Se compounds,11,12 a feature that the natural amino 
acid Ser cannot mimic.13 However, although both Se and S are Group VIA elements with 
similar physical characteristics, they exhibit different reactivities. Most notably, the pKa 
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of Sec (5.2) is much lower than that of Cys (8.6), suggesting that at physiological pH Sec 
will be in its anionic selenolate form rendering it more nucleophilic than Cys.11,14 
Unfortunately the replacement of Cys with Sec is not easily accomplished by site directed 
mutagenesis and requires the use of alternative techniques for its incorporation (see 
Chapter 1, section 1.6). 
 
Figure 3.1: Comparison of the physiochemical properties of cysteine and selenocysteine. 
 
Using EPL Sec was successfully incorporated into azurin in place of Cys112 
(C112U Azurin).8-10 The C112U azurin variant demonstrated distinct differences from the 
WT protein.8-10 The first characteristic change was a red shift in the UV-Vis spectrum 
from 625 nm for WT to 677 nm for the C112U mutant likely resulting from the lower 
ionization energy of Se when compared to S.8,9 More dramatically are the changes noted 
in the EPR spectra between the two proteins.9 A marked increase of the parallel hyperfine 
splitting (100 G) of the C112U mutant compared to WT azurin (56 G) suggests that the 
Se-Cu bond is less covalent in nature than the S-Cu bond.9 Furthermore, the observed 
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increased rhombic character of the site with a larger increase in gy than in the gz tensor is 
consistent with increased axial interaction or loss of Cu(II) interaction with the 
selenolate.9 This finding was expected as Se is softer than S and thus would prefer 
coordination with Cu(I) rather than Cu(II).  Surprisingly however, no dramatic change 
was noted in the reduction potential of the site when the ligand was changed from Cys to 
Sec.8 
Though the C112U azurin mutant provided a unique view of the type I site, many 
questions still stand regarding the electron densities residing on the Cu and ligands in the 
azurin type I site.15 Thus it was proposed that incorporating an isotopically enriched 77Se-
Sec analogue into azurin could provide a means through Electron-Nuclear Double 
Resonance (ENDOR) spectroscopy to empirically evaluate these densities. Such a 77Se-
Sec derivative is prohibitively expensive to synthesize. Therefore, with the low yields of 
protein obtained during the semi-synthesis of non-enriched C112U azurin, it became 
evident that optimization of the synthetic and EPL schemes would be necessary to justify 
incorporation of an expensive 77Se derivative. 
 
3.3 OPTIMIZATION OF THE SYNTHESIS OF SEC(PMB). 
In order to accomplish substitution of Cys112 with selenocysteine, a derivative of 
selenocysteine was needed that was suitable for standard Fmoc-based Solid Phase 
Peptide Synthesis (SPPS).  The most common derivative of selenocysteine used for SPPS 
has been Fmoc-Sec(PMB)-OH (PMB: p-methoxybenzyl) primarily due to 
incompatibilities with the trityl (Trt) protecting group.16-18 Many procedures have been 
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developed over the years to synthesize Fmoc-Sec(PMB)-OH from various starting 
materials.  In recent years, a scheme originating from the van der Donk laboratory has 
emerged as a convenient methodology for Sec(PMB) synthesis.19 While this route is 
already highly optimized (Scheme 3.1), the final allyl deprotection step suffers from 
incidental Fmoc-deprotection when using morpholine as the allyl transfer agent. By 
changing the allyl transfer reagent to sodium 2-ethylhexanoate, the partial removal of the 
Fmoc group was eliminated and yields were modestly increased (99% from 95%). 
 
 
Scheme 3.1: Synthetic route for Fmoc-Sec(PMB)-OH (3.5) from Fmoc-Ser-OH.19 Conditions in bold are 
modified and optimized conditions used for allyl deprotection differing from ref 19. 
 
Starting from the inexpensive Fmoc-Ser-OH starting material, the precursor 
Fmoc-Se(PMB)-Sec-OAll was prepared in 3 steps (Scheme 3.1). Selective installation of 
the allyl ester was followed by activation of the alcohol with p-toluenesulfonyl chloride. 
Installation of the p-methoxylbenzyl selenol was accomplished through reduction of the 
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(PMBSe)2 and displacement of the p-tolunenesulfonate group in basic conditions. The 
final optimized step to selectively remove the allyl ester protection was carried out as 
described by McCombie with slight modifications and by using sodium 2-ethylhexanoate 
as the allyl scavenger rather than morpholine to reduce undesired Fmoc-deprotection (see 
experimental).20 After successful synthesis of Fmoc-Sec(PMB)-OH, the final amino acid 
derivative was incorporated into the C-terminal 17 amino acid sequence of azurin using 
standard Fmoc-based chemistry.  
 
3.4 SOLID PHASE PEPTIDE SYNTHESIS OF C112U 17-MER 
Substitution of Cys112 with selenocysteine requires a synthetic peptide with an 
N-terminal Sec residue that participates directly in the ligation reaction, substituting for 
the role of cysteine. The use of Sec residues to facilitate the trans-selenoesterification 
needed for peptide ligation in EPL has been previously been reported. Hondal showed 
that replacement of Cys110 in RNase A with Sec could be accomplished using a 
synthetic 15 amino acid peptide containing an N-terminal Sec residue.21 The EPL product 
protein was indistinguishable from the WT protein with similar rates of catalysis 
indicating that replacement of Cys with Sec does not dramatically perturb either function 
or protein folding. More recently, Hondal has demonstrated Sec incorporation into High 
Mr thioredoxins without disruption of protein folding.22,23 Concurrently, the van der Donk 
lab developed and used similar methods for azurin.8,9,19  
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Figure 3.2: Azurin 17-mer peptides for incorporating selenocysteine at position 112 (C112U Az). 
 
The C-terminal 17-mer of azurin was synthesized as reported using Fmoc-SPPS 
but with a cysteine to selenocysteine mutation at position 112 (H2N-
U(PMB)TFPGHSALMKGTLTLK-OH) to make peptide 3.10 (Figure 3.2).8 Because the 
PMB protecting group is resistant to removal using standard peptide cleavage cocktails 
like H2O/triisopropylsilane(TIPS)/ethanedithiol (EDT) in TFA, an alternative procedure 
was used to afford the free selenol needed for the ligation. Gieselman reported that 
oxidative cleavage of the PMB group could be accomplished with I2 in AcOH and was 
the preferred method for PMB deprotection in early C112U azurin studies.19 However, 
this procedure is known to cause deselenization and was noted to decrease overall peptide 
yields. Additionally, other reagents have been reported to successfully deprotect PMB 
protected selenols and thiols but many of these reagents are harsh, do not result in full 
deprotection of the thiol/selenol, and promote deselenization.24-26 A review of these 
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techniques was published explaining the advantages and disadvantages of each of these 
techniques.27,28  
The first method to remove the PMB group, affording peptide 3.11, was following 
the deprotection scheme from Gieselman by oxidative cleavage using I2 in AcOH 
(Scheme 3.2). The peptide was dissolved in 50% AcOH in 1:1 ACN/H2O containing I2 
and stirred at room temperature (RT) under N2 for 5 min. The peptide was then 
precipitated with cold Et2O and purified via RP-HPLC. This method yielded the selenol 
monomer (m/z = 1852.5) as well as the diselenide dimer (m/z = 3703) but contained 
significant levels of deselenated product (m/z = 1771). Peptide 3.11 is very susceptible to 
deselenization using these conditions as the Se-C bond is weaker compared to the 
selenyliodide anion27,28 (Scheme 3.2). Using I2 in AcOH yielded product that while PMB 
deprotected, resulted in high amounts of deselenated peptide and thus decreased overall 
yield of the desired C112U 17-mer peptide.   
 
 
Scheme 3.2: Oxidative PMB deprotection of peptide 3.10 with I2 in AcOH to synthesize peptide 3.11. 
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A second method to deprotect the PMB group is the use of catalysis with strong 
Lewis acids such as trimethylsilyl trifluoromethanesulfonate (TMSOTf) (Scheme 3.3). 
The unpurified PMB protected peptide 3.10 was dissolved in a ratio of 50:120:690:194 
m-cresol/thioanisole/TFA/TMSOTf and stirred under N2 for 30 min. The TFA and 
TMSOTf were removed carefully under reduced pressure, the peptide was lyophilized, 
and purified via RP-HPLC. MALDI-MS analysis showed the desired product (m/z = 
1852.06) but also large amounts of uncharacterized impurities. Deselenization occurs 
rapidly with this method because TMSOTf is a very strong Lewis acid. Furthermore, the 
reaction product oils out since m-cresol is retained with the peptide after extraction with 
ether. Like the oxidative deprotection with I2, deprotection with strong Lewis acids 
results in poor yields and impure material. 
 
 
Scheme 3.3: Lewis-acid catalyzed removal of PMB protection from peptide 3.10 to synthesize 3.11. 
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Removing the PMB protection through formation of a selenyl-sulfide by 
treatment with 2-nitrophenyl sulfenyl chloride (NpsCl) is an alternative route to harsh 
chemicals that result in deselenization (Scheme 3.4). However, Se-S bonds can be quite 
strong and difficult to break, even with reducing agents such as tris(2-
carboxyethyl)phosphine (TCEP). However, Hondal and coworkers noted that TCEP can 
reduce Se-S bonds when used in greater than a two-fold excess.21,28 Peptide 3.10 was 
treated with NpsCl in 50% MeCN, H2O, AcOH, and HCl (5:16:1) and stirred at RT for 
30 min. (Scheme 3.4). The volatile organics were removed under reduced pressure and 
the peptide was precipitated and purified via RP-HPLC. Using NpsCl for PMB 
deprotection results in peptide mixtures consisting of the free selenol peptide 3.11 (m/z = 
1852), the dimer peptide (m/z = 3704), and the Se(Nps) peptide (m/z = 2006). MALDI 
MS analysis showed a 1:2 ratio of the SeH:Se(Nps) monomers. Though yielding a ratio 
of products when using this method, all products are useful in EPL reactions because the 
Nps protection and diselenide peptide dimers can be reduced with reducing agents such 
as TCEP in the ligation buffer, freeing the selenol for participation in trans-
selenoesterification. Although resulting in functional peptides for EPL reactions, free Nps 
is very reactive and is known to produce side reactions with Trp residues within peptide 
sequences.29 Thus Trp oxidation was noticeable on the EPL ligated product and although 
such oxidized proteins could be removed during purification, such a deprotection scheme 
is not optimal. 
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Scheme 3.4: NpsCl mediated removal of PMB protection from peptide 3.10. 
 
 Hondal and coworkers recently developed an alternative selenyl-sulfide exchange 
group to remove the PMB group from selenols.27 Instead of NpsCl, 2,2’dithiobis(5-
nitropyridine) (DTNP) was used to facilitate PMB removal (Scheme 3.5). Therefore, 
Wang-resin bound peptide 3.10 was treated with 2% H2O, 2% triisopropylsilane, 2.5% 
thioanisole, and 1.3 equiv. DTNP in neat TFA at RT for 2 h. Similar to the NpsCl 
reaction, the DTNP reaction results in peptide mixtures of peptide 3.11, the free selenol 
peptide (m/z = 1852), the dimer peptide (m/z = 3704), and the Se(DTNP) peptide (m/z = 
2006). By minimizing the amount of DTNP used, higher yields of the free selenol peptide 
are achievable. However, an insufficient quantity of DTNP results in incomplete PMB 
deprotection. The quantity used by Hondal (1.3 equiv.) was sufficient to remove all PMB 
protection.27 Using DTNP to deprotect the selenol resulted in a product ratio of 1:3:3:4 
deselenization product:free selenol:dimer:Se(pys). All the peptides but the deselenated 
material are functional in EPL reactions because the Se bond and diselenide dimers are 
reduced by the TCEP present in the ligation buffers.  
Using DTNP to remove the PMB group is a superior methodology to using 
NpsCl. First, using DTNP yields more free selenol than when using NpsCl. Secondly, in 
contrast to NpsCl, the released pys group is non-reactive with other residues in the 
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protein. Finally, unlike NpsCl, where an additional reaction is required to remove the 
PMB group after cleavage from the resin, DTNP is added during the cleavage from the 
resin, eliminating the need for a separate reaction. Moreover, NpsCl reactions were 
usually completed after full purification of peptide 3.10, therefore requiring an additional 
HPLC purification step. With DTNP, only a single HPLC purification step is necessary, 
saving time and money.  
 
 
 
Scheme 3.5: DTNP mediated removal of PMB protection from peptide 3.10. 
 
 Once the purified peptide was available it was assessed by MALDI MS to ensure 
that Se was present. Because deselenization occurs in the presence of piperidine during 
the final Fmoc cleavage, verification that the correct mass was attributable to Se was 
necessary. The C112U 17-mer peptide isotopic distribution (C80H133N21O22SSe, Exact 
Mass: 1851.88) was simulated using the Applied Biosystems Data Explorer program 
(version 4). The peptide was then checked using MALDI MS TOF analysis in reflective 
mode to get the monoisotopic mass of the peptide, verifying the correct isotopic 
distribution (Figure 3.3). The analysis showed that the monoisotopic mass and isotopic 
distribution of the C112U 17-mer matched the simulated data, thereby verifying the 
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correct isotopic distribution pattern expected for a peptide containing one selenium atom. 
 
 
 
Figure 3.3: Isotopic distribution of non-enriched C112U azurin 17-mer. A) Raw experimental data shows 
expected distribution for a 17-mer peptide containing a single Se atom. B) Simulated data 
(C80H133N21O22SSe, m/z = 1851.88) using Applied Biosystems Mass Explorer program.  
 
 
A 
B 
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3.5 OPTIMIZATION AND SEMI-SYNTHESIS OF C112U AZURIN 
Azurin is well suited for EPL because the protein is relatively small at 128 amino 
acids in length (Figure 3.4). Furthermore, three of the four copper binding ligands are 
found within the C-terminal 17 amino acids (H2N-CTFPGHSALMKGTLTLK-COOH) of 
the protein, making substitutions at these positions conveniently accessible.  
 
AECSVDIQGN DQMQFNTNAI TVDKSCKQFT 
VNLSHPGNLP KNVMGHNWVL STAADMQGVV 
TDGMASGLDK DYLKPDDSRV IAHTKLIGSG 
EKDSVTFDVS KLKEGEQYMF FCTFPGHSALMKGTLTLK 
 
Figure 3.4: N-terminal to C-terminal amino acid sequence of Pseudomonas aeruginosa azurin. Bold 
residues are those involved in copper binding. The final 17 amino acids synthesized by SPPS are italicized. 
 
To accomplish incorporation of selenocysteine into azurin using EPL, the 
procedures established by Berry were followed.8 The first 111 amino acids of azurin were 
recombinantly expressed as an Intein-Chitin binding domain (CBD) fusion using NEB 
vector PtxB1 intein splicing technology. Attempts to isolate the recombinant azurin-
thioester were unsuccessful due to its insolubility and facile thioester hydrolysis. 
Attempts at solubilizing the precipitated protein with guanidinium hydrochloride 
(GdmCl) were also unsuccessful when attempting to run EPL reactions. Therefore 
ligations were performed on column with the final 17 amino acid peptide in the presence 
of an external thiol catalyst.  
Initial EPL reactions were completed in TRIS 
(tris(hydroxymethyl)aminomethane) buffer. However, after exchanging buffers to MOPS 
(3-(N-morpholino)propanesulfonic acid), large amounts of white precipitate, attributable 
!!!!
!
!
83 
to hydrolyzed thioester, as well as full length (FL) product were present. To test both the 
performance of different buffers during the ligation step and the optimal pH, ligation 
experiments were performed in various buffers at various pH values. HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), MOPS, TRIS, tricine (N-
(tri(hydroxymethyl)methyl)glycine), and potassium phosphate buffers were tested at 50 
mM concentrations at pH 7.2 and 8.0 (Figure 3.5). EPL reactions performed in HEPES 
buffer at pH 8 yielded the most ligated protein and the least amount of precipitate 
following buffer exchange (Figure 3.5). Interestingly, close inspection of the byproducts 
of EPL reactions that were performed in TRIS buffer revealed peptide masses consistent 
with the sequential addition of TRIS by MALDI-MS. Calculations show that the TRIS 
ligand may be adding into Lys residues and interferes with trans-selenoesterification. 
Therefore, EPL reactions were completed in HEPES buffer at pH 8. 
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Figure 3.5: EPL performed in differing buffers at pH 8.0. HEPES buffer displays the best RL ratio. 
 
The ratio of the A280 and A675 peaks, RL [=#(high energy)/#(low energy)], 
provides a means to measure the contribution of the LMCT and serves as a crude method 
to determine Cu binding efficiency.30 Even in the optimized buffer system, the RL value 
of C112U (RL = 15) compared to WT azurin (RL = 2) was low, suggesting the protein 
inefficiently bound Cu, even though the C112U azurin variant has a lower extinction 
coefficient than WT azurin.9 Decreased Cu binding can be attributed to poor protein 
folding. The folding of azurin has long been studied and debated throughout the 
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literature,31-38 but one facet clearly aids in determining how well the protein is folded. A 
buried tryptophan residue (Trp48) located at the " turn within the azurin structure 
displays an extraordinary pronounced absorbance at 291 nm when the protein is correctly 
folded.33 This is due to the rigidity from the hydrophobic area of the protein that the Trp 
residue is buried within. When the Cu is correctly bound, and the protein is folded 
correctly, the A280 shows a sharp peak at A291.33 However, if the protein is incorrectly 
folded or conformational heterogeneity of the active site exists, this sharp peak is absent.  
The apo-C112U Az A280 peak showed a broad A291 peak, suggestive of poor 
folding which ultimately contributes to poor Cu binding. To increase proper protein 
folding apo-C112U azurin was refolded in the presence of GdmCl and DTT 
(dithiothreitol), a process used in the Lu laboratory to refold WT azurin that typically 
results in higher RL values for mutants that are poorly folded. When used for C112U 
azurin, the procedure resulted in complete loss of the A280 and no protein with the C112U 
mutant. The protein degradation is likely a result of oxidative damage to the protein 
scaffold and deselenization of the Sec112 residue in the presence of DTT. The C112U 
protein may be more susceptible to both inefficient ligation and improper protein folding 
as the selenol is much easier to oxidize than the free thiol, supporting why the C112U 
protein is unable to be properly refolded. 
 Though unable to solve the refolding issue via a refolding step, another method to 
reduce folding issues was to perform ligations anaerobically under an Ar atmosphere. 
The EPL reactions were run in an Ar purged column under an Ar atmosphere for 66 h 
before elution under Ar. Performing the ligations in an anaerobic environment increased 
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protein yields (0.32 mg/L growth) as well as the amount of correctly folded protein. 
Having now established a new buffer condition (HEPES, pH 8) and that ligations 
required an anaerobic environment to provide better yields of correctly folded protein, the 
only remaining variable to further increase ligation efficiency was the thiol catalyst. Kent 
demonstrated that the leaving group reactivity of the thiol catalyst balanced with its 
thiophilicity are important for efficient transthioesterification.39 Thus alkyl-thiols are 
inferior to aryl-thiols because they are poor leaving groups. Aryl-thiols with pKa values 
higher than 6.5 selectively participate in transthioesterification. To test whether MESNa 
(sodium 2-mercaptoethanethiosulfonate) used in ligations discussed thus far, was an 
inferior thiol catalyst choice in C112U azurin EPL reactions, four alternative thiols, N-
methylmercaptoacetamide (NMA), 4-methylbenzenethiol (4-MeBzlthiol), 4-
methoxybenzenethiol (4-MeOBzlthiol), and 4-mercaptophenylacetic acid (MPAA) were 
tested for their ability to increase the yield of the obtained product. NMA, 4-MeBzlthiol, 
and 4-MeOBzlthiol have prohibitive smells whereas MPAA has no discernable smell. 
Neither NMA nor 4-MeOBzl thiol resulted in appreciable increases in protein yields, 
likely due to NMA’s poor leaving group efficiency and 4-MeBzlthiol’s low solubility in 
water. No ligation was noted in ligations using the MeBzlthiol likely due to its lower 
solubility in water than 4-MeOBzlthiol. However, using MPAA resulted in significant 
yield increases (0.42 mg/L growth) and was used exclusively thereafter. 
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3.6 CHARACTERIZATION OF SELENOCYSTEINE AZURIN 
The optimized procedure using HEPES buffer, pH 8, anaerobic conditions, and 
MPAA as the thiol catalyst resulted in a C112U azurin mutant that was spectroscopically 
identical to the previously reported protein but with better yield (~0.4 mg/L cell growth) 
than the previously reported yield (~0.25 mg/L cell growth) (Figure 3.6).8,9 With the 
optimized procedures in place, semi-synthesis of a 77Se enriched C112U variant was 
undertaken. 
 
  
Figure 3.6: Spectroscopic characterization of C112U azurin compared to WT azurin A) UV-Vis spectrum 
B) EPR spectrum. 
 
3.7 SYNTHESIS OF 77SE-SEC(PMB) AND SPPS OF 77SE-C112U 17MER. 
Introducing 77Se enriched Sec into azurin can provide insight into the location of 
the electron density of the free electron in the cuprice type I site. Laboratories have 
debated for decades about the distribution of the free electron on the bound Cu(II) in 
azurin.5,40-42 Recent DFT calculations using crystal structures of azurin, its mutants, and 
some relatives, suggested that approximately 27% of the electron density resides on the 
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Cu and 60% resides on the Cys(S) ligand.15 The remaining 3% is scattered through the 
His ligands.40 Using ENDOR spectroscopy and incorporating a $ spin labeled 77Se-Sec 
ligand in the azurin type I site could provide precisely calculated electron contributions 
for the Cu and the Sec(Se) ligand. 
 Fmoc-77Se-Sec(PMB)-OAll was previously synthesized through a collaborative 
effort between the van der Donk laboratory and Pete Silks at Los Alamos National 
Laboratory. Only the final allyl deprotection step was necessary. Therefore, the optimized 
allyl deprotection strategy from Scheme 1 was used to afford the enriched Fmoc-77Se-
Sec(PMB)-OH derivative in a 90% yield. The optimized SPPS techniques outlined for 
the non-isotopic enriched sample where followed to make peptide 3.20 and the PMB 
group was removed using DTNP to afford the free selenol peptide 3.21. The peptide was 
analyzed for the correct monoisotopic mass and simulations were run using the Applied 
Biosystems Data Explorer program (version 4) to simulate the isotopic distribution 
pattern for the 17-mer peptide containing a 77Se enriched Sec atom (C80H133N21O22S77Se, 
Exact Mass: 1848.89). Figure 3.7 shows that the synthesized peptide has the correct 
monoisotopic mass and the correct isotopic distribution pattern expected for a peptide 
containing one 77Se enriched selenium atom. 
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Figure 3.7: Isotopic distribution of 77Se-enriched C112U azurin 17-mer. A) Raw experimental data shows 
expected distribution for a 17-mer peptide containing a single 77Se atom. B) Simulated data 
(C80H133N21O22S77Se, Exact Mass: 1848.89) using Applied Biosystems Mass Explorer program. 
 
A 
B 
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3.8 SEMI-SYNTHESIS OF 77SE-C112U AZURIN 
The optimized EPL conditions developed for non-isotopically enriched C112U 
azurin were used for the incorporation of the enriched 77Se-Sec into azurin. Ligations 
proceeded for 66 h on the chitin column and were eluted, concentrated, and titrated with 
Cu(II). As shown in Figure 3.8, the 77Se-C112U variant bound copper in an acceptable 
RL ration of 3.5. The LMCT band remained red-shifted from WT azurin at 675 nm 
(Figure 3.8). 
 
 
Figure 3.8: UV-Vis spectrum for 77Se C112U azurin. 
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With the semi-synthesis and purification of the 77Se-C112U azurin protein 
complete, X-Band EPR was performed before shipping the sample to Dr. David Britt’s 
laboratory at the University of California, Davis for ENDOR spectroscopy (Figure 3.9). 
The 77Se-C112U azurin spectrum displayed the same g values as the non-enriched protein 
but had more features along g#, suggesting that the $ spin of the 
77Se atom may be 
altering the spectrum.8,9 
 
Figure 3.9: X-band EPR spectrum for 77Se C112U azurin. 
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3.9 77SE C112U AZURIN ENDOR ANALYSIS 
 The 77Se-C112U protein was shipped to David Britt’s laboratory with the 
intention of obtaining clean Electron-Nuclear Double Resonance (ENDOR) spectroscopy 
corroborating electron contributions of the Cu and the Sec(Se) ligand. However, no 
simulation parameters were available for a 77Se atom and had to be created before any 
simulations could be performed. Once the parameters were created, initial ENDOR 
spectra showed narrow nitrogen couplings (Figure 3.10). Nitrogens in the WT and 
nonenriched sample have quadrupolar couplings that broaden the ENDOR signal beyond 
detection while the nitrogens in the 77Se mutant do not broaden the signal and are 
detectable.  
 
Figure 3.10: Proton Q-band ENDOR. Larmor frequency set to zero. 
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After struggling to find a region for the 77Se signal, EPR power dependency on 
the 77Se C112U protein revealed an unusual contribution to the signal on the high field 
end (Figure 3.11 blue arrow). The feature grows in with increased power, and the signal 
appears saturated. However, after running ENDOR in the expected region of the 77Se 
hyperfine tensor, 1-150 MHz, no signal was detectable. Numerous setbacks, including 
instrumentation failure, cavity contamination, and insufficient concentrations of protein 
have thus far limited progress in providing evidence for the electron contributions of Cu 
and Sec(Se) in azurin. 
 
 
Figure 3.11: ENDOR preparation. EPR power dependency for 77Se C112U Az. The blue arrow indicates 
the location of the unknown growing feature. 
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3.10 CONCLUSIONS 
 Optimizing the incorporation of Sec into azurin using EPL resulted in significant 
yield increases of holo-protein (0.42 mg/L from 0.2 mg/L).8,9 The newly optimized 
synthetic schemes for synthesis of the Sec(PMB) derivative and the SPPS of the 17-mer 
peptide were used to synthesize a 77Se enriched C112U 17-mer peptide in high yields 
(60-80 mg). The same optimized EPL reactions for the non-enriched C112U azurin 
variant were used to semi-synthesize a 77Se-C112U azurin variant that displayed similar 
spectra to the non-enriched species. However, using the enriched holo-protein has yet to 
reveal the electron contribution of the Cu and the Sec(Se) ligand due to unforeseen 
complications in the laboratory of our ENDOR collaborator.  
 
3.11 FUTURE DIRECTIONS 
 New enriched protein is necessary in a higher concentration to hopefully provide 
sufficient material for ENDOR. Conditions that identify the 77Se signal in the ENDOR 
spectra are absolutely necessary before continuing with the project. If parameters cannot 
be established to identify and simulate 77Se signals to compare with both WT azurin and 
the non-enriched C112U azurin variant, then a new strategy must be adopted to 
experimentally determine the electron density of the free electron in the azurin type I site.  
 
3.12 EXPERIMENTAL 
General. All chemicals used were obtained from Aldrich. All amino acids were 
purchased from Novabiochem, Advanced Chemtech, or Chem-Impex International. 
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Protecting groups used for Fmoc-SPPS were Cys(Trt), Ser(OtBu), Glu(OtBu), 
Cys(StBu), Asn(Trt), His(Trt), Lys(Boc), Thr(OtBu). Methylene chloride (DCM) was 
distilled from calcium hydride. Tetrahydrofuran (THF) was distilled from sodium and 
benzophenone. All aqueous buffers were degassed under Ar or N2 as specified 
immediately prior to use.  
All NMR spectra were obtained with either a Varian U400 or U500 NMR 
Spectrometer in CDCl3. UVVis spectra were taken on an HP Diode Array Spectrometer 
or a Cary 5000 spectrometer. X-band EPR spectra were collected on a Varian E-122 
spectrometer at the Illinois EPR Research Center (IERC). The samples were run at ~30 K 
using liquid He and an Air Products Helitran cryostat without glassing agents. The 
magnetic field was calibrated using a Metrolab PT 2025 NMR Gaussmeter, and the 
microwave frequency was measured with an EIP model 578-frequency counter equipped 
with a high-frequency option.  
Mass spectral data was collected by the Mass Spectrometry Laboratory, School of 
Chemical Sciences, University of Illinois by either Electrospray Ionization (ESI MS), or 
matrix assisted laser desorption ionization (MALDI) techniques as indicated. Mass 
spectral data are reported as – mass, peak (percent).  
Preparative RP-HPLC was performed with a Waters Delta 600 system. Solution A 
was 0.1 % TFA in H2O, and solution B was 80 % MeCN/20 % H2O with 0.1 % TFA. 
Unless otherwise stated, a linear gradient of 20% to 70% B over 23 min was used for all 
runs. Solid phase peptide synthesis (SPPS) was performed on a Rainin PS3 automated 
peptide synthesizer or manually using medium Büchner fritted funnels.43 
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Fmoc-L-Serine-OAll (3.1), Lab Book I, page 6.  
Fmoc-L-Serine (10.0 g, 30.5 mmol) and NaHCO3 (2.56 g, 30.5 mmol) were 
dissolved in ddH2O (46.9 mL) under N2. Allyl bromide (2.91 mL, 33.49 mmol) and 
aliquat-336 (12.33 g, 30.5 mmol) were dissolved in CH2Cl2 (46.9 mL) and added to the 
amino acid mixture mixture. The reaction was stirred vigorously at 25 °C under N2 for 24 
h. Allyl bromide (2.91 mL, 33.49 mmol) was added after 24 h of stirring and the reaction 
was stirred at 25 °C under N2 for another 48 h. The reaction was extracted with CH2Cl2, 
dried over MgSO4, filtered, and the solvent evaporated. The mixture was purified by 
silica gel flash chromatography (2:1 hexane/EtOAc) to obtain product as a white solid (Rf 
= 0.12, 2:1 hexane/EtOAc). (Yield: 10.7 g, 95%). 1H NMR (CDCl3, 500 MHz) $ 2.33 (s, 
1 H), 3.96 (d, 1 H, J = 10.3 Hz), 4.03 (d, 1 H, J = 10.1 Hz), 4.23 (t, 1 H, J = 6.9 Hz), 4.43 
(m, 2 H), 4.48 (m, 1 H), 4.69 (d, 2 H, J = 5.3 Hz), 5.26 (dd, 1 H, J = 0.8, 10.5 Hz), 5.37 
(dd, 1 H, J = 0.8, 17.2 Hz), 5.69 (d, 1 H, J = 7.4 Hz), 5.91 (ddt, 1 H, J = 16.6, 11.0, 5.5 
Hz), 7.32 (t, 2 H, J = 7.4 Hz), 7.41 (t, 2 H, J = 7.4 Hz), 7.60 (m, 2 H), 7.76 (d, 2 H, J = 
7.6 Hz). 
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Fmoc-(OTs)-L-Serine-OAll (3.2), Lab Book I,  page 88.  
TsCl (5.19 g, 27.21 mmol) was dissolved in pyridine (11 mL) and stirred at 25 °C 
for 5-10 min. The reaction mixture was added to solid Fmoc-L-Serine-OAll (2.0 g, 5.44 
mmol) under Ar and stirred under Ar for 14 h at 0 °C. The reaction was quenched with 
EtOAc (50 mL) and the organic layer was washed with ddH2O, 10% KHSO4, saturated 
NaHCO3, and brine. The organic layer was dried over MgSO4, filtered, and the solvent 
evaporated. The reaction was purified quickly by silica gel flash chromatography (3:1 
hexane/EtOAc) to obtain a clear oil. The oil was azeotroped with CH2Cl2 (3 x 50 mL) 
and with Et2O (3 x 50 mL) to obtain product as a white solid. (Rf = 0.19, 3:1 
hexane/EtOAc). (Yield: 4.2 g, 79%). 1H NMR (CDCl3, 500 MHz) $ 2.36 (s, 3 H), 4.19 (t, 
1 H, J = 7.5 Hz), 4.27 (dd, 2 H, J = 10.2, 7.2 Hz), 4.36 (m, 2 H), 4.45 (dd, 2 H, J = 10.2, 
3.0 Hz), 4.61 (m, 2 H), 4.67 (m, 1 H), 5.27 (dd, 2 H, J = 10.4, 0.9 Hz), 5.33 (dd, 1 H, J = 
17.2, 1.0), 5.65 (d, 1 H, J = 7.7 Hz), 5.84 (m, 1 H), 7.26 (t, 2 H, J = 8.7 Hz), 7.33 (m, 2 
H), 7.42 (t, 2 H, J = 7.1, 2.2 Hz), 7.60 (t, 2 H, J = 8.4 Hz), 7.77 (m, 4 H). 
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Di-p-methoxybenzyl diselenide ((PMBSe)2) (3.3). Lab Book I, page 80.  
Selenium powder (2.0 g, 25.3 mmol) was suspended in dry THF (12 mL) and 
purged with Ar. The mixture was brought to a reflux prior to adding 1 M LiB(Et3)H (25.1 
mL, 25.1 mmol) dropwise. The mixture was refluxed for 45 min under Ar. In a separate 
round bottom flask, p-methoxybenzylchloride (PMBCl) (3.62 mL, 26.6 mmol) was 
dissolved in dry THF (12 mL) and cooled to -78 °C. The refluxing mixture was cooled to 
25 °C and transferred to the cold flask containing PMBCl via cannulation. The mixture 
was stirred at -78 °C for 45 min and then slowly warmed to 25 °C over 1 h. The reaction 
mixture was quickly run through a silica gel plug using 5:1 hexane/EtOAc and purified 
by silica gel flash chromatography (9:1 hexane/EtOAc) to obtain yellow solid which was 
recrystallized in EtOH to obtain final product as light yellow solid. (Rf = 0.5, 5:1 
hexane/EtOAc). (Yield: 3.99 g, 81%). 1H NMR (CDCl3, 400 MHz) $ 3.80 (s, 6 H), 3.84 
(s, 4 H), 6.83 (d, 4 H, J = 8.4), 7.17 (d, 4 H, J = 8.4). 
 
 
  
!!!!
!
!
99 
 
Fmoc-(Se)-p-methoxybenzylselenocysteine-OAll (3.4), Lab book II, page 36.  
A three-necked round bottom flask was charged with compound 3.3 (2.56 g, 6.39 
mmol), purged with Ar and dissolved in dry THF (15 mL). The mixture was brought to a 
reflux prior to adding 50% H3PO2 (23 mL) dropwise. The reaction was then refluxed for 
an additional 1 h. The refluxing mixture was cooled to ambient temperature, quickly 
extracted with Et2O, and washed with brine. The combined organic layers were dried 
with MgSO4, filtered, and the solvent removed to obtain a yellow oil. The resultant 
selenol was dissolved in degassed DMF (15 mL), purged with Ar, and cooled to 0 ºC. 
Degassed 1 M NaOH in ddH2O (4.5 mL, 4.5 mmol) was added to the flask followed 
immediately by compound 3.2 (2.1 g, 4.03 mmol) dissolved in degassed acetone (15 mL). 
The mixture was stirred at 0 °C for 2-4 h. The reaction was taken up in EtOAc (50 mL) 
and washed with saturated NH4Cl and brine (3 x 75 mL each). The organic layer was 
dried over MgSO4 and the solvent evaporated. The reaction was purified by silica gel 
flash chromatography (6:1 hexane/EtOAc) to obtain final product as white solid. (Rf = 
0.29, 6:1 hexane/EtOAc). (Yield: 1.85 g, 84%). 1H NMR (CDCl3, 400 MHz) $ 2.94 (1H, 
B of ABX, JAB = 13.0 Hz, JBX = 5.5 Hz), 3.77 (s, 5 H), 4.24 (t, 1 H, J = 6.8 Hz), 4.42 (d, 2 
H, J = 6.8 Hz), 4.66 (d, 2 H, J = 5.6 Hz), 4.7 (1H, X of ABX, JBX = 5.5 Hz, JAX = 4.4 Hz), 
5.26 (dd, 1 H, J = 10.4, 1.1 Hz), 5.36 (dd, 1 H, J = 17.2, 1.0 Hz), 5.55 (d, 1 H, J = 7.9 
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Hz), 5.90 (m, 1 H), 6.83 (d, 1 H, J = 8.4 Hz), 7.20 (d, 2 H, J = 8.4 Hz), 7.31 (m, 2 H), 
7.40 (m, 2 H), 7.61 (t, 2 H, J = 6.2 Hz), 7.77 (dd, 2 H, J = 7.8, 2.1 Hz). 
 
 
Fmoc-Se-p-methoxybenzylselenocysteine-OH (3.5), Lab book II, page 41.  
Pd(PPh3)4 (31.4 mg, 0.027 mmol) and PPh3 (8 mg, 0.027 mmol) were combined 
in a dried round bottom flask and purged with Ar. The flask was covered with aluminum 
foil and CH2Cl2 (5 mL) was added. Na-2-ethylhexanoate (181 mg, 1.09 mmol) dissolved 
in CH2Cl2 (5 mL) was added to the Pd catalyst and the reaction was stirred vigorously at 
25 °C for 15 min under Ar. The reaction was taken up in EtOAc (50 mL) and washed 
with 2 M HCl and 4 M HCl (2 x 50 mL each). The organic layer was dried over MgSO4 
and the solvent evaporated to obtain a yellow oil. The mixture was purified by silica gel 
flash chromatography (35:1 CH2Cl2/MeOH with 0.1% AcOH (v/v)) to obtain final 
product as white solid. (Rf = 0.5, 9:1 CH2Cl2/MeOH). (Yield: 430 mg, 93%). 1H NMR 
(CDCl3, 500 MHz) $ 2.96 (br s, 2 H), 3.75 (s, 3 H), 3.76 (br s, 2 H), 4.23 (t, 1 H, J = 6.8 
Hz), 4.42 (d, 2 H, J = 6.8 Hz), 4.67 (m, 1 H), 5.52 (d, 1 H J = 7.2 Hz), 6.80 (d, 2 H, J = 
8.3 Hz), 7.18 (d, 2 H J = 8.1 Hz), 7.30 (t, 2 H, J = 7.4 Hz), 7.39 (m, 2 H), 7.60 (t, 2 H, J = 
6.7 Hz), 7.76 (d, 2 H J = 7.6 Hz). 
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H2N-U(PMB)TFPGHSALMKGTLTLK-COOH 
Synthesis of Peptide 3.10, Lab book IV, page 178.  
The peptide was synthesized on a 0.1 mmol scale. Fmoc Wang resin preloaded 
with Fmoc-Lys(Boc) was pre-swelled in DMF (6 x 10 min, 6 mL). Synthesis of the 
peptide from Lys128 through Thr113 was completed using a four-fold excess of amino 
acids pre-activated with 0.4 M N-methylmorpholine (NMM) (6 mL) and O-
benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (4 equiv) 
for 2 min prior to coupling to the resin. All Fmoc-deprotections were accomplished using 
20% piperidine/DMF (v/v) (3 x 3 min, 6 mL). Fmoc-Sec(PMB)-OH (3.5) (4 equiv.) was 
coupled manually in the presence of 1-hydroxybenzotriazole (HOBt) (8 equiv.) and N,N'-
diisopropylcarbodiimide (DIC) (8 equiv.) in DMF at room temperature (RT) for 2-5 h. 
The Fmoc was removed with 20% piperidine and the resin washed with DCM before 
cleavage. Amino acids were double coupled when necessary and couplings were 
monitored by qualitative ninhydrin test. (Yield: 90 mg). MALDI MS: Expected. 1972.2 
Observed. 1972.6. 
 
H2N-UTFPGHSALMKGTLTLK-COOH 
Synthesis of Peptide 3.11 Using I2 in AcOH, Lab book 4, page 106.  
Peptide 3.10 (40 mg, 0.02 mmol) was placed into a round bottom flask and 
purged with N2.  I2 (6 mg, 0.02 mmol) dissolved in 8:1:1 AcOH/MeCN/H2O (10 mL) was 
added to the peptide and the reaction was stirred at 25 °C for 5 min. The reaction was 
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quenched with 10% Na2S2O3 (10 mL) and lyophilized overnight before purifying by 
preparative RP-HPLC to yield the final product as white solid after lyophilization. (Yield: 
15 mg). MALDI MS. Expected: 1852.06 (SeH), Observed: 1774.1 (-Se), 1852.06 (SeH), 
1972.8 (SePMB); 3:1:2.  
 
H2N-UTFPGHSALMKGTLTLK-COOH 
Synthesis of Peptide 3.11 using TMSOTf, Lab book 4, page 107.  
Peptide 3.10 (12 mg, 0.006 mmol) was placed into a round bottom flask and 
purged with N2. Then 2.1 mL of 50:120:690:194 m-cresol/thioanisole/TFA/TMSOTf was 
added to the peptide and the reaction was stirred rapidly under N2 for 30 min. The solvent 
was removed via rotary evaporation and the crude product was lyophilized. The crude 
material was purified by preparative RP-HPLC to obtain a white solid that was later 
identified as deselenated peptide. No product was yielded. MALDI MS. Expected: 
1852.06, Observed: 1774.1 (-Se).  
 
H2N-UTFPGHSALMKGTLTLK-COOH 
Synthesis of Peptide 3.11 Using NpsCl, Lab book 4, page 106.  
Peptide 3.10 (49 mg, 0.025 mmol) and NpsCl (4.7 mg, 0.25 mmol) were 
combined in a round bottom flask and dissolved in 1:1 MeCN/H2O. The reaction was 
initiated by adding AcOH (3 mL) and 2 M HCl (75 µL) and stirred at 25 °C for 30 min. 
The solvent was removed by rotary evaporation and the peptide was triturated with cold 
!!!!
!
!
103 
Et2O. The peptide was dissolved in 1:1 MeCN/H2O (10 mL) and lyophilized prior to 
purification by preparative RP-HPLC to obtain a yellow solid. (Yield: 35 mg). MALDI 
MS. Expected: 1852.06 (SeH), 2006.6 (SeNps), Observed: 1852.06 (SeH), 2006.6 
(SeNps); 1:2. 
 
H2N-UTFPGHSALMKGTLTLK-COOH 
Synthesis of Peptide 3.11 Using DTNP, Lab book IV, page 178.  
Resin bound, Fmoc-deprotected peptide 3.10 (0.1 mmol) was washed with DCM 
and dried under reduced pressure for 10 min. The resin was transferred to a scintillation 
vial and 2,2’-dithiobis(5-nitropyridine) (DTNP) (1.3 mol equiv., 41 mg) was added. 2% 
(v/v) triisopropylsilane (100 µL) and 2% H2O (100 µL) were added followed by the 
addition of 2.5% (v/v) thioanisole (125 µL). Cleavage was initiated by the addition of 5 
mL of neat TFA and the reaction was stirred at 25 °C for 2 h.  The reaction was filtered 
through a coarse grain Büchner funnel and the resin was washed with neat TFA (3 x 5 
mL). The solvent was removed via rotary evaporation to obtain a yellow oil. The peptide 
was precipitated by the addition of cold Et2O and pelleted by centrifugation at 2000 x g 
for 5 min. The pellet was washed iteratively with Et2O (3 x 30 mL) with centrifugation 
steps between each washing. The peptide was dissolved in a minimal amount of 1:1 
MeCN/H2O and lyophilized overnight. The crude lyophilized product was purified by 
RP-HPLC C18 column to obtain final product as yellow solid. (Yield: 81 mg). MALDI 
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MS. Expected: 1852.06 (SeH), 2006.21 (Se(pys)), 3704.1 (Dimer), Observed: 1853.18 
(M+1H), 3703.69 (Dimer). 
 
 
Fmoc-77Se-p-methoxybenzylselenocysteine-OH (3.7), Lab book V, page 8.  
A round bottom flask was charged with Pd(PPh3)4 (21.07 mg, 0.05 mmol) and 
PPh3 (4.72 mg, 0.05 mmol) and purged with Ar. A second round bottom flask was 
charged with Fmoc-(77Se)-p-methoxybenzylselenocysteine-OAll (3.6) (200 mg, 0.365 
mmol) and 1.3 equiv. sodium 2-ethylhexanoate (61.22 mg, 0.368 mmol) and purged with 
Ar. The contents of each flask were dissolved in dry THF (5 mL). The contents of the 
amino acid flask were transferred to the Pd catalyst via cannulation under Ar pressure. 
The reaction was covered with foil and stirred vigorously at 25 °C for 15-20 min. The 
reaction was quenched with EtOAc (50 mL) and the organic solution was washed with 2 
M, 4 M, and 6 M HCl (2 x 40 mL each). The organic layer was dried over MgSO4 and 
the filtrate stirred gently with PS-PPh3 resin at 25 °C for 10-20 min. The organics were 
filtered from the PS-PPh3 resin using a coarse fritted Büchner funnel and the resin was 
washed with EtOAc (3 x 20 mL). The solvent was removed by rotary evaporation to 
obtain a yellow oil. The oil was purified by silica gel flash chromatography (35:1 
CH2Cl2/MeOH with 0.1% AcOH (v/v)) to obtain final product as white solid. (Rf = 0.5, 
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9:1 CH2Cl2/MeOH). (Yield: 164.2 mg, 89%). 1H NMR (CDCl3, 500 MHz) $ 2.94 (d, 2 
H), 3.75 (s, 2 H), 3.77 (br s, 2 H), 4.23 (t, 1 H, J = 6.8 Hz), 4.41 (d, 2 H, J = 6.8 Hz), 4.67 
(m, 1 H), 5.51 (d, 1 H, J = 7.2 Hz), 6.81 (d, 2 H, J = 8.3 Hz), 7.17 (d, 2 H, J = 8.1 Hz), 
7.30 (t, 2 H, J = 7.4 Hz), 7.39 (m, 2 H), 7.60 (t, 2 H, J = 6.7 Hz), 7.76 (d, 2 H, J = 7.6 
Hz). 
 
H2N-77U(PMB)TFPGHSALMKGTLTLK-COOH 
Synthesis of Peptide 3.20, Lab book V, page 9.  
The peptide was synthesized on a 0.1 mmol scale. Fmoc Wang resin preloaded 
with Fmoc-Lys(Boc) was pre-swelled in DMF (6 x 10 min, 6 mL). Synthesis of the 
peptide from Lys128 through Thr113 was completed using a five-fold excess of amino 
acids pre-activated with 0.4 M N-methylmorpholine (NMM) (6 mL) and O-
benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (5 equiv) 
for 2 min prior to coupling to the resin. All Fmoc-deprotections were accomplished using 
20% piperidine/DMF (v/v) (3 x 3 min, 6 mL). Fmoc-77Se-Sec(PMB)-OH (3.7) (3 equiv.) 
was coupled manually in the presence of hydroxybenzotriazole (HOBt) (6 equiv.) and 
N,N'-diisopropylcarbodiimide (DIC) (6 equiv.) in DMF at room temperature (RT) for 2-5 
h under N2 sparging. The Fmoc group was removed with 20% piperidine and the resin 
washed with DCM before cleavage. Amino acids were double coupled when necessary 
and couplings were monitored by qualitative ninhydrin test. (Yield: 50 mg). 
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H2N-77UTFPGHSALMKGTLTLK-COOH 
Synthesis of Peptide 3.21, Lab book V, page 9. 
Resin bound, fully protected peptide was washed with DCM and dried under 
reduced pressure for 10 min. The resin was transferred to a scintillation vial and 2,2’-
dithiobis(5-nitropyridine) (DTNP) (1.3 mol equiv., 41 mg) was added to the resin. 2% 
(v/v) triisopropylsilane (100 µL) and 2% H2O (100 µL) were added to the scintillation 
vial followed by the addition of 2.5% (v/v) thioanisole (125 µL). Cleavage was initiated 
by the addition of 5 mL of neat TFA and the reaction was stirred at 25 °C for 2 h.  The 
cleavage mixture was filtered through a coarse grain Büchner funnel and the resin was 
washed with neat TFA (3 x 5 mL). The solvent was removed by rotary evaporation to 
obtain a yellow oil. The peptide was precipitated by the addition of cold Et2O. The 
peptide was pelleted by centrifugation at 2000 x g for 5 min and the pellet was washed 
iteratively with Et2O (3 x 30 mL) with centrifugation steps between each washing. The 
peptide was then dissolved in a minimal amount of 1:1 MeCN/H2O and lyophilized 
overnight. The crude lyophilized product was purified by RP-HPLC C18 column to 
obtain final product as yellow solid. (Yield: 50 mg). MALDI MS; Calculated. 1850.06 
(SeH), 2004.21 (Se(pys)), 3700.1 (Dimer) Observed. 1850.29 (M), 3698.9 (Dimer). 
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General procedure for expressed protein ligation for nonenriched C112U Azurin, 
Lab Book VI, page 174. 
Cultures of E. coli BL21 (DE3) cells containing a plasmid to express the azurin(1-
111)-Intein-CBD fusion protein were grown in LB media for 8 h at 37 ºC and were used 
to inoculate eight 2 L flasks of LB media containing 100 mg/mL ampicillin. The cells 
were grown at 37 ºC for 16 h with shaking at 210 rpm. Protein expression was induced at 
~16 h with 0.3 mM IPTG and induction was continued for 4 h at 37 ºC. The cells were 
then harvested at 9800 x g, stored at -20 ºC and used when needed.  
Frozen azurin-thioester cell stock was re-suspended in a lysis buffer containing 20 
mM HEPES, pH 7.2, 250 mM NaCl, 1 mM EDTA, 1 mM PMSF, and 0.1% Triton-X-
100. The crude lysate was by lysed sonication (9 min work time: 6 s on, 10 s rest). After 
the second pass, the lysate was treated with 2 M urea for 10 min with gentle stirring at 4 
°C. The lysate was centrifuged at 13250 x g for 30 min. at 4 °C. The fusion protein was 
then bound by batch absorption to 70 mL of chitin resin that had been pre-equilibrated 
with 20 mM HEPES, pH 8.0, 250 mM NaCl, and 1 mM EDTA (buffer 1) for 1-2 h at 4 
ºC. The chitin resin was then poured into a column and the column headspace was purged 
with Ar. The column was then washed with 3 column volumes of degassed buffer 1 
containing 2 M urea under Ar pressure followed by 5-7 column volumes degassed buffer 
1.  
Ligation was initiated by the addition of peptide (0.52 mM, 50 mg) and tris-(2-
carboxyethyl)phosphine (TCEP) (1.2 mM, 17 mg) in 50 mL of buffer 1 containing 50 
mM sodium 2-mercaptoethansulfonate (MESNa) under Ar directly to the column. The 
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chitin resin was then re-suspended in the column and the entire column was agitated 
gently at 4 ºC for 66 h.  
After ligation, the column was eluted under Ar pressure and washed with 1 
column volume of buffer 1. The eluent was centrifuged at 13250 x g for 30 min and the 
supernatant was concentrated 5x using 10,000 MWCO Centricon concentration spin 
tubes at 2000 x g and the buffer exchanged to 50 mM MOPS, pH 6.6 via G25 sephadex 
PD-10 columns. The desalted sample was then titrated with incremental additions of 
freshly made CuSO4 solution (20 mM) in ddH2O that had been pretreated with chelex. 
The titration was performed at 4 ºC until maximal absorbance at 675 nm was reached. 
Samples were then purified via FPLC using anion exchange chromatography. The 
samples were purified using a Pharmacia Q HiTrap HP column (5 mL) which had been 
washed with 10 column volumes of buffer B (A: 50 mM MOPS, pH 6.6; B: 1 M NaCl in 
H2O) and then equilibrated with 10 column volumes of buffer A.  
 
General procedure for expressed protein ligation for 77Se enriched C112U Azurin, 
Lab Book VII, page 94.   
The ligations were carried out identically to the non-isotopically enriched samples 
with the following changes. The 77Se-Sec 17-mer peptide (1.3 mM, 71 mg) and tris-(2-
carboxyethyl)phosphine TCEP (2.6 mM, 23 mg) were dissolved in 30 mL Buffer 1 
containing 50 mM 40-mercaptophenylacetic acid (MPAA) under Ar and transferred to 
the column under Ar. The column was then shaken gently at 4 °C for 66 h. After ligation, 
the column was eluted under Ar pressure and washed with 1 column volume of Buffer 1. 
!!!!
!
!
109 
The eluent was centrifuged at 13250 x g for 30 min and the supernatants were combined 
and concentrated using 10,000 MWCO centricon concentration spin tubes at 2000 x g. 
The buffer was exchanged to 50 mM MOPS Buffer, pH 6.6 via PD10 (G25 sephadex) 
columns. The desalted sample was then concentrated to 2 mL and purified by a S-100HR 
SEC column (20 mL bed volume). The fractions containing protein were pooled, 
concentrated and titrated with incremental additions of freshly made CuSO4 solution (20 
mM) in ddH2O that had been pretreated with chelex. The titration was performed at 4 ºC 
until maximal absorbance at 675 nm was reached. Samples were then purified via a 
second S-100HR SEC column. 
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CHAPTER 4: 
TRANSFORMING BLUE COPPER TO RED COPPER: MET121HCY AZURINi ii 
 
4.1 INTRODUCTION 
Mononuclear copper sites are separated into two distinct classes, the type 1 or 
blue copper proteins and type 2 copper proteins. The blue copper proteins are 
characterized by their unique strong blue color due to an intense visible absorption 
around 600 nm (! ~ 5000 M-1cm-1).1-3 They also exhibit narrow hyperfine coupling 
constants (A|| < 100 x 10-4 cm-1) in the electron paramagnetic resonance (EPR) spectrum 
and the spectra can be either axial (gz>gy"gx) or rhombic (gz>gy>gx) in nature.1,2 The type 
1 copper protein spectral features are in direct contrast to the type 2 copper proteins that 
have much weaker absorption in the visible region (! ~ 40 M-1cm-1) and wider hyperfine 
coupling constants (A|| > 150 x 10-4 cm-1).4,5  
The success in defining the spectroscopic properties of each site has advanced our 
knowledge in not only biocoordination chemistry but also has elucidated the biological 
functions of copper proteins. The unique type 1 copper structure is responsible for the 
interesting spectroscopic features,6-8 the high redox potentials,9-13 and the efficient 
electron transfer (ET) rates seen in type 1 proteins.14-18 As electron transfer proteins, type 
1 copper proteins participate in a myriad of biological processes and are required to 
possess tunable redox potentials and ET rates to match those of their partners.14-16,18 A 
current challenge in the field is to understand how type 1 copper proteins can tune their 
redox potentials and ET rates without losing their structural identity and functional 
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properties. A major avenue for such tuning is through the interaction between the axial 
ligand and copper.19,20 When the axial ligand is weakly coordinated to the copper ion, 
such as in azurin from Pseudomonas aeruginosa (Figure 4.1), the unique trigonal 
geometry makes it possible for the dx2-y2 ground state of Cu2+ to overlap most favorably 
with p# of the Cys ligand, resulting in the short Cu-S bond and giving a strong p#(Cys)-
to-Cu2+ charge transfer band around 600 nm.21,22 However, when the axial ligand 
becomes stronger, such as in nitrite reductase, a model called “coupled distortion” has 
been proposed where the strong axial ligand interaction with copper ion results in a 
correspondingly longer Cu-Cys bond and rotation of the dx2-y2 ground state of the Cu2+ 
ion so that it overlaps better with the p$ orbital of Cys.22 Thus a more intense p$(Cys)-to-
Cu2+ charge transfer band at higher energy (~ 400 nm) is observed while the p#(Cys)-to-
Cu2+ charge transfer band around 600 nm becomes less intense. This change results in a 
strong green color instead of blue color, and therefore these proteins with stronger 
“coupled distortion” are often called green copper proteins. For different type 1 copper 
proteins, the relative absorption ratios of 400 nm and 600 nm is a good measure of how 
strong the axial ligand-copper and Cu-Cys bonds are.23,24 The best manifest of the 
“coupled distortion” model is a recently discovered red copper protein called 
nitrosocyanin, that exhibits the strongest p$(Cys)-to-Cu2+ charge transfer band around 
390 nm and weakest p#(Cys)-to-Cu2+ charge transfer band around 600 nm.25-29 In 
addition, it also has a longer Cu-S(Cys) bond (2.26 Å) and wider A|| (150 x 10-4 cm-1).25-29   
Because of these interesting differences, a number of spectroscopic6-8,30-37 and x-
ray crystallographic studies17,38-41 have been carried out to better define the structural 
origin of these spectral properties. Recent analysis using nuclear magnetic resonance 
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(NMR) spectroscopy has also helped to assign structural and electrostatic interactions.42-
44 Combined, these studies have established that the mononuclear copper bound by type 1 
copper proteins is coordinated by one cysteine (Cys112 in azurin) and two histidines 
(His46 and His117 in azurin) in a trigonal plane. A weak axial ligand, often a methionine 
(Met121 in azurin) is present approximately perpendicular to the plane. The intense 
absorption at ~ 600 nm has been attributed to the allowed Cys ligand-to-copper charge 
transfer transition (LMCT) while the weak absorption bands in the same region for the 
normal type 2 copper proteins have been assigned as the parity-forbidden d-d 
transitions.1-3 In addition, the narrow A|| and the EPR spectral shape have been ascribed to 
the short Cu-Cys bond found in type 1 copper sites (~ 2.1 Å).1-3 This short bond results in 
strong covalent interaction between copper and Cys, allowing the unpaired electron on 
Cu(II) to be delocalized onto Cys. This delocalization makes the hyperfine coupling less 
effective than type 2 copper that has a normal Cu-Cys bond length (2.29 Å).4,5  
 
4.2  INTERCONVERTING BLUE AND GREEN COPPER SITES BY SITE DIRECTED MUTAGENESIS 
While it is interesting to show the “coupled distortion” model may explain the 
properties of different copper proteins, an ultimate test of the model and our 
understanding of the copper proteins is demonstration of the “coupled distortion” in a 
single protein by transforming one protein into another through axial ligand mutations. 
Replacement of the weak axial Met121 residue in azurin to stronger coordinating ligands 
such as His45-48 and Glu,13,38,49,50 resulted in proteins that displayed spectral similarities to 
green copper proteins, with narrow EPR hyperfine couplings (A|| < 100 x 10-4 cm-1). A 
strong pH dependence of the ratio between the p$(Cys)-to-Cu2+ charge transfer band 
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around 400 nm and the p#(Cys)-to-Cu2+ charge transfer band around 600 nm has been 
observed in these mutants.38,45 Concurrently, a green copper protein nitrite reductase was 
converted into a blue copper protein through mutation of Met182 into the much weaker 
ligand Thr.27  
However, examples in which a blue copper protein was transformed into a red 
copper protein have not been reported, probably because such a transformation requires 
replacing a weak axial ligand with a stronger ligand while maintaining a short bonding 
distance to the equatorial Cys112. Such a demonstration of a strong axial ligand 
interaction that transforms a blue copper into a red copper protein is an important piece of 
the puzzle in this “coupled distortion” model to explain both structural and functional 
tuning of this important class of ET proteins.   
 
Figure 4.1: Schematic representation of the Pseudomonas aeruginosa azurin type I Cu site. The WT 
protein has an axial Met at residue 121. The two proposed substituted stronger ligands, Cys and Hcy, are 
shown in comparison to Met121. 
 
4.3 PREPARATION OF MET121CYS AZURIN  
Although azurin has been subjected to numerous site-directed mutagenesis studies 
to investigate the effects of substitution by proteinogenic and nonproteinogenic amino 
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acids on redox and ET properties, these studies have provided little information regarding 
how to create red copper sites in blue copper scaffolds to test the “coupled distortion” 
model.19,51-54 Previous reports of Met121His and Met121Glu variants of azurin show the 
transformation of blue copper proteins into green copper proteins, but not into red copper 
proteins.8,19,20,38,45,47,48,50-60 However, replacing the Met with a stronger ligand such as 
Cys, may provide the ligand strength necessary to create a red copper site and help 
confirm the “coupled distortion” model by possibly allowing more overlap of p$(Cys) 
and the dx2-y2 ground state of Cu2+. Although the Met121Cys mutation has been listed as 
part of Met121 site-saturated cassette mutagenesis studies, a full report characterizing an 
azurin containing a free thiolate amino acid in the Met121 axial position is not 
available.13,52,53  
Therefore replacement of Met121 in azurin with cysteine was completed using 
standard site-directed mutagenesis protocols. Following verification of the correct 
nucleotide changes, the protein was expressed analogously to azurin mutants previously 
reported.61 The yield of recombinant expressed Met121Cys azurin mutant was ~30 mg/L 
growth media, comparable to that of WT azurin. The protein was then directly titrated 
with Cu(II)SO4 resulting in a color change from colorless to blue. UV-visible 
spectroscopy (Figure 4.3) verified a strong absorption band around 610 nm and a weaker 
band around 440 nm, reminiscent of the absorption spectra found for both the Met121His 
and Met121Glu proteins at low pH. ESI-MS and MALDI-MS analysis of the protein 
showed only a single copper ion bound in the protein.  
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4.4 UV-VIS SPECTRAL CHARACTERIZATION OF MET121CYS AZURIN 
A comparison between the UV-Vis spectrum of Met121Cys azurin with that of 
wild type (WT), Met121His and Met121Glu azurins reveals that the Met121Cys behaves 
like the Met121His and Met121Glu mutants. Like WT azurin, Met121Cys azurin 
displays a strong absorption band around 610 nm while displaying a weaker band at 420 
nm (Figure 4.2, Table 4.1). Since the more intense peak is closer to the LMCT band 
found in WT azurin, we assigned the absorbance at 610 nm as the p#(Cys)-to-Cu2+ 
charge transfer (CT) band, similar to how the bands were assigned for Met121His azurin 
and Met121Glu azurin at pH 4.38,45 In contrast to WT azurin, but similar to Met121His 
and Met121Glu azurin at pH 4, the intensity of the absorbance at 440 nm, assigned to the 
p$(Cys)-to-Cu2+ charge transferd is higher than that of WT azurin, suggesting that 
introduction of the stronger axial ligand Cys resulted in more overlap of p$(Cys) and the 
dx2-y2 ground state of Cu2+. The ratio of the two peaks, RL [=!(high energy)/!(low 
energy)] can provide a means to measure contributions of each transition, as a lower RL 
value indicates more p#(Cys)-to-Cu2+ charge transfer and more “blue” character while a 
higher RL suggests more p$(Cys)-to-Cu2+ charge transfer and more “red” 
character.18,24,57,62 
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Figure 4.2: UV-visible spectrum for Met121Cys azurin at pH 5 in UB buffer (See experimental). 
Absorption bands are at 440 nm, and 610 nm. 
 
While it is interesting to find that a stronger axial ligand (e.g., Cys) resulted in a 
higher ratio, a trend predicted by the “coupled distortion” model and found in both 
Met121His and Met121Glu azurin, the magnitude of the ratio is not consistent with the 
model, since the stronger Cys ligand should result in a much higher RL value than that of 
nitrite reductase because nitrite reductase has a Met at the axial ligand position. Therefore 
the Met121Cys copper site was subjected to a pH titration analysis to determine if at 
higher pH values, potential deprotonation of Cys121 would result in more interaction 
with the Cu(II) ion. 
As shown in Figure 4.3, adjusting the pH values from 4.3 to 9.6 resulted in a 
decrease of the 610 nm band and increase of the 420 nm band, and thus the RL value. 
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Furthermore, the color of the protein changes from blue to blue-green as the pH is 
increased, following the predicted trend of “coupled distortion” associated with more 
p$(Cys)-to-Cu2+ charge transfer. These changes are not found in similar experiments with 
WT azurin. Thus deprotonation of Cys121 at higher pH increases axial interaction with 
Cu. At high pH values (9.6), the RL ratio is one indicating equal contribution of CT from 
both Cys112 and Cys121. While suggestive of a stronger axial interaction, and in support 
of the blue-green “coupled distortion” theory, the strength of the axial interaction is too 
weak to attribute the changes to creation of a “red” Cu site. The changes occurring upon 
changing the pH are not due to a simple two-state equilibrium but likely involve multiple 
structural changes as isosbestic points are not observed. 
 
 
Figure 4.3: UV-visible spectrum for Met121Cys azurin at varying pH values. pH range is from 4.3-9.6 in 
UB Buffer. 
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4.5 X-BAND EPR CHARACTERIZATION OF MET121CYS AZURIN 
X-band EPR spectroscopy was used to probe for changes in the site geometry 
(Figure 4.4). At pH 4, the observed Met121Cys azurin spectrum is very similar to that of 
WT azurin at pH 5. Though the hyperfine splitting is not as clear as that found in WT 
azurin, the hyperfine splitting of the mutant (A|| = 95 x 10-4 cm-1) is similar to the type 1 
copper site in WT azurin (Table 4.1). When the pH is increased, however, these splittings 
disappear with the generation of a new, more rhombic species with A|| = 195 x 10-4 cm-1, 
characteristic of a type 2 copper-thiolate center. This site distortion is not found in WT 
azurin. These EPR spectral changes indicate that increasing pH may cause deprotonation 
of the axial Cys121 thiolate and thus stronger interaction with the Cu ion, which in turn 
resulted in significant change in the copper center geometry to a more type 2 copper.  
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Figure 4.4: X-band EPR spectra of Met121Cys azurin at different pH values. The EPR spectra are in black 
while the simulated spectra are in red. X-band experimental conditions: microwave frequency, 9.04 GHz; 
power, 0.2 mW; modulation amplitude 5 G, time constant, 32 ms; sweep time, 60 s; number of scans, 10; 
gain, 8000; temperature, 29 K. The spike at g=2.0 signal is an artifact of the EPR tubes used. 
 
Interestingly, the spectral changes monitored by UV-vis (Figure 4.3) do not 
correlate directly with spectral changes in the EPR spectra (Figure 4.4). For example, at 
pH 6, the UV-vis indicates minimal change in the RL from that at pH 5, while the EPR 
suggests significant changes from pH 5 to 6, with appearance of a type 2 copper species. 
The main difference between the conditions of the two spectroscopic methods is that the 
UV-Vis spectra were collected at room temperature while the EPR data were obtained at 
29 K. It is well established that the pH of buffers is dependent on temperature63 and the 
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discrepancies between the EPR and UV-Vis spectra seen here are likely attributable to 
pH changes in the buffering system upon cooling to 29 K that was required for EPR 
spectroscopy. We, therefore, tested the pH change upon cooling in the buffer system used 
for this study according to the previously published method and found that the increased 
rhombicity found in the EPR spectra was reduced, suggesting the EPR spectra are not 
reminiscent of the true pH values before freezing with the temperature independent 
buffer.63 The reported EPR spectra of Met121Cys from pH 5-9 are, therefore, actually at 
higher pH than it is indicated at room temperature. This temperature effect on pH caused 
a higher proportion of deprotonated Cys and more distorted tetragonal, rhombic, 
character to the EPR spectra. At intermediate pH values, where mixed deprotonation 
states of the Cys ligands would exist, a mixture of the two species can be seen in the EPR 
spectrum (Figure 4.4).  
 
Table 4.1: EPR parameters for Met121X variants. 
 
The presence of different species in the EPR spectrum at different pH for the 
Met121Cys azurin variant may be attributed to site destabilization. The anticipated 
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Cys121-Cu bond length (> 5 Å) is exceptionally long and lies outside the expected 
distance required for a strong Cys(S)-Cu covalent interaction. This distance is expected to 
result in a very weak axial Cys-Cu interaction. This interaction would be further 
weakened if the Cys121 thiol remains protonated. Based on the UV-Vis and EPR data, 
increased pH results in deprotonation, likely at Cys121 (similar spectral changes are not 
noted in WT Azurin suggesting Cys112 remains bound to the Cu), and seems to 
strengthen the Cys121-Cu interaction causing significant re-arrangement of the copper 
site. Thus because the Cys seems too short for the thiolate to fully interact with the Cu, 
incorporation of a nonproteinogenic amino acid with a longer side chain may allow an 
axial thiolate to interact with the Cu. Homocysteine (Hcy) was chosen as the Cys 
derivative because its side-chain is one methylene group longer than Cys and would 
therefore be in approximately the same position as the Met thioether would reside. The 
decreased distance should permit interaction with the copper at any pH, and result in a 
stable “coupled distorted” complex. 
  
4.6 PREPARATION OF MET121HCY AZURIN 
Replacing Met121 with Hcy should provide a more stable copper center than Cys 
since the extra methylene group in Hcy can provide a shorter bond distance between the 
thiolate and copper. As discussed in chapter 2, EPL can be used to incorporate Hcy in 
place of Cys112. Furthermore, our laboratory has successfully shown that substitution of 
Met121 with nonproteinogenic amino acids can be accomplished using EPL (See Figure 
1.15).19,20 In the presence of synthetic peptides containing free thiols in the side chain of 
the N-terminal residue such as Cys, the protein thioester can undergo a chemoselective 
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transthioesterification to perform native chemical ligation creating a protein that is 
indistinguishable from recombinantly expressed WT protein (Figure 4.5). 
Therefore, similar to studies discussed in chapters 2 and 3, the synthesis of a 17-
mer peptide consisting of the final C-terminal 17 amino acids of azurin with a 
Met121Hcy mutation Met was completed. The typical yields of the purified peptide were 
approximately 60-80 mg of peptide for a 0.1 mmol synthesis affording ample material for 
semi-synthesis of Met121Hcy azurin using EPL. EPL reactions were first carried out in 
the presence of sodium 2-mercaptoethanesulfonate (MESNa) or N-
methylmercaptoacetamide (NMA) as the transthioesterification catalyst. However, as 
discussed in chapter 3, recent work from the Kent group demonstrated that the 
nucleophilicity and leaving group ability of the catalyst play key roles in the rate of 
transthioesterification.66 Topping the list with the fastest transfers and reduced hydrolysis 
rates was 4-mercaptophenylacetic acid (MPAA).66 In this work, reactions with all 
mediators yielded correctly ligated full length (FL) mutant proteins but ligations with 
MPAA resulted in yields 2x-3x higher than the other mediator used. Thus all subsequent 
ligations were performed using MPAA. In subsequent attempts to further increase the 
yield of the Hcy protein variant, a modified procedure, prompted by the studies discussed 
in chapter 3, was performed in which an anaerobic environment was maintained for the 
duration of the ligation. This modification resulted in moderate yield improvements 
(improvement of 2-3 mg/L growth) over using aerobic conditions and was used 
thereafter. 
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4.7 UV-VIS SPECTRAL CHARACTERIZATION OF MET121HCY AZURIN 
UV-Vis spectroscopy was used first to characterize Met121Hcy azurin. Upon 
addition of Cu(II) to apo-Met121Hcy azurin, a stronger peak was observed around 410 
nm, together with a weaker peak around 590 nm (Figure 4.5). This higher RL ratio is in 
direct contrast to that of WT azurin and different from the Met121Cys azurin at low pH. 
If not coordinated to the copper, the Hcy thiolate is expected to remain protonated at low 
pH (as the calculated pKa value for Hcy is ~10) and resulting in spectra similar to 
Met121Cys azurin. However, the RL ratio is reversed from Met121Cys azurin, 
suggesting a strong interaction between the copper ion and Hcy. Most importantly, the 
spectrum is remarkably similar to that seen in the red copper protein nitrosocyanin even 
though the molar absorptivities of the peaks are lower (Figure 4.5, insert).25-29 
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Figure 4.5: Visible spectra of WT and Met121Hcy azurin in 50 mM MOPS, pH 7. Nitrosocyanin (insert) 
shows absorptivities at 400 nm and 510 nm.25 
 
The apo protein was refolded and titrated anaerobically using Cu(I) and Cu(II) to 
verify that both thiolates (Cys112 and Hcy121) were free to participate in Cu binding and 
are not involved in a disulfide. No significant changes were observable. Because binding 
Cu could potentially cause oxidation and create a disulfide between Hcy121 and Cys112, 
holo-protein samples were also titrated with Cu(II) and Cu(I) in the presence of tris(2-
carboxyethyl)phosphine (TCEP). Again, no spectral changes were observable in the 
presence of TCEP, suggesting that the final holo-Met121Hcy azurin variant is fully 
reduced both prior and after Cu binding (Figure 4.6). 
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Figure 4.6: Met121Hcy titrations in the presence of TCEP. A) Met121Hcy titrated with 0.25 equivalents of 
TCEP. No changes to the LMCT peaks are noticeable. B) WT Azurin titrated with 0.25 equivalents TCEP. 
No changes to the LMCT peak are present. C) Met121Hcy azurin titrated with 1 equivalent TCEP. Only 
baseline shifts are noticeable and attributable to reduced protein that has been unfolded in the presence of 
TCEP. D) WT azurin titrated with 1 equivalent of TCEP. Similarly only baseline shifts are noticeable due 
to protein unfolding.  
 
4.8 X-BAND EPR CHARACTERIZATION OF MET121HCY AZURIN 
The similarity of Met121Hcy to red copper protein is further supported by EPR 
spectroscopy. The X-band EPR spectrum shown in Figure 4.8 displays a much larger 
parallel hyperfine splitting in the Met121Hcy mutant when compared to both WT azurin, 
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the green copper azurin mutants (Met121His and Met121Glu) as well as the Met121Cys 
mutant at low pH (Table 4.1). Both the shape and the hyperfine splitting of the spectrum 
are almost identical to that of red copper nitrosocyanin (Figure 4.7, Table 4.1).26-29 The 
additional hyperfine splitting along g! indicates a stronger interaction between the copper 
and two equivalent nitrogen atoms, a feature also found in native nitrosocyanin.25,26 The 
A values of ~15 x 10-4 cm-1 for the hyperfine pattern are also consistent with nitrogen 
ligands coordinated to a copper.25,26 In contrast to the EPR spectrum for Met121Cys, the 
EPR spectrum for Met121Hcy indicates a single species at multiple pH values, 
suggesting that the M121Hcy azurin is a more stable site and not subject to pH dependent 
changes (Figure 4.7). Surprisingly, in contrast to Met121Cys azurin, Met121Hcy azurin 
is unstable and looses copper at pH values lower than 5 and higher than 8 (data not 
shown). 
These results strongly suggest that introducing the nonproteinogenic amino acid 
Hcy has transformed the blue copper protein, Az, into a red copper protein; the extra 
methylene group provides sufficient length to allow for a strong Hcy-Cu interaction. 
Previous demonstrations of the “coupled distortion” model have focused on replacing a 
medium strength ligand such as Met with weaker ligands, such as Thr.27 This is the first 
time that a medium strength ligand has been replaced with a much stronger ligand 
(thioether vs. thiolate). Though Met121Hcy shares spectroscopic similarities with 
nitrosocyanin, it was imperative to identify the ligand set bound to the Cu ion. The 
nitrosocyanin ligand set does not contain two thiolates, rather an exogenous water is 
bound fulfilling the Cu coordination sphere. Therefore it was necessary to perform 
EXAFS to eliminate any possibilities of exogenous ligands such as water. 
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Figure 4.7: Met121Hcy azurin and WT X-band EPR spectra. X-band experimental conditions: microwave 
frequency, 9.05095 GHz; power, 0.2 mW; modulation amplitude 5 G, time constant, 32 ms; sweep time, 60 
s; number of scans, 30; gain, 1000; temperature, 29 K. Nitrosocyanin EPR spectrum is shown in the insert 
for comparison.26 
 
4.9 EXAFS CHARACTERIZATION OF MET121CYS AND MET121HCY AZURINS 
In order to determine the coordination environment of Cu(II) in the Met121Cys 
and Met121Hcy derivatives in more details, EXAFS data was collected by Dr. Ninian 
Blackburn, calibrating the data against the well studied EXAFS-derived structure of the 
WT azurin.19 EXAFS data for the WT and Met121 variant proteins were generated by Dr. 
Blackburn and are shown in Figure 4.10 with the EXAFS generated structural parameters 
listed in Table 4.2. As expected, the WT protein can be simulated with two histidines and 
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one cysteine residue coordinated to Cu at distances of 1.95 and 2.18 Å respectively 
(Figure 4.8a). The latter distance is 0.04 Å longer than reported previously, but is within 
the range of values typically reported by EXAFS and crystallography for the Cu(II)-
Cys112 interaction.30,67   
For the Met121Cys variants the data show definitively that only a single cysteine 
coordinates as a strongly bound (covalent) ligand with a Cu-S bond length of 2.17 Å. 
Therefore we investigated whether the thiolate at residue 121 could form a longer weaker 
bond to copper.  At pH 5, a slight improvement (13%) in the goodness of fit parameter 
was obtained when an additional S was included in the fit refining to 2.76 Å, while at pH 
7 the data is unambiguous in defining the presence of an additional Cu-S interaction at 
2.74 Å (Figure 4.8b).  Here the improvement in the fit is dramatic when the longer 
distance to a second S is included with the F value dropping by 55%.  Figure 4.8c shows 
the result of eliminating the long distance sulfur ligand, which causes inadequate 
intensity in the Fourier transform (FT) peak around R=2.7 Å.   
Since the pH values were recorded at room temperature and the effective pH of 
the buffer used for these experiments increased with decreasing temperature, the actual 
pH values at 29 K should be higher. In addition, the UV-vis and EPR data suggest 
mixture of species at both pH 5 and 7. Therefore these results suggested the presence of 
mostly mono-thiolate copper interaction at low pH, with the second Cys, most likely 
Cys121 remaining protonated and not interacting with copper strongly. At high pH, 
however, deprotonation of a second thiolate, likely Cys121, resulted in coordination of 
two thiolates to Cu(II) with the second Cys121(S)-(Cu) bond at a distance equivalent to 
that of the native Met121. This suggests that protein-folding constraints prevent the 
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thiolate from bonding more strongly to the copper center and causes the geometric strain 
noted in the EPR spectra.  This contrasts with other (Cys)2His ligand sets such as that 
found in Cu(II)-Sco1 where both Cys residues coordinate Cu(II) at an average distance of 
2.21 Å.68 
 
Figure 4.8: Fourier transform and EXAFS (inset) for WT azurin, Met121Cys and Met121Hcy variants. 
Experimental data are shown as solid black lines and the simulation is shown by dashed red lines.  
Parameters used to fit the data are listed in Table 4.2. A) WT azurin at pH 5.0; B) Best fit of Met121Cys 
variant at pH 7 (bolded in Table 3) with one short (2.17 Å) and one long (2.74 Å) Cu-S interaction; C) The 
best fit of Met121Cys variant at pH 7, obtainable using only the short Cu-S distance; D) Met121Hcy 
variant at pH 7. Spectra were collected and analyzed by Dr. Ninian Blackburn. 
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Table 4.2: EXAFS fitting parameters. Best fits are shown in bold. 
 
a  F is a least-squares fitting parameter defined as  
b  Fits modeled histidine coordination by an imidazole ring, which included single and multiple scattering 
contributions from the second shell (C2/C5) and third shell (C3/N4) atoms respectively.  The Cu-N-Cx 
angles were as follows: Cu-N-C2 126°, Cu-N-C3 -126°, Cu-N-N4 163°, Cu-N-C5 -163°. 
c  Coordination numbers are generally considered accurate to ± 25% 
d  In any one fit, the statistical error in bond-lengths is ±0.005 Å.  However, when errors due to imperfect 
background subtraction, phase-shift calculations, and noise in the data are compounded, the actual error  is 
probably closer to ±0.02 Å. 
e Debye-Waller factors are quoted as 2$2 
 
The best fit for the EXAFS spectrum of Met121Hcy Az shows two Cu-S 
interactions (Figure 4.8d, Table 4.2, bolded), presumably arising from Cys112 and 
Hcy121. The shorter Cu-S interaction in Met121Hcy, which is likely from Cys112, is the 
same as the Cys(S)-Cu bond length in WT Az. The longer of the two Cu-S bonds is 
similar in length, but slightly shorter than the Met(S)-Cu distance in Wt Az (2.77 Å vs. 
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2.9 Å). The shortening of this interaction is likely a consequence of the thiolate of 
Hcy121 being a stronger copper ligand when compared to the thioether in Met.  
Therefore, the EXAFS spectra, in conjunction with the EPR and UV-vis data, 
support the model that Hcy is sufficiently long to form a strong copper-thiolate 
interaction regardless of temperature or pH, resulting in a “coupled-distorted” cupredoxin 
site. Cys at position 121 in Az is, conversely, too short to strongly interact with the 
copper and remains as a thiol at low pH. If Cys121 is deprotonated by raising the pH, the 
resulting thiolate becomes a copper ligand and distorts the copper site to a Type 2 copper 
site. 
 
4.10 ELECTROCHEMICAL STUDIES 
Other than the Met121Cys and Met121Hcy mutations characterized here, no other 
free thiolate mutation in the axial position 121 has been described. Our successful 
generation of these proteins allows us to address the question as to how the reduction 
potentials of a bis-thiolate site in azurin have changed in comparison to WT azurin. To 
probe the effects of a stronger ligand on the redox behavior of azurin, the redox potentials 
of Met121Cys and Met121Hcy azurin were measured using cyclic voltammetry. In 
comparison with WT azurin and the “green” azurin mutants (Met121His and 
Met121Glu), replacing Met121 with Cys resulted in lowering the reduction potential 
from 345 mV to 246 mV while replacing Met121 with Hcy resulted in lowering the 
potential to 295 mV at pH 5.0 (Table 4.3).13,38,46,48,60 Since the reported reduction 
potential of nitrosocyanin25 (~80 mV vs. NHE) was measured at pH 7.0, we repeated the 
reduction potential measurement of our Met121Cys and Met121Hcy azurins at the same 
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pH. Interestingly, at pH 7.0, the Met121Cys azurin has an almost identical reduction 
potential (83 mV) to that of nitrosocyanin, while the Met121Hcy azurin has a slightly 
higher potential of 119 mV, even though Met121Hcy azurin is much closer in 
spectroscopic properties to nitrosocyanin than Met121Cys azurin. Furthermore the 
Met121His (E1/2 = 350 mV) or Met121Glu (E1/2 = 370 mV) azurins have reduction 
potentials that are ~200 mV higher than that of nitrosocyanin at pH 7.13,38,46,48,60 
According to “coupled distortion” model, the stronger axial ligand should result in more 
tetragonal geometry thus lowering the reduction potential. Though WT azurin and the 
“green” azurins have been shown to display a decrease of their reduction potentials with 
increased pH, this trend is more noticeable in the mutants described in this chapter.  
!
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The Met121Cys/Hcy mutants display reduction potentials very similar to 
nitrosocyanin. Comparison of the nitrosocyanin site to azurin reveals that the dipole of 
azurin runs perpendicular to the equatorial plane and through the axial Met ligand at a 
slight angle.26 In contrast, in nitrosocyanin the dipole axis travels through the equatorial, 
stronger ligands.3,26,36 Because the spectroscopic properties of Met121Hcy are so similar 
to nitrosocyanin it suggests that the geometry of the site has significantly been altered so 
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that the 121 position may no longer be axial to the Cu in the Met121Hcy azurin variant, 
instead possibly making one of the His ligands axial and the new equatorial plane 
consisting of Hcy121, Cys112, and the remaining His. This helps support the larger 
parallel hyperfine splitting and tetragonal geometry seen in Met121Hcy azurin and not in 
Met121Cys azurin. Additionally, Met121Hcy azurin displayed scan rate dependence in 
CV, that is also not a feature in Met121Cys, suggesting perturbed electron transfer 
kinetics and a change in electronic structure.  
 
 
Figure 4.9: Cyclic voltammetry for Met121Hcy azurin. A) CV scans show strong scan rate dependence. As 
the scan rate is increased the potential decreases. Graphs B-D all demonstrate the dependency of the redox 
event on the scan-rate: B) Scan-rate vs. Ip C) Potential vs Scan-rate D) Current vs. Scan-rate. 
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4.11 CONCLUSIONS 
In conclusion, successful incorporation of thiolate functional groups as strong 
axial ligands into azurin has been performed. Replacing Met121 with Cys using site-
directed mutagenesis resulted in more tetragonal character, but not enough distortion to 
transform blue azurin to a red copper spectral mimic, due to longer and thus weaker 
interaction between Cys and Cu. Interestingly, adding an extra methylene group by 
introducing unnatural amino acid Hcy in azurin at the same position using EPL resulted 
in much stronger interaction and converted the blue site to a red copper site completely. 
The results firmly establish the “coupled distortion” model and demonstrate the power of 
using nonproteinogenic amino acids to address critical chemical biological questions.  
 
4.12 FUTURE DIRECTIONS 
To fully compare the engineered red copper site with nitrosocyanin, a crystal 
structure would be useful. While spectroscopically, the two proteins appear very similar it 
would be useful to see the changes in the geometry of the site and make a direct 
comparison of those changes with the WT nitrosocyanin site. To fully determine the 
electronic changes of the Met121Hcy site and compare it to the site in nitrosocyanin 
ESEEM and XANES are needed to determine where the dipole axis lies and to see if the 
Hcy121 still resides in the axial position. 
 
4.13 EXPERIMENTAL 
General. All chemicals were purchased from Sigma-Aldrich and were reagent 
grade or higher purity, and used without further purification. 
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Peptide Synthesis. All amino acids were purchased from Chem-Impex 
International (Wooddale, IL) and Advanced Chemtech (Louisville, KY). Protecting 
groups used for Fmoc-SPPS were Cys(Trt), Ser(OtBu), Glu(OtBu), Cys(StBu), Asn(Trt), 
His(Trt), Lys(Boc), Thr(OtBu). Preloaded Fmoc-Lys(Boc)-Wang resin was purchased 
from Advanced Chemtech and used after swelling for 3 x 8 min in dimethylformamide 
(DMF). Methylene chloride (DCM) was distilled from calcium hydride. Tetrahydrofuran 
(THF) was distilled from sodium and benzophenone. All aqueous buffers were degassed 
under Ar or N2 as specified immediately prior to use.  
UV-Vis spectra were taken on an HP Diode Array Spectrometer or a Cary 5000 
spectrometer. X-band EPR spectra were collected on a Varian E-122 spectrometer at the 
Illinois EPR Research Center (IERC). The samples were run at ~30 K using liquid He 
and an Air Products Helitran cryostat without glassing agents. The magnetic field was 
calibrated using a Metrolab PT 2025 NMR Gaussmeter, and the microwave frequency 
was measured with an EIP model 578-frequency counter equipped with a high-frequency 
option.  
Mass spectral data was collected by the Mass Spectrometry Laboratory, School of 
Chemical Sciences, University of Illinois by either Electrospray Ionization (ESI MS), or 
matrix assisted laser desorption ionization (MALDI) techniques as indicated. Mass 
spectral data reported as – mass, peak (percent).  
Preparative RP-HPLC was performed with a Waters Delta 600 system. Solution A 
was 0.1 % TFA in H2O, and solution B was 80 % MeCN/20 % H2O with 0.1 % TFA. 
Unless otherwise stated, a linear gradient of 20% to 70% B over 23 min was used for all 
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runs. Solid phase peptide synthesis (SPPS) was performed on a Rainin PS3 automated 
peptide synthesizer or manually using medium fritted funnels. 
 
Met121Cys Azurin Preparation and Expression, Lab Book 5, page 199.  
A construct containing a methionine-to-cysteine mutation at position 121 in 
azurin was created using the Quikchange mutagenesis method (Stratagene, La Jolla, CA). 
The gene for WT azurin located in a pET9a plasmid was used as the template. The 
primers used were as follows: 
 
-Forward: 5’-CACTCCGCACTGTGCAAAGGTACCCTG-3’ 
-Reverse: 5’-CAGGGTACCTTTGCACAGTGCGGAGTG-3’ 
 
The parental DNA was digested with Dpn1 at 37 °C for 2 h following the completion of 
PCR and E. coli BL21 (DE3) cells were transformed with the plasmid. The mutation was 
confirmed by sequencing of the insert DNA.  The protein was then over-expressed and 
purified using methods analogous to previous protocols. The protein was titrated with 
Cu(II)SO4 as a single batch and exchanged into a Universal Buffer (UB) buffer (50 mM 
NaOAc, 40 mM each MES/MOPS/TRIS/CAPS) at pH 5.0 by G25 Sephadex PD10 
columns (GE Lifesciences). 
 
Met121Cys Cu Titrations At Varying pH, Lab Book 7, page 55.  
Holo-Met121Cys azurin protein was exchanged into UB buffer at the desired pH 
values. Samples were immediately placed in quartz cuvettes and a spectrum taken upon 
reaching the desired pH value. 
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General Procedure for Refolding EPL Products, Lab Book 7, page 37. 
Dithiothreitol (DTT) (final concentration = 0.9 mM) and guanidinium 
hydrochloride (GdmHCl) (final concentration = 4 M) were added directly to a 
concentrated protein sample (~ 1 mL). After full dissolution, the sample was then left to 
sit at 25 ºC without disruption for 20 min. The denatured sample was then added 
dropwise to a 50-fold excess volume of 50 mM UB buffer, pH 5 at 4 ºC containing DTT 
(0.9 mM) at 1 mL/min at stirred for 10 min. The refolded sample was then immediately 
exchanged into fresh 50 mM UB buffer, pH 7.0 at 4 ºC using G25 Sephadex. Following 
concentration of the sample, the protein was titrated with either Cu(II)SO4 (10 mM) or 
tetrakis(acetonitrile)copper(I) hexafluorophosphate (10 mM). 
 
General Procedure for Titrating Proteins, Lab Book 7, page 37. 
Samples titrated with Cu(II) were titrated with subequivalent additions of Cu(II) 
until saturation of the LMCT at 590 nm. Samples titrated with Cu(I) were titrated with 
subequivalent additions of Cu(I) to the previously established saturation point of the 
Cu(II) titrated sample. The samples that were titrated with Cu(I) were then exposed to 
gentle O2 sparging overnight. The individually titrated samples were purified separately 
using a Pharmacia Q HiTrap HP column (5 mL) which had been washed with 10 column 
volumes of 1 M NaCl in H2O and then equilibrated with 10 column volumes of 50 mM 
UB buffer, pH 7. 
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H2N-CTFPGHSALMHcyKGTLTLK-COOH 
Synthesis of Met121Hcy Azurin 17-mer Peptide (3.1). Lab Book 7, page 35. 
Solid Phase Peptide Synthesis. The 17-mer peptide was synthesized on a 0.1 
mmol scale with a Rainin model PS3 peptide synthesizer (Woburn, MA) using standard 
Fmoc-based chemistry. Synthesis from Lys128 through Lys122 was completed using a 
four-fold excess of amino acids pre-activated with 0.4 M N-methylmorpholine (NMM) (6 
mL) and O-benzotriazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) 
(4 equiv) for 2 min prior to coupling to Wang resin preloaded with Fmoc-Lys(Boc) for 1-
2 h. All Fmoc deprotections were accomplished using 20% piperidine/DMF (v/v) (3 x 3 
min, 6 mL). Fmoc-Hcy(Trt)OH (3 equiv) was coupled to Lys122 in the presence of 1-
hydroxybenzotriazole hydrate (HOBt) (6 equiv) and N,N’-diisopropylcarbodiimide (DIC) 
(6 equiv) in DMF at 25 °C for 2-4 h until full coupling could be observed by qualitative 
Kaiser tests. Synthesis was continued from Leu120 through Thr113 using a four-fold 
excess of amino acids pre-activated with 0.4 M NMM and HBTU (4 equiv) for 1-2 h. The 
N-terminal Cys112 was coupled as Boc-Cys(Trt)-OH (4 equiv) in the presence of 
HOBt/DIC (8 equiv each) with N2 sparging for 5 h. Amino acids were double coupled 
when necessary and couplings were monitored by qualitative ninhydrin test.  
Peptide Cleavage. The resin carrying the fully protected peptide was washed with 
dichloromethane (3 x 15 mL) and dried under reduced pressure. Peptide cleavage from 
the resin was achieved by treating the resin with 2% triisopropylsilane 
(TIPS)/dH2O/ethanedithiol (EDT) in neat trifluoroacetic acid (TFA) (5 mL) at 25 °C for 2 
h. The cleaved peptide was isolated from the resin by filtration and the residual TFA was 
removed by rotary evaporation to afford a yellow oil. The peptide was precipitated by 
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trituration with cold diethyl ether and centrifuged at 2000 x g for 5 min. The peptide was 
iteratively washed with cold diethyl ether and centrifuged. The crude peptide was 
dissolved in 1:1 dH2O/acetonitrile (~10-15 mL) and lyophilized prior to purification. The 
crude lyophilized product was purified by preparative RP-HPLC on a Waters Delta Pak 
C18 column (130 mm x 25 mm). The purified peptide was lyophilized directly after 
purification to afford a white solid and analyzed by MALDI-TOF-MS. M121Hcy Azurin 
17-mer (H2N-CTFPGHSALHcyKGTLTLK-OH), Expected: 1791.14, Observed: 1791.5. 
 
Procedure for Expressed Protein Ligation, Lab Book 7, page 33.  
Cultures of E. coli BL21 (DE3) cells containing a plasmid to express the azurin(1-
111)-Intein-CBD fusion protein were grown in LB media for 8 h at 37 ºC and were used 
to inoculate eight 2 L flasks of LB media containing 100 mg/mL ampicillin. The cells 
were grown at 37 ºC for 16 h with shaking at 210 rpm. Protein expression was induced at 
~16 h with 0.5 mM IPTG and induction was continued for 4 h at 37 ºC. The cells were 
then harvested at 9800 x g, stored at -20 ºC and used when needed.  
Frozen azurin-thioester cell stock was re-suspended in a lysis buffer containing 25 
mM HEPES, pH 7.2, 250 mM NaCl, 1 mM EDTA, 1 mM PMSF 0.1% Triton-X-100. 
The suspension was lysed using sonication (Misonix Sonicator 4000, 0.5 inch diameter 
probe) for a total work time of 9 min (6 sec. on, 10 sec. rest). The lysate was centrifuged 
at 13250 x g for 30 min. at 4 °C. The supernatant was carefully decanted. The fusion 
protein was then bound by batch absorption to 100 mL of chitin resin that had been pre-
equilibrated with 20 mM HEPES, pH 8.0, 250 mM NaCl, and 1 mM EDTA (buffer 1) for 
1-2 h at 4 ºC. The chitin resin was poured into a column and the column headspace was 
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purged with Ar. The column was then washed with 3 column volumes of buffer 1 under 
Ar pressure by cannulation.  
Ligation was initiated by the addition of the 17-mer peptide (1.5 mM, 80 mg) and 
tris-(2-carboxyethyl)phosphine (TCEP) (1.5 mM, 14 mg) in 30 mL of buffer 1 containing 
50 mM 4-mercaptophenylacetic acid (MPAA) under Ar and transferred directly to the 
column by Ar pressure. The chitin resin was then re-suspended in the column and the 
entire column was agitated gently at 4 ºC for 66 h.  
After ligation, the column was eluted under Ar pressure and washed with 1 
column volume of buffer 1. The eluent was centrifuged at 13250 x g for 30 min and the 
supernatant was concentrated using 10,000 MWCO Centricon concentration spin tubes at 
2000 x g to a final volume of ~20 mL. The concentrated protein was then exchanged into 
50 mM MOPS buffer, pH 7 using a G25 sephadex column.  
 
Electrochemical Measurements, Lab Book 6, page 41.  
Before running mutant samples, the WT azurin reduction potential was measure 
to standardize the electrode. Once stable, the reduction potential of each mutant 
(Met121Hcy and Mey121Cys Azurins) was determined by cyclic voltammetry using a 
CH Instruments 617A potentiostat equipped with a picoamp booster and a faraday cage. 
A pyrolytic graphite edge (PGE) electrode was polished and 2-3 mL protein solution was 
applied directly to the electrode following previously described methods. After a short 
incubation time, the electrode was immersed in either 20 mM NaOAc, pH 4.0 with 100 
mM NaCl, 20 mM NH4OAc, pH 5.0 with 100 mM NaCl, or 25 mM KH2PO3, 100 mM 
KCl before data collection.  Each protein was then sampled at varying scan rates between 
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10 mV and 500 mV. The reduction potentials were measured against Ag/AgCl and 
converted to NHE. 
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CHAPTER 5 
PROBING BACKBONE CARBONYL INTERACTIONS OF CUA AZURIN. 
 
5.1 INTRODUCTION 
Engineering and exploring the function of metalloproteins requires intimate 
knowledge of the metal binding residues. Without establishing specific function of 
residues, further optimization or protein design becomes difficult. Traditionally, the 
function of metal binding residues is investigated using site-directed mutagenesis (SDM) 
with proteinogenic amino acids. As discussed in previous chapters, more recently, the 
incorporation of nonproteinogenic amino acid analogues has been favored over SDM in 
the study of specific residue function because the dramatic geometric and electronic 
changes associated with SDM are constrained using nonproteinogenic amino acids. 
Expressed Protein Ligation (EPL) has previous been used to incorporate 
nonproteinogenic amino acids into metalloprotein scaffolds to clarify residue function 
and further aid attempts at protein engineering.1-6 The CuA azurin scaffold however has 
not been subjected to analysis using EPL. 
As discussed in chapter 1, the CuA site geometry is different than its electron 
transfer cousins, the type 1 copper proteins.7 Its geometry is more similar to dinuclear 
non-heme iron proteins than to other Cu electron transfer sites (See Figure 1.8). The two 
Cu ions sit in a rigid diamond core consisting of µ2 bridging thiolates from two cysteine 
residues (Figure 5.1).8-15 The Cu ions are coordinated by the ! nitrogens from two His 
imidazole rings and two additional axial ligands.8-11,13-15 Typically these axial ligands are 
Met thioethers and backbone carbonyl groups of nearby residues.13-15  
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As described previously in chapter 1, the study of the CuA site in its native 
scaffold is challenging since the native proteins contain multiple other metal-binding sites 
giving rise to cross signals that interfere with data collection and make interpretation 
difficult. To alleviate these troubles, the CuA azurin scaffold was created to easily express 
a stable spectroscopic mimic of native CuA sites. The engineered site mimics both the 
geometry and spectroscopic signatures of natural CuA sites.10,13,14,23,24 The protein has 
LMCT bands at 480 nm and 530 nm resulting from the S(Cys) ! Cu(II) charge transfer 
transition.13,14,19,20 An additional d-d transition between the Cu ions results in a third 
LMCT band at 775 nm. The site also has a small A|| value in the EPR spectrum from its 
delocalized electrons, resulting in a 7-line hyperfine splitting (See Figure 1.9).13,14,19,20 
Thus far substitution of residues in metalloproteins with nonproteinogenic amino 
acids has probed the function of ligands that use a side chain to bind Cu.1-3,6 While 
researchers are intensely interested in substituting Cu ligands in CuA azurin with 
nonproteinogenic amino acid side-chain analogues, efforts are lacking with respect to 
elucidating the function of the unique backbone carbonyl of Glu114 that is a key part of 
the Cu coordination in the site. As seen in Figure 5.1, one copper in the active site is 
bound by the backbone carbonyl of Glu114.  Replacing the Glu114 amide moiety with 
isosteres could help to establish a new set of data that better explains backbone carbonyl 
contribution in Cu coordination. While the synthesis of backbone analogues can be more 
straightforward than the synthesis of nonproteinogenic amino acids with altered side 
chain functionality, peptide synthesis using backbone analogues is more difficult with 
respect to standard solid-phase peptide synthesis (SPPS) strategies because forming the 
peptide bond is crucial to peptide elongation. Three isosteres of peptide bonds have been 
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incorporated into peptide chains: 1) amide-to-ester, 2) amide-to-thioamide, and 3) amide-
to-amine isosteres. Incorporating these three isosteres into CuA azurin, may provide new 
insights into the Cu-to-carbonyl interaction. 
 
5.2 EPL OF WT CUA AZURIN 
As a control prior to synthesizing any peptides containing nonproteinogenic 
amino acid residues, the WT CuA azurin sequence (N2H-CSELCGINHALMKGTLTLK-
COOH) consisting of the final 19 residues in the CuA azurin protein was synthesized 
following standard SPPS strategies using Fmoc-Cys(Trt)-OH as the Cys116 derivative 
(Peptide 5.1, Figure 5.1). The peptide was cleaved from standard Wang resin using a 
cocktail of 2% H2O/TIPS/EDT in neat TFA at RT for 2 h. Following synthesis and 
purification of the peptide 5.1, EPL reactions were run. Samples were taken at 24 h, 48 h, 
and 66 h and checked for ligation progress. However, even in the presence of excess 
TCEP, the ligations failed to proceed resulting only in hydrolyzed azurin-thioester and 
free peptide. 
 Inefficient ligation was attributed to potential disulfide bond formation. Cys112 
and Cys116 are three residues apart, on the same face of the peptide, and are likely to 
form an intramolecular disulfide bond. This intramolecular disulfide bond impedes 
participation of the Cys112 thiol in the transthioesterification of the peptide with the 
azurin-thioester. Thus, the efficiency of the ligation is poor resulting in extensive time for 
hydrolysis of the azurin-thioester and no ligated product. To prevent inefficient ligation 
an alternative peptide was synthesized replacing Cys116 with Fmoc-Cys(StBu)-OH 
(N2H-CSELC(StBu)GINHALMKGTLTLK-COOH) (Peptide 5.2 Figure 5.1). The StBu 
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protected Cys116 prevents intramolecular disulfide formation and increases ligation 
efficiency. However, use of TCEP is limited because it breaks the Cys(StBu) disulfide. 
Thus any intermolecular disulfides between Cys112 residues cannot be reduced except 
through disulfide exchange and reduction with the thiol catalyst, sodium 2-
mercaptoethanesulfonate (MESNa). 
Peptide 5.2 was synthesized using standard Fmoc-based SPPS strategies and 
cleaved from standard Wang resin in the conditions already described. EPL reactions 
were carried out with the Cys116StBu protected peptide in the presence of MESNa and in 
the absence of TCEP. Samples taken after 24 h, 48 h and 66 h all contained correctly 
ligated protein with fully ligated protein yields increasing with time. The EPL eluent was 
purified by cation exchange chromatography, resulting in two separate protein isoforms; 
one with a free Cys116 thiolate (likely from reduction by MESNa) and another with the 
Cys116StBu disulfide intact as determined my MALDI-MS.   
 
 
Figure 5.1: 19-mer peptides synthesized for EPL reactions for WT CuA azurin. The free thiolate on Cys116 
results in intramolecular disulfide bond formation and a lack of efficient transthioesterification in the EPL 
reaction. 
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 The first fractions from the purification contained Full Length (FL) WT CuA Az 
correctly folded with both thiolates of Cys112 and Cys116 free. The combined fractions 
were titrated without any need for refolding. The protein correctly bound Cu(II) but at a 
R/Z ratio of 7, nearly double that of recombinant WT CuA Az (R/Z = 3), suggesting that 
the protein is not entirely correctly folded or that a portion of the protein is damaged and 
unable to bind Cu (Figure 5.2 A, D).13 The second set of fractions contained FL WT CuA 
Az that was poorly folded as determined by the A291 peak.28 The sharp shoulder on the 
A280 band is indicative of proper folding of azurin by the burying of Trp48 into the 
protein.28 When the band is sharp, the protein is deemed well folded. When the band is 
broad, it indicates improper folding and the necessity to refold the apo protein.28 Because 
the A291 peak for the second fraction set is broad, it is indicative of improper folding and 
may explain why the apo protein was unable to bind Cu since Cys116 remained protected 
by the StBu disulfide and was therefore unable to participate in Cu binding (Figure 5.2 
B).28  
To remove the remaining StBu protecting group bound to Cys116, the sample was 
refolded in the presence of dithiothreitol (DTT). The DTT treatment was able to remove 
all remaining StBu groups resulting in better folded protein that was able to bind Cu with 
a high R/Z ratio (R/Z = 3) (Figure 5.2 C, E). The R/Z value of the refolded protein was 
equivalent to correctly folded recombinant WT CuA Az and the shoulder at A291 was now 
present as a sharp peak (Figure 5.2 C).13,14 This increase in Cu binding suggests that the 
protein is better folded than the first fraction set that contained FL WT CuA Az without 
the StBu group bound to Cys116. Thus, while it appeared not necessary to refold the first 
fraction set since examination of the A291 peak indicative of correct folding was sharp and 
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the protein correctly bound Cu(II), to increase Cu binding and thus the yield of holo-
protein, in further studies the entire eluent after the EPL reactions was refolded prior to 
cation exchange purification. Refolding ensured that not only the Cys116 thiolate was 
free, but also that more protein was correctly folded before titrating with Cu(II).  
 
Figure 5.2: FL EPL of WT CuA azurin. A) First fraction set without any refolding steps and before 
titration. The fractions contain protein with free thiolates for Cys112 and Cys116. The peak at A291 is 
indicative of well-folded protein. B) Second fraction set without refolding steps and before titration. The 
fractions contain protein with the Cys116StBu intact. The fraction is poorly folded as seen by the broad 
A291 peak. C) Second fraction set after refolding and before titration. The protein now has free thiolates for 
Cys112 and Cys116 and is very well folded by a well-defined A291 peak. D) First fraction set without any 
refolding steps fully titrated with Cu at an R/Z value of 7 (WT R/Z = 3). E) Second fraction set after 
refolding and fully titrated with Cu at the WT R/Z ratio (R/Z = 3). 
 159 
After refolding the semi-synthesized WT CuA Az, the resulting apo-protein was 
titrated with Cu(II)SO4 to verify its spectroscopic properties matched recombinant WT 
CuA Az. All titrations of EPL product were completed at pH 5.1 in NH4OAc buffer. 
Titration of the EPL produced WT CuA Az protein yielded a purple colored solution that 
deepened in color with increasing additions of Cu(II). Once fully titrated (at saturation of 
A480), the buffer was exchanged to fresh 50 mM NH4OAc and the UV-Vis spectra 
reexamined to verify the LMCT bands remained unchanged. As shown in Figure 5.3, the 
LMCT bands of EPL generated WT CuA Az at 480 nm, 530 nm, and 750 nm matched the 
LMCT bands of recombinant WT CuA Az (480 nm, 530 nm, 750 nm). X-band EPR also 
verified correct formation of the CuA site in EPL WT CuA Az.13,14 Consequently, EPL 
generated WT CuA Az is spectroscopically indistinguishable from recombinant WT CuA 
Az. 
 
 
Figure 5.3: Spectroscopic comparison of EPL WT CuA azurin with recombinantly expressed WT CuA 
azurin. Both proteins were titrated with the same equiv. of Cu(II) and the spectra were normalized by 
concentration. A) UV-Vis spectroscopic comparison of EPL and recombinant WT CuA Az shows very 
similar LMCT bands. B) X-band EPR analysis of EPL and recombinant WT CuA Az shows 7-line 
hyperfine splitting indicative of CuA sites with identical g values. 
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5.3 SYNTHESIS OF BACKBONE ANALOGUE PEPTIDES 
 Two analogues were chosen for investigating the Cu-carbonyl interaction: 1) 
amide-to-ester replacement and 2) amide-to-thioamide replacement (Figure 5.4). These 
two analogues are very similar in size and thus will likely minimally perturb the 
geometry of the site. The analogues also permit precise study of the Cu-carbonyl 
electronic interaction. Additionally, the amide-to-ester and amide-to-thioamide 
replacements alter the basicity of the carbonyl potentially reducing or increasing the 
electron density of the carbonyl and altering its interaction with the Cu. 
  
 
Figure 5.4: Peptides for investigation of the Cu-carbonyl interaction in CuA azurin. All peptides contain the 
Cys116StBu protection to prevent intramolecular disulfide formation.  
 
 Design of nonproteinogenic amino acid analogues for metal ligand substitution in 
metalloproteins typically focuses on altering side chain functionality retaining both the 
amine and carboxylate functionalities necessary for amide synthesis in standard SPPS 
chemistry.1-3,6 However, since it is the carboxylate on the backbone analogues that is 
modified, alternative Fmoc-based SPPS strategies are necessary to form linkages in 
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peptides containing backbone carbonyl analogues. Installing an ester mimics installing an 
amide so very little deviation from standard SPPS strategies is required; only different 
coupling agents are necessary.29,30 Similarly, installing the thioamide does not deviate 
from standard SPPS strategies; the thioamide moiety is built with the activating agent in 
place.31 However, installing a reduced isostere moiety in replacement of an amide 
requires chemistry not typically found in standard SPPS schemes.32  
 
5.4 INSTALLING AN ESTER INTO CUA AZURIN 
Installing ester linkages into peptides creates chains termed depsipeptides. Any 
number of ester linkages into a peptide sequence can be made. Linear synthesis of 
depsipeptides is well established in the literature and the current interest in depsipeptides 
has prompted exploration of methodologies for automated syntheses.29,30,33-36 Initially 
depsipeptides were synthesized as peptidomimetics of antimicrobials that reportedly had 
increased stability and protection against degradation by proteases.36 Because of the 
changes in H-bonding properties of ester linkages when compared to amides in peptides, 
depsipeptides have also been used to study "-helical H-bonding networks and have aided 
in the study of ion transporters.4,5,34,35 
Synthesis of depsipeptides involves extensive optimization to reduce racemization 
typically found in protocols for ester synthesis.4,5,36 Additionally, esters are more 
susceptible to base hydrolysis than their amide counterparts. Consequently, depsipeptides 
are known to fragment in the presence of strong bases.4,36 Moreover, forming esters is a 
slower process than forming amides and requires increased reaction times to ensure 
complete coupling.4,5,36 Racemization, fragmentation, and long reaction times associated 
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with installing esters resulted in development of alternative routes to synthesize 
depsipeptides using standard Fmoc-based SPPS. Many available schemes limit exposure 
of synthesized depsipeptides to the strong bases normally used for Fmoc-deprotection 
(piperidine) in Fmoc-based SPPS by using other bases such as 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU).4,5,29,30,37,38 While decreasing potential base 
hydrolysis of installed esters, using different bases does not eliminate racemization and 
the long reaction times associated with ester synthesis. Less than 1% racemization after 
ester coupling is present when esters in depsipeptide sequences are installed using 
diisopropylcarbodiimide (DIC)/4-dimethylaminopyridine (DMAP) chemistry.4,5,36 
Additionally, DIC/DMAP chemistry was shown to be extremely efficient at installing 
esters in resin bound peptides, reducing coupling times to approximately 1-2 h.  
However, installation of ester linkages in peptides sequences while 
simultaneously reducing base hydrolysis, racemization and maintaining short coupling 
times is extremely dependent on the peptide sequence. Thus when installing ester 
moieties in peptides, every sequence must be optimized to limit byproducts.4,36 
Sequences that contain regions prone to "-helix formation severely limit the efficiency of 
installing esters in the absence of chaotropic agents such as trifluoroethanol (TFE).30,36 
Additionally, the presence of acidic residues such as Glu and Asp can result in 
cyclization and hydrolysis of the ester.4,36  
 
5.5 SPPS OF PEPTIDE 5.3 BY FMOC CHEMISTRY 
Synthesis of a 19-mer peptide (H2N-CSE[#COO]LC(StBu)GINHALMKGTLTLK-
OH) containing an ester between residues Glu114 and Leu115 was required for ester 
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installation. Initial syntheses using Cys116 as the free thiolate instead of the StBu 
disulfide resulted in inefficient ligation similar to the observations in WT ligations. Thus 
SPPS of the peptide 5.3 was completed using Cys116 protected with the StBu disulfide to 
prevent intramolecular disulfide formation. Installing the ester required a different 
strategy from the SPPS of peptide 5.2. Forming an ester bond is slower than forming an 
amide bond since the hydroxyl group is less nucleophilic than an amine.4,39 Because the 
reaction is slower, coupling times for forming the ester were longer than those for amide 
bond couplings. To minimize racemization, no base was used during the coupling to 
install the ester and DIC/DMAP chemistry was used to speed the reaction (Scheme 5.1). 
The coupling was monitored using a hydroxyl specific test similar to the Kaiser Test (see 
experimental).40 The two residues following Glu114 (Ser113 and Cys112) were coupled 
using standard HOBt/DIC chemistry.  
 
 
Scheme 5.1: Fmoc-SPPS of the peptide 5.3. Standard HOBt/DIC coupling with Leucic acid and a pre-
formed 15-mer generates the hydoxyl peptide for esterification. The ester is installed by DIC/DMAP 
chemistry with Fmoc-Glu(OtBu)-OH. Following Fmoc-deprotection, the final two amino acids are added 
using HOBt/DIC chemistry and cleaved in neat TFA with scavengers. 
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Initial peptide synthesis attempts used piperidine for Fmoc-deprotection of the 
residues following the ester at Glu114 (Ser113 and Cys112) and exclusively resulted in 
truncated peptide containing residues Leu115-Lys130. Two potential routes may have 
caused poor product yield. First, the esterification itself may be incomplete, leading to 
peptide truncated at Leu115 and the ensuing couplings of Ser113 and Cys112 would fail 
using HOBt/DIC chemistry (Scheme 5.2A).4 A second potential problem is 
diketopiperazine (DKP) formation upon deprotection of Fmoc-Ser(OtBu) using 
piperidine. The cyclized DKP results in breakage of the ester linkage (Scheme 5.2B).4  
 
Scheme 5.2: Potential explanations for failure of synthesis of FL peptide 5.3. A) Synthesis up to the 
installation of leucic acid is standard. Incomplete installation of the ester results in failure to complete route 
1 and thus to install Glu114. This failure means that the hydroxyl of Leu115 remains and is therefore 
unable to participate in further SPPS to install Ser113 and Cys112 and FL peptide 5.3 is therefore 
unattainable. B) Diketopiperazine (DKP) formation occurs when the amine of Ser113 attacks the ester after 
Fmoc-deblocking with piperidine. Glu114 and Ser113 are cyclized into the piperazine ring, releasing the 
free hydoxyl peptide. 
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The first hypothesis that the esterification itself was inefficient was ruled out by 
testing with a hydroxyl specific colorimetric test similar to the Kaiser test.40 The test is 
able to determine the presence of free hydroxyls at extremely low percentages (~1%).36,40 
After triple coupling of Glu114 no free hydroxyls were present as determined by the test. 
Furthermore, trial cleavage of the peptide determined that Glu114 was present with the 
Fmoc protecting group intact, also ruling out breakage of the ester by ionization. The 
hypothesis that DKP formation resulted in cleavage of the ester was tested by using a 
weaker base, 1% DBU at reduced times for Fmoc-deprotection of Glu114 and Ser113.37 
To further limit exposure to base, Cys112 was coupled as the Boc-protected amine that 
could be removed during cleavage of the peptide. Reduced exposure to base afforded 
increased peptide yields but retained significant hydrolyzed peptide byproduct (Figure 
5.5). Therefore an alternative strategy, Boc-SPPS, was used. 
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Figure 5.5: MALDI-MS analysis of the Peptide 5.3 synthesized via Fmoc-SPPS. DBU was used to 
deprotect residues after installation of the ester. Even in the presence of weaker base, DKP formation 
results, causing ester hydrolysis and resulting in a large proportion of truncated peptide with a mass of 1802 
Da. 
 
5.6 SPPS OF PEPTIDE 5.3 BY BOC CHEMISTRY 
As an alternative to Fmoc-based SPPS, peptide 5.3 was synthesized using Boc-
SPPS chemistry. Boc chemistry eliminates exposure to base, eliminating DKP formation 
and base hydrolysis. Peptide synthesis using Boc chemistry however is a much more 
harsh route to synthesize peptides because of the strong acids necessary during synthesis 
and for peptide cleavage from the resin. Though alternative routes for Boc removal exist 
other than using TFA, many of these strategies employ expensive reagents or require long 
deprotection times.41-43 Resins exist that do not require HF for cleavage and instead use 
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superacids such as trimethylsilyl trifluoromethanesulfonate (TMSOTf) or 
trifluoromethanesulfonic acid (TFMSA) for cleavage.  
 
 
Scheme 5.3: Boc-SPPS of the peptide 5.3. Standard coupling of leucic acid with 20% DIPEA prepares the 
hydroxyl peptide for esterification. The ester is installed by DIC/DMAP chemistry with Boc-Glu(OBn)-
OH. Following Boc-deprotection, the final two amino acids are added using HOBt/DIC chemistry and the 
peptide was cleaved from the resin in neat TFA with TFMSA with scavengers. TMSOTf was shown to be 
insufficient to fully cleave the peptide. 
 
Synthesis of peptide 5.3 using Boc chemistry was completed on H-Lys(2-Cl-Z)-
PAM resin using the Boc amino acid derivatives listed in the experimental section 
(Scheme 5.3). Trial cleavages of a shorter peptide (H2N-ALMKGTLTLK-OH) using 
TMSOTf or TFMSA were completed before the FL peptide was synthesized to verify 
that cleavage procedures were sufficient to fully cleave the peptide. Samples taken at 2 h 
and 4 h showed no peptide product from the TMSOTf mixture and cleavage was deemed 
insufficient. Cleavage of the shorter peptide with TFMSA showed fully cleaved peptide 
of the correct mass. Following trial cleavages, the synthesized FL peptide was completed 
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using Boc-Cys(StBu)-OH at position 116 to prevent intramolecular disulfide formation 
during future EPL ligations.  
The ester was installed using DIC/DMAP chemistry identically to the methods 
used in Fmoc-based SPPS and the FL peptide was cleaved from the resin in a 10% 
TFMSA cocktail in TFA for 2-4 h. Precipitation of the FL peptide was difficult as 
extraneous organics in the cleavage cocktail prevented peptide trituration, instead 
yielding a golden oil. Therefore, prior to trituration, the cleavage cocktail was extracted 
three times with dH2O and the aqueous layer triturated with cold Et2O. This procedure 
was sufficient to obtain the peptide as a white powder. However, yields after 
lyophilization were low. Instead, the cleavage cocktail was taken up in THF/TFA and 
extracted with dH2O. The aqueous layer was then extracted with Et2O, resulting in 
peptide yields after lyophilization of the aqueous layer that corresponded to the expected 
yield of crude peptide (150-250 mg crude material for a 0.1 mmol synthesis).  
MALDI-MS characterization of the peptide synthesized via Boc chemistry 
showed less than 5% hydrolyzed product and the correct m/z of the peptide 5.3 (Figure 
5.6). Though purified yields via Boc-SPPS (50-65 mg peptide) were lower than typical 
purified yields from Fmoc-SPPS (50-100 mg peptide), the lower yields are likely a result 
of cleavage of the peptide from the resin throughout the synthesis, a known problem 
using TFA to remove N-terminal Boc protection during Boc-SPPS.41,43 Additionally, 
purified peptide from Fmoc syntheses contained significant amounts of other peptide 
impurities, including the hydrolyzed byproduct, likely resulting in inflated yields when 
compared to the higher purity peptide obtained through Boc-SPPS. Thus, the yield of FL 
correct mass peptide from Boc chemistry was superior to the same scheme using Fmoc 
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chemistry. However, though yields are higher, peptides synthesized via Boc chemistry in 
our lab cannot be automated and thus all synthesis must be done manually. 
 
 
Figure 5.6: MALDI-MS analysis of peptide 5.3 synthesized via Boc-SPPS. Very little hydrolysis was 
noted and the peptide was clean prior to purification.  
 
5.7 SEMI-SYNTHESIS OF ESTER-CUA AZ BY EPL 
The FL peptide 5.3 was purified by RP-HPLC and used in EPL reactions 
following the same methodology described for WT CuA Az reactions. Noteworthy 
however is the sensitivity of the ester linkage (both the peptide and the subsequent FL 
protein) in buffers at pH > 7.5. No ligated products were observed using buffers at pH > 
7.5 during the course of the EPL reaction. MALDI-TOF MS analysis of EPL elutions in 
buffer at pH > 7.5 showed peptide that was fully hydrolyzed between Glu114 and Leu115 
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and was therefore unable to participate in transthioesterification with the protein-
thioester. To increase the rates of transthioesterification and reduce hydrolysis, buffers at 
pH 7.2 were used for all ester CuA EPL reactions. 
 
 
Figure 5.7: UV-Vis overlay of WT EPL CuA azurin and Ester CuA azurin. The LMCT bands are red shifted 
for the ester protein (475 nm, 530 nm, and 750 nm). The WT LMCT bands are at 480 nm, 530 nm and 775 
nm. 
 
Full length apo protein from EPL reactions was refolded immediately following 
ligation and titrated to 1 equiv. Cu(II)SO4 where the protein solution turned purple in 
color. Holo-ester CuA azurin (hereafter ester CuA) showed three LMCT bands that 
corresponded very closely to, but were red-shifted from the ligand-to-metal charge 
transfer (LMCT) bands found in WT CuA azurin (hereafter WT) suggesting a stronger 
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carbonyl-Cu interaction (Figure 5.7). Ester CuA LMCT bands were noted at 475 nm, 530 
nm, and 750 nm whereas the WT CuA LMCT bands are at 480 nm, 530 nm, and 775 nm. 
To verify that the ester CuA protein contained the ester moiety, hydrolysis of the protein 
by exposure to 1 M NaOH was performed. Because the ester is susceptible to base 
hydrolysis, exposure of the protein to 1 M NaOH will preferentially cleave the ester while 
the WT protein will remain intact. SDS-PAGE gel analysis was performed to observe the 
expected MW shifts of the cleaved ester protein. WT CuA Az (protein with a native 
amide bond) was not susceptible to hydrolysis using 1 M NaOH for 20 min at RT (Figure 
5.8, lane 2). However, exposure of ester CuA protein to 1 M NaOH at 20 min and 60 min 
showed an incomplete hydrolysis product (lanes 4 and 5) that was not found in ester 
protein unexposed to 1 M NaOH (lane 3), verifying correct incorporation of the ester 
moiety. 
 
 
Figure 5.8: SDS-PAGE gel analysis of ester incorporation into CuA azurin. See text for details. Lane 1 = 
FL WT EPL CuA Az, Lane 2 = FL WT EPL CuA Az exposed to 1 M NaOH, 20 min., Lane 3 = FL Ester 
CuA Az, Lane 4 = FL Ester CuA Az exposed to 1 M NaOH, 20 min., Lane 5 = FL Ester CuA Az exposed to 
1 M NaOH, 60 min. 
 
Additionally, X-band EPR spectroscopy displayed the 7-line hyperfine splitting 
indicative of a CuA site, with g values equivalent to the WT protein (Figure 5.9).13,14 As 
expected, modifying a single amide in the backbone to an ester does not significantly 
alter the geometry of the site. However, esters are structurally more flexible than amides 
because rotation about the C-O-C bonds has a lower barrier and therefore should permit 
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greater numbers of conformations and potential changes to the engineered site’s 
geometry. That changes in both g value and hyperfine splittings are not present suggests 
that rotation is limited and that the backbone carbonyl interaction therefore likely does 
not play a significant role in maintaining the site geometry.  
 
 
Figure 5.9: X-Band EPR spectrum of Ester CuA azurin. Ester CuA Az displays the same 7-line hyperfine 
splitting though not quite as clear as the WT CuA Az protein and identical g values. 
 
While the geometry of the site likely remained unchanged, changes in the 
reduction potential could be expected. Because the ester is less structurally rigid than the 
amide, even small rotations of the ester that are not permissible in the WT protein could 
alter the reorganization energy by allowing more conformational states of the backbone. 
Changes in reorganization energy could be reflected in changes in redox behavior. 
 Additionally, the ester should participate in Cu binding less efficiently than the 
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amide carbonyl oxygen. To test the effect that the amide-to-ester replacement has on the 
redox behavior of CuA azurin, ester CuA was subjected to cyclic voltammetry (CV) 
following the outlined procedure for CV of WT CuA azurin.16,44 Ester CuA displayed the 
same redox potential as WT CuA azurin within experimental error (Figure 5.10). The 
experimental WT protein redox potential vs. NHE was 277 ± 3 mV and matches reported 
values.44 The redox potential determined for the ester variant was 278 ± 5 mV. The 
similar potentials suggest that the overall contribution from the ester moiety does not 
substantially alter the interaction of the Glu114-carbonyl to the Cu ion. It further suggests 
that the amide backbone carbonyl found in WT CuA does not impart the redox behavior 
of the CuA site. 
 
 
Figure 5.10: CV of Ester CuA azurin overlaid with WT CuA azurin. The additional peak in the ester 
spectrum at ~174 mV is attributed to background noise from the electrode and can also be seen in the WT 
spectrum. 
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5.8 INSTALLING A THIOAMIDE INTO CUA AZURIN 
Inclusion of thioamide moieties into peptides creates peptidomimetics termed 
thioxopeptides. Similar to depsipeptides, interest in installing thioamide moieties into 
peptides has been geared towards modifying peptide stability against protease 
degradation.45,46 Because thioamides have different hydrogen bonding properties than 
amides, thioxopeptides are used to investigate H-bonding in "-helices.31,47,48 The 
thioamide hydrogen is a stronger hydrogen bond donor than the amide hydrogen, but the 
sulfur is a weaker hydrogen bond acceptor than the oxygen.39,48,49 However, in copper 
coordination chemistry, sulfur is a stronger ligand because it is softer than oxygen and 
thus a thioamide could more readily and strongly bind copper into the CuA site.50 Though 
many different routes exist for thioacylation of amino acids (including Lawesson’s 
reagent), many of these routes suffer from lack of specificity, low yield, and 
racemization.51-54 A popular methodology that uses phosphorous pentasulfide (P4S10), 
specifically thionates amide carbonyls while maintaining high yields.47  
Incorporating thioamide analogues using SPPS necessitates that the amino acid 
derivates be synthesized as preformed activated species.55 Two problems are commonly 
associated with synthesizing preformed activated species of thioamides, racemization and 
poor yields.47 Early synthetic schemes using preformed benzimidazolinones suffer from 
significant benzimidazole formation and therefore poor overall yields (<20%) (Scheme 
5.4).47,56,57 These syntheses also relied on Lawesson’s reagent rather than P4S10 and thus 
typically resulted in substantial levels of byproduct.47,56,57 Additionally, these schemes 
often result in racemized final products and decreased enantiomeric purity. Synthesizing 
preformed benzotriazoles can circumvent these problems because it is a very good 
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leaving group.47,58 Moreover, use of P4S10 reduces byproduct formation found when using 
Lawesson’s reagent. Adding electron-withdrawing groups para to the unacylated amino 
group reduces the amine’s nucleophilicity and inhibits its participation in forming the 
benzimidazole. The benzotriazole also helps reduce racemization (Scheme 5.4).47  
 
 
Scheme 5.4: Synthesis of benzimidazolinones for incorporation of thioamides into peptides. Use of 
Lawesson’s reagent results in 90% yield of benzimidazole byproduct and is therefore a poor route to obtain 
thioamide derivatives. 
 
Preparing a preformed benzotriazole was chosen to synthesize a thioacylated Glu 
derivative (Glu(S)). Using mixed carbonic anhydride methodology for peptide synthesis, 
the starting material, Fmoc-Glu(OtBu)-OH, was coupled with 4-nitro-1,2-
phenylenediamine to afford anilide 5.15 in a near quantitative yield (97%) (Scheme 5.5, 
Step 1). Thioacylation of 5.15 was completed with P4S10 in the presence of Na2CO3 to 
synthesize the thioamide 5.16 (Scheme 5.5, Step 2). Though no purification of thioamide-
intermediates in the original published scheme was noted,47 a Glu(S) derivative was not 
reported and significant byproducts and excess P4S10 were noticeable by 1H NMR 
spectroscopy and TLC. An additional spot, attributed to acylthioimidate via competitive 
cyclization of the Glu side chain carbonyl with the nucleophilic thioamide sulfur was also 
found.47 The impurities were not further characterized and were removed by silica gel 
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flash chromatography before proceeding to the final compound as the byproducts proved 
problematic during later synthetic steps.  
The final nitro-benzotriazole product 5.17 was formed through intramolecular 
diazonium cyclization using nitrous acid generated in situ with acetic acid and NaNO2 
(Scheme 5.5, Step 3). It should be noted that the final nitro-benzotriazole product is not 
stable for significant periods of time at -20 ˚C and should be used soon after synthesis.  
 
 
Scheme 5.5: Synthesis of Glu(S) thioamide derivative for installation of a thioamide in CuA azurin. See text 
for details. Modified from Ref. 23. 
 
Standard Fmoc-based SPPS was used to synthesize the first 16 amino acids (H2N-
LC(StBu)GINHALMKGTLGLK-OH) of the peptide 5.4 (Figure 5.11). Following Fmoc-
deprotection of Leu115, compound 5.17 was added to the resin bound peptide in dry THF 
and activated 2 Å molecular sieves and stirred rapidly in a round bottom glass flask for 5 
h or until complete coupling was noted by qualitative ninhydrin testing. Once complete, 
the peptide was quickly deprotected with 20% piperidine and the synthesis finished by 
coupling Ser113 and Cys112. Following cleavage however, the truncated peptide missing 
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Cys112 - Glu(S)114 was the primary product. Deprotection of Glu(S)114 and Ser113 
with 1% DBU and installation of Boc-amine protected Cys112 was sufficient to eliminate 
formation of truncated peptide.37,38  
 
 
Figure 5.11: MALDI-MS of FL peptide 5.4 via Fmoc-SPPS. FL peptide m/z = 2139. Less than 10% of the 
truncated peptide at Leu115 is found when using DBU to deprotect the Fmoc from residues after Leu115. 
 
5.9 SEMI-SYNTHESIS OF THIOAMIDE-CUA AZURIN BY EPL 
The FL peptide derived from Fmoc-SPPS was purified and used in EPL reactions 
following the same methodology described for the WT CuA Az reactions. No pH 
sensitivity of the thioamide was noticeable. The FL apo protein from EPL reactions was 
immediately refolded in the presence of DTT after ligation and titrated with Cu(II)SO4. 
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The protein was titrated with 0.7 equiv. Cu(II)SO4 when the protein turned pale purple in 
color. Holo-thioamide CuA Azurin showed three LMCT bands though they were weak. 
The LMCT bands were at 455 nm, 510 nm, and a d-d transition at 730 nm (Figure 5.12), 
and all were red-shifted from the WT bands at 475 nm, 530 nm, and 750 nm. The 
thioamide protein LMCT peaks displayed much greater shift than those of the ester CuA 
Az variant, suggesting that the additional thiocarbonyl from the thioamide may indeed be 
binding the Cu stronger.  
 
 
Figure 5.12: UV-Vis overlay of WT EPL CuA azurin and Thioamide CuA azurin. The LMCT bands are red 
shifted for the thioamide protein (455 nm, 510 nm, and 730 nm). The WT LMCT bands are at 480 nm, 530 
nm and 775 nm. 
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Unfortunately insufficient protein was obtained through EPL reactions to afford a 
concentration acceptable for EPR experimentation; something that will need to be 
examined before coming to major conclusions about this protein. 
 
5.10 CONCLUSIONS 
 Incorporation of nonproteinogenic amino acid backbone analogues into 
engineered CuA azurin has successfully been completed. Correct incorporation of an ester 
and thioamide moiety into the scaffold to alter the behavior of the Glu114 backbone 
carbonyl interaction with Cu was achieved using EPL. The insertions were designed to 
minimally perturb the geometry of the CuA site to specifically isolate any potential 
electronic interactions the Glu114 carbonyl had with Cu.  
 Incorporating an ester at Glu114 deleted a hydrogen bond partner and was 
originally thought to possibly alter geometry because the hydrogen bonding of the residue 
may be key to correct folding. Additionally, increased rotational flexibility about the ester 
compared to the native amide was thought to alter the geometry of the site. However, 
EPR analysis and determination of the variant’s redox behavior showed that the geometry 
of the site was very similar to WT CuA azurin with similar g values found in the EPR 
spectrum and a virtually identical reduction potential for the ester variant and WT CuA 
azurin.  
 Moreover, the ester variant displayed a red-shifted UV-Vis spectrum when 
compared to the WT CuA Az scaffold under identical conditions. One of the LMCT 
bands found at 480 nm in WT CuA Az was red-shifted to 475 nm and the d-d transition 
between the bound Cu ions was red-shifted from 775 nm in the WT scaffold to 750 nm. 
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These shifts suggest increased energy in binding of the Cu though UV-Vis spectra are not 
determinative of binding affinity. Regardless, CV did not confirm any potential increased 
binding affinity since no redox changes were observed. While new data has established 
that the Glu114 carbonyl does not appear to play a significant role in instituting correct 
geometry or in determining the redox behavior of the CuA site in engineered CuA Az, it 
appears that on at least some level, the amide-to-ester replacement affects the binding of 
Cu from UV-Vis studies.  
 A synthetic scheme for successful incorporation of thioamides into CuA Az has 
been devised. This scheme is capable of making thioamide derivatives in a minimal 
number of steps with high overall yields of pure product. However, the final activated 
synthesized species is unstable and degrades over extended time. Regardless, successful 
peptide synthesis and ultimate semi-synthesis of a CuA Az variant containing an amide-
to-thioamide replacement has been completed. Insertion of a thioamide was expected to 
cause significant disruption of the CuA features because the S is much softer than O and a 
preferred ligand in Cu coordination.50 Though extremely preliminary at this time, the 
UV-Vis spectroscopy displays dramatic shifts of LMCT bands that could be associated 
with distorted Cu binding and altered Cu binding affinity.  
 
5.11 FUTURE DIRECTIONS 
 Before coming to major conclusions about the effect the amide-to-ester 
replacement has on the CuA scaffold, more detailed information regarding the structure is 
necessary. While crystallization of EPL proteins is notoriously difficult due to low yields 
of pure holo-protein when compared to yields available through recombinant protein 
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expression, other spectroscopic methods such as ENDOR and ESEEM could help 
establish changes in bond lengths and angles demonstrating geometric changes to the site. 
Previous collaborations with the Blackburn lab at Oregon have provided such insights in 
other EPL metalloproteins semi-synthesized in our laboratories. 
 Disappointingly, yields of the thioamide CuA Az protein are low. Because of such 
low yields, no spectroscopic work other than UV-Vis studies has been completed at this 
time. The thioamide UV-Vis spectrum shows strongly red-shifted LMCT bands 
suggesting that the additional S may bind Cu stronger than its natural amide counterpart. 
However, the data are very preliminary and conclusions cannot be made about the amide-
to-thioamide replacement with the lack of other evidence available at this time. Thus 
what, if any effect the amide-to-thioamide replacement has on Cu binding efficiency, 
geometry, and redox behavior must be further investigated using a wide range of 
techniques including EPR, ENDOR, and CV. 
 
5.12 EXPERIMENTAL 
General. All chemicals used were obtained from Aldrich. All amino acids were 
purchased from Novabiochem, Advanced Chemtech, or Chem-Impex International. 
Protecting groups used for Fmoc-SPPS were Cys(Trt), Ser(OtBu), Glu(OtBu), 
Cys(StBu), Asn(Trt), His(Trt), Lys(Boc), Thr(OtBu). Protecting groups used for Boc-
SPPS were Cys(Trt), Ser(OBzl), Glu(OBzl), Cys(StBu) Asn(Xan), His(DNP), Lys(Z), 
Thr(OBzl). Methylene chloride (DCM) was distilled from calcium hydride. 
Tetrahydrofuran (THF) was distilled from sodium and benzophenone. All aqueous 
buffers were degassed under Ar or N2 as specified immediately prior to use.  
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All NMR spectra were obtained with a Varian U500 NMR Spectrometer in 
CDCl3. UV-Vis spectra were taken on an HP Diode Array Spectrometer or a Cary 5000 
spectrometer. X-band EPR spectra were collected on a Varian E-122 spectrometer at the 
Illinois EPR Research Center (IERC). The samples were run at ~30 K using liquid He 
and an Air Products Helitran cryostat without glassing agents. The magnetic field was 
calibrated using a Metrolab PT 2025 NMR Gaussmeter, and the microwave frequency 
was measured with an EIP model 578-frequency counter equipped with a high-frequency 
option.  
Mass spectral data was collected by the Mass Spectrometry Laboratory, School of 
Chemical Sciences, University of Illinois by either Electrospray Ionization (ESI MS), or 
matrix assisted laser desorption ionization (MALDI) techniques as indicated. Mass 
spectral data are reported as – mass, peak (percent).  
Preparative RP-HPLC was performed with a Waters Delta 600 system. Solution A 
was 0.1 % TFA in H2O, and solution B was 80 % MeCN/20 % H2O with 0.1 % TFA. 
Unless otherwise stated, a linear gradient of 20% to 70% B over 23 min was used for all 
runs. Solid phase peptide synthesis (SPPS) was performed on a Rainin PS3 automated 
peptide synthesizer or manually using medium fritted funnels.59 
 
H2N-CSELCGINHALMKGTLTLK-COOH 
Synthesis of Peptide 5.1, Lab Book VI, page 24. 
The peptide was synthesized on a 0.1 mmol scale. Fmoc Wang resin preloaded 
with Fmoc-Lys(Boc) was pre-swelled in DMF (6 x 10 min, 6 mL). Synthesis of the 
peptide from Lys130 through Gly117 was completed using a six-fold excess of amino 
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acids pre-activated with 0.4 M N-methylmorpholine (NMM) (6 mL) and O-
benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (6 equiv) 
for 2 min prior to coupling to the resin. All Fmoc-deprotections were accomplished using 
20% piperidine/DMF (v/v) (3 x 3 min, 6 mL). Fmoc-Cys(Trt)-OH (4 equiv.) was coupled 
after Gly117 in the presence of hydroxybenzotriazole (HOBt) (8 equiv.) and N,N'-
diisopropylcarbodiimide (DIC) (8 equiv.) in DMF at room temperature (RT) for 2-5 h. 
After Fmoc-deprotection with 20% piperidine, Leu115, Glu114, and Ser113 were 
coupled using 6 equiv HBTU in 0.4 M NMM after a 2 min pre-activation. The N-
terminal Cys112 was coupled as Boc-Cys(Trt)-OH (4 equiv.) in the presence of 
HOBt/DIC (8 equiv. each) with N2 sparging for 5 h. Amino acids were double coupled 
when necessary and couplings were monitored by qualitative ninhydrin test. Following 
addition of the last residue, the resin was washed with DCM and dried for 10 min under 
reduced pressure before the peptide was cleaved from the resin in a cocktail of 2% H2O 
(100 !L), triisopropylsilane (TIS) (100 !L), and ethanedithiol (EDT) (100 !L) in neat 
trifluoroacetic acid (TFA) (5 mL) with stirring at RT for 2 h. The solvent was evaporated 
and the peptide was precipitated using cold Et2O to obtain a white solid. The solid was 
dissolved in a minimal amount of 1:1 H2O/MeCN (5-10 mL) and lyophilized prior to 
purification by preparative RP-HPLC using a C18 column to obtain the final products as 
a white solid after lyophilization. (Yield: 82 mg). MALDI MS. Expected: 2032.45, 
Observed: 2032.8. 
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H2N-CSELC(StBu)GINHALMKGTLTLK-COOH 
Synthesis of Peptide 5.2, Lab Book VI, page 137. 
The peptide was synthesized on a 0.15 mmol scale. Fmoc Wang resin preloaded 
with Fmoc-Lys(Boc) was pre-swelled in DMF (6 x 10 min, 6 mL). Synthesis of the 
peptide from Lys130 through Gly117 was completed using a six-fold excess of amino 
acids pre-activated with 0.4 M N-methylmorpholine (NMM) (6 mL) and O-
benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (6 equiv) 
for 2 min prior to coupling to the resin. All Fmoc-deprotections were accomplished using 
20% piperidine/DMF (v/v) (3 x 3 min, 6 mL). Fmoc-Cys(StBu)-OH (4 equiv.) was 
coupled after Gly117 in the presence of hydroxybenzotriazole (HOBt) (8 equiv.) and 
N,N'-diisopropylcarbodiimide (DIC) (8 equiv.) in DMF at RT for 2-5 h. After Fmoc-
deprotection with 20% piperidine, Leu115, Glu114, and Ser113 were coupled using 6 
equiv HBTU in 0.4 M NMM after a 2 min pre-activation. The N-terminal Cys112 was 
coupled as Boc-Cys(Trt)-OH (4 equiv.) in the presence of HOBt/DIC (8 equiv. each) 
with N2 sparging for 5 h. Amino acids were double coupled when necessary and 
couplings were monitored by qualitative ninhydrin test. Following addition of the last 
residue, the resin was washed with DCM and dried for 10 min under reduced pressure 
before the peptide was cleaved from the resin in a cocktail of 2% H2O (100 !L), 
triisopropylsilane (TIS) (100 !L), and ethanedithiol (EDT) (100 !L) in neat 
trifluoroacetic acid (TFA) (5 mL) with stirring at RT for 2 h. The solvent was evaporated 
and the peptide was precipitated using cold Et2O to obtain a white solid. The solid was 
dissolved in a minimal amount of 1:1 H2O/MeCN and lyophilized prior to purification by 
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preparative RP-HPLC using a C18 column to obtain the final products as a white solid 
after lyophilization. MALDI MS. (Yield: 48 mg). Expected: 2120.62, Observed: 2120.3. 
 
H2N-CSE[$COO]LC(StBu)GINHALMKGTLTLK-COOH 
Synthesis of Peptide 5.3 on Wang Resin, Lab Book VI, page 125. 
The peptide was synthesized on a 0.35 mmol scale. Wang resin preloaded with 
Fmoc-Lys(Boc) was swelled in DMF (6 x 10 min, 6 mL). Synthesis of the peptide from 
Lys130 through Gly117 was completed using a six-fold excess of amino acids pre-
activated with 0.4 M N-methylmorpholine (NMM) (6 mL) and O-benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (6.6 equiv) for 2 min 
prior to coupling to the resin. All Fmoc-deprotections were accomplished using 20% 
piperidine/DMF (v/v) (3 x 3 min, 6 mL). Fmoc-Cys(StBu)-OH (4 equiv.) was coupled 
after Gly117 in the presence of hydroxybenzotriazole (HOBt) (8 equiv.) and N,N'-
diisopropylcarbodiimide (DIC) (8 equiv.) in DMF at RT for 2-5 h. After Fmoc-
deprotection with 20% piperidine, leucic acid (11 equiv) was coupled to the peptide in 
the presence of HOBt (12.5 equiv.), DIC (11 equiv.), and NMM (4.4 equiv.) at RT for 3 
h. Fmoc-Glu(OtBu)-OH (11 equiv.) was triple coupled to the resin in the presence of DIC 
(11 equiv.), NMM (4.4 equiv.), and 5 mol% 4-dimethylaminopyridine (DMAP) (0.55 
equiv.). The completion of the couple was monitored using a hydroxyl specific 
colorimetric test similar to the Kaiser test (see below). Glu114 and Ser113 were Fmoc-
deprotected with 1% 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in DMF (w/v). The N-
terminal Cys112 was coupled as Boc-Cys(Trt)-OH (4 equiv.) in the presence of 
HOBt/DIC (8 equiv. each) with N2 sparging for 5 h. Amino acids were double coupled 
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when necessary and couplins were monitored by qualitative ninhydrin test. The peptide 
was cleaved from the resin in a cocktail of 2% triisopropylsilane (TIS) (200 !L), 2% 
ethanedithiol (200 !L) in neat TFA (10 mL) with stirring at -5 °C for 2 h and at RT for an 
addition 0.5-1 h. The solvent was evaporated and the peptide precipitated using cold Et2O 
to obtain a white solid. The solid was dissolved in a minimal amount of 1:1 H2O/MeCN 
(5-10 mL) and lyophilized prior to purification by preparative RP-HPLC using a C18 
column to obtain a white solid after lyophilization. (Yield: 18 mg) MALDI MS. 
Expected: 2121.62, Observed: 2121.45. 
 
H2N-CSE[$COO]LC(StBu)GINHALMKGTLTLK-COOH 
Synthesis of Peptide 5.3 Using PAM Resin, Lab Book VI, page 187. 
The peptide was synthesized on a 1.0 mmol scale. 4-Hydroxymethyl-
phenylacetamidomethyl (PAM) resin preloaded with H-Lys(2-Cl-Z) was swelled in DMF 
(6 x 10 min, 6 mL). Synthesis of the peptide from Lys130 through Gly117 was completed 
using a four-fold excess of amino acids pre-activated with 20% diisopropylethylamine 
(DIPEA) in DMF (v/v) for 5 min prior to coupling to the resin. All Boc-deprotections 
were accomplished using neat trifluoroacetic acid (TFA) with N2 sparging (1 x 3 min, 6 
mL) and the resin was washed with 1:1 DCM/DMF by continual flow through for 1-2 
min before completing the next coupling. Boc-Cys(StBu)-OH (4 equiv.) was coupled in 
the presence of hydroxybenzotriazole (HOBt) (8 equiv.) and N,N'-
diisopropylcarbodiimide (DIC) (8 equiv.) in DMF with N2 sparging for 5 h. Amino acids 
were double coupled when necessary. Leucic acid (4 equiv.) was coupled in the presence 
of HOBt (16 equiv), DIC (8 equiv) and NMM (1.6 equiv) at RT for 3 h. Boc-Glu(OBz.)-
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OH (7.7 equiv.) was triple coupled to the resin in the presence of DIC (7.7 equiv.), and 5 
mol% 4-dimethylaminopyridine (DMAP). The completion of the coupling was monitored 
using a hydroxyl specific colorimetric test similar to the Kaiser test (see below). The 
remaining residues (Ser113 and Cys112) were coupled using 4 equiv. amino acid in the 
presence of HOBt/DIC (8 equiv. each). The N-terminal Boc residue was removed with 
neat TFA (6 mL) for 10 min prior to cleavage of the peptide from the resin. The resin was 
then washed iteratively with DCM and DMF and dried for 10 min under reduced 
pressure. The peptide was cleaved from the resin in a cocktail of 10% 
trifluoromethanesulfonic acid (TFMSA) (400  µL), 2.5%  dH2O (100 µL), 
triisopropylsilane (100 µL), and thioanisole (100 !L) in neat TFA (4 mL) with stirring at 
RT for 3 h. The solvent was evaporated carefully under reduced pressure and the 
resultant oil redissolved in 2:1 THF/TFA (15 mL). The organic layer was then extracted 
with dH2O (3 x 15 mL) and the aqueous layers combined and extracted with Et2O. The 
aqueous layer was then lyophilized to yield a white solid. The solid was purified by 
preparative RP-HPLC using a C18 column to obtain a white solid after lyophilization. 
(Yield: 55 mg) MALDI MS. Expected: 2121.62, Observed: 2121.51. 
 
Hydroxyl specific test for SPPS40 
 The resin with peptide was washed with dry DCM (5 x 25 mL). A few beads of 
resin were removed and placed into a small flint tube (Sample 1). Two other flint tubes 
were used as controls. Sample 2 contained fully unprotected alanine in DMF. Sample 3 
contained fully unprotected leucic acid in DMF. To each sample was added 3 drops of 
0.01 M tosyl chloride (TsCl) in dry toluene followed by addition of 3 drops of 0.025 M 4-
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(4-nitrobenzyl) pyridine (PNBP). The orange colored solutions were heated using a 
handheld heat gun until the solution turned clear. Without cooling, 5 drops of 10% 
piperidine in CHCl3 (v/v) was added. Positive tests for unprotected hydroxyl groups 
appear pink/purple in color similar to Sample 3. Negative tests for unprotected hydroxyls 
appear clear in color similar to Sample 2. Double coupling of leucic acid was completed 
when samples appeared pink/purple in color. 
 
H2N-CSE[$CSN]LC(StBu)GINHALMKGTLTLK-COOH 
Synthesis of Peptide 5.4, Lab Book VI, page 127. 
The peptide was synthesized on a 0.2 mmol scale. Wang resin preloaded with 
Fmoc-Lys(Boc) was swelled in DMF (6 x 10 min, 3 mL). Synthesis of the peptide from 
Lys130 through Gly117 was completed using a six-fold excess of amino acids pre-
activated with 0.4 M N-methylmorpholine (NMM) (6 mL) and 2-(6-chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) (6 equiv.) 
for 2 min prior to coupling to the resin. All Fmoc-deprotections were accomplished using 
20% piperidine/DMF (v/v) (3 x 3 min, 6 mL). Fmoc-Cys(StBu)-OH (4 equiv.) was 
coupled after Gly117 in the presence of hydroxybenzotriazole (HOBt) (8 equiv.) and 
N,N'-diisopropylcarbodiimide (DIC) (8 equiv.) in DMF at RT for 2-5 h. Fmoc-Leu-OH 
(6 equiv.) was coupled in the presence of HOBt/DIC (8 equiv. each) in DMF for 3 h. 
Amino acids were double coupled when necessary. 1-(N-Fmoc-L-thionoglutyamyl), 
(compound 5.17, 4 equiv.) was dissolved in dry THF (4 mL), added to the resin in dry 
THF (4 mL) with stirring, and stirred under Ar for 4 h. The resin was then washed with 
fresh dry THF and the amino acid coupled a second time for 4 h. Coupling was 
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monitored by qualitative ninhydrin test. All Fmoc-deprotections after installation of the 
thioamide were completed with 1% 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in DMF 
(w/v). Boc-Cys(Trt)-OH (4 equiv.) was coupled in the presence of  HOBt/DIC (8 equiv. 
each). The resin was washed with DCM and dried for 10 min under reduced pressure. 
The peptide was cleaved from the resin in a cocktail of 82.5%/5%/5%/5%/2.5% 
TFA/thioanisole/Triisopropylsilane/dH2O/ethanedithiol (5 mL total volume) and stirred 
at RT for 2 h. The solvent was evaporated and the peptide precipitated using cold Et2O to 
obtain a white solid. The solid was dissolved in a minimal amount of 1:1 H2O/MeCN and 
lyophilized prior to purification by preparative RP-HPLC using a C18 column to obtain a 
white solid after lyophilization. (Yield: 33 mg) MALDI MS. Expected: 2136.69, 
Observed: 2137.1. 
 
 
Fmoc-Glu(OtBu)-2-amino-5-nitroanilide (5.15), Lab Book VI , page 118. 
To a solution of Fmoc-Glu(OtBu)-OH (2.5 g, 5.88 mmol) dissolved in dry THF 
(20 mL) and cooled to -20 °C was added N-methylmorpholine (NMM) (1.2 g, 11.8 
mmol) followed by the dropwise addition of 1 equiv. of ethyl chloroformate (638 mg, 
5.88 mmol). The reaction was stirred at -20 °C under nitrogen for 10 min. A separate 
flask charged with 1 equiv. of 4-nitro-1,2-phenylenediamine (900 mg, 5.88 mmol) was 
 190 
purged with Ar and dry THF (20 mL) was added. The flask was cooled to -20 °C and half 
of the flask contents were transferred to the flask containing the amino acid by 
cannulation under Ar pressure. The reaction was then stirred at -20 °C for 2 min before 
transferring the contents of the the amino acid flask to the remaining 4-nitro-1,2-
phenylenediamine by cannulation under Ar pressure. The reaction was then stirred at -15 
°C for 2 h. The flask was removed from the bath and warmed to RT overnight (16 h). The 
solvent was removed by rotary evaporation and the resulting oil dissolved in EtOAc. The 
crude product was washed with sat. NaH2PO4 (aq), 5% NaHCO3, and brine. The product 
was dried under reduced pressure to afford the final product as a yellow solid without 
further purification. (Yield: 3.11 g, 95%) 1H NMR (500 MHz, CDCl3) ! 1.48 (s, 9 H), 
2.18 (d, 2 H, J = 48 Hz) 2.58 (d, 2 H, J = 67.5 Hz), 4.2 (t, 1 H, J = 7 Hz), 4.25 (br s, 1 H), 
4.43 (d, 2 H, J = 6 Hz), 6.13 (br s, 1 H), 6.68 (d, 1 H, J = 10 Hz), 7.36-7.26 (m, 2 H), 7.38 
(t, 2 H, J = 5.5 Hz), 7.58 (d, 2 H, J = 10 Hz), 7.76 (d, 2 H, J = 5 Hz), 7.98 (d, 1 H J = 15 
Hz), 8.17 (d, 1 H, J = 57.5 Hz). 13C NMR (125.6 MHz, CDCl3) ! 28.2 (CH3), 30.5 (CH2), 
32.1 (CH2), 47.2 (CH2), 55.6 (CH), 64.8 (CH), 67.5 (CH), 82.1 (Cq), 115.4 (Cq), 120.2 
(CH), 123.2 (CH), 124.2 (CH), 125.1 (CH), 127.3 (CH), 128.1 (CH), 138.7 (CH), 141.5 
(CH), 143.7 (Cq), 149.1 (Cq), 158.3 (Cq), 170.8 (Cq).  
 
 
 191 
 
Fmoc-Glu(OtBu)-2-amino-5-nitrothioanilide (5.16), Lab Book VI, page 122.  
A round bottom flask was charged with 0.5 equiv. of P4S10 (793 mg, 1.8 mmol) 
and 0.5 equiv. of Na2CO3 (189 mg, 1.8 mmol) and purged with Ar. Dry THF (37 mL) 
was added and the flask contents were stirred at RT for 1 h. The flask was cooled to 0 °C 
before adding compound 5.15 dissolved in dry THF (20 mL). The reaction was stirred at 
0 °C for 30 min and warmed to RT. The reaction was monitored until determined 
complete by TLC (2 h). The solvent was removed by rotary evaporation and the resulting 
oil was purified directly by flash chromatography (2:1 EtOAc/Hexane) to obtain the final 
product as a yellow powder. (Yield: 1.43 g, 70%). 1H NMR (500 MHz, CDCl3) ! 1.48 (s, 
9 H), 2.27 (d, 2 H, J = 40 Hz), 2.58 (d, 2 H, J = 55 H), 4.2 (t, 1 H, J = 7 Hz), 4.42-4.36 
(m, 2 H), 4.6 (br s, 1 H), 6.32 (br s, 1 H), 6.74 (d, 1 H, J = 10 Hz), 7.32-7.28 (m, 2 H), 
7.38 (t, 2 H, J = 7.5 Hz), 7.58 (d, 2 H, J = 7 Hz), 7.77 (d, 2 H, J = 7 Hz), 8.07 (d, 1 H, J = 
7 Hz), 8.13 (s, 1 H). 13C NMR (125.6 MHz, CDCl3) ! 28.2 (CH3), 30.3 (CH2), 32.1 
(CH2), 47.1 (CH2), 61.9 (CH), 66.1 (CH), 67.7 (CH), 82.1 (Cq), 115.4 (Cq), 120.31 (CH), 
125.1 (CH), 125.7 (CH), 127.3 (CH), 128.1 (CH), 138.6 (CH), 141.1 (CH), 143.6 (CH), 
148.5 (Cq), 157.1 (Cq), 173.7 (Cq), 205.2 (Cq). 
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1-(N-Fmoc-L-thionoglutamyl)-6-nitrobenzotriazole (3), Lab Book VI, page 123.  
To a solution of compound 2 (1 g, 1.7 mmol) in 1:1 THF/AcOH (19 mL) was 
added 1.5 equiv. of NaNO2 (180 mg, 2.6 mmol). The reaction was stirred at RT for 75 
min and quenched with 3:1 EtOAc/Heptane (30 mL). The organics were then washed 
with dH2O, sat NaHCO3, and brine and dried over MgSO4. The solvent was removed by 
rotary evaporation to afford the final compound as a yellow powder which was used 
without further purification. (Yield: 908 mg, 90%) 1H NMR (500 MHz, CDCl3) ! 1.48 (s, 
9 H), 2.27 (d, 2 H, J = 40 Hz), 2.58 (d, 2 H, J = 55 H), 4.2 (t, 1 H, J = 7 Hz), 4.42-4.36 
(m, 2 H), 4.6 (br s, 1 H), 6.32 (br s, 1 H), 7.32-7.28 (m, 2 H), 7.38 (t, 2 H, J = 7.5 Hz), 
7.58 (d, 2 H, J = 7 Hz), 7.77 (d, 2 H, J = 7 Hz), 8.22 (d, 1 H, J = 10 Hz), 8.38 (d, 1 H, J = 
10 Hz), 8.89 (s, 1 H). 
 
General procedure for expressed protein ligation, Lab Book VI, page 141. 
Cultures of E. coli BL21 (DE3) cells containing a plasmid to express the azurin(1-
111)-Intein-CBD fusion protein were grown in LB media for 8 h at 37 ºC and were used 
to inoculate eight 2 L flasks of LB media containing 100 mg/mL ampicillin. The cells 
were grown at 37 ºC for 16 h with shaking at 210 rpm. Protein expression was induced at 
~16 h with 0.5 mM IPTG and induction was continued for 4 h at 37 ºC. The cells were 
then harvested at 4,000 x g, stored at -20 ºC and used when needed.  
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Frozen azurin-thioester cell stock was re-suspended in a lysis buffer containing 20 
mM HEPES, pH 7.2, 250 mM NaCl, 1 mM EDTA, 1 mM PMSF 0.1% Triton-X-100, and 
1 M urea. The suspension was then lysed using sonication (Misonix Sonicator 4000, 0.5 
inch diameter probe) for a total work time of 9 min (6 on, 10 rest). The lysate was 
centrifuged at 13,250 x g for 30 min. at 4 °C. The fusion protein was then bound by batch 
absorption to 100 mL of chitin resin that had been pre-equilibrated with 20 mM HEPES, 
pH 7.2, 250 mM NaCl, and 1 mM EDTA (buffer 1) for 1-2 h at 4 ºC. The chitin resin was 
then poured into a column and the column headspace was purged with Ar. The column 
was then washed with 3 column volumes of degassed buffer 1 under Ar pressure.  
Ligation was initiated by the addition of peptide and in 35 mL of buffer 1 containing 50 
mM 4-mercaptophenylacetic acid (MPAA) under Ar and transferred directly to the 
column by Ar pressure. The chitin resin was then re-suspended in the column and the 
entire column was agitated gently at 4 ºC for 66 h.  
After ligation, the column was eluted under Ar pressure and washed with 1 
column volume of buffer 1. The eluent was centrifuged at 13,250 x g for 30 min and the 
supernatant was concentrated ~5x using 10,000 MWCO Centricon concentration spin 
tubes at 3000 x g and exchanged into 50 mM NH4OAc, pH 5.1 via G25 sephadex PD-10 
columns. 
 
General Procedure for Refolding and Titration, Lab Book 6, page 146. 
Dithiothreitol (DTT) (0.9 mM), guanidinium hydrochloride (GdmHCl) (4 M) and 
ZnCl2 (1 mM) were added directly to a concentrated protein sample (~ 1 mL). After full 
dissolution, the sample was then left to sit at 25 ºC without disruption for 15 min. The 
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denatured sample was then added dropwise to a 50x excess volume of 50 mM NH4OAc 
buffer, pH 5.1 at 4 ºC containing DTT (0.8 mM). The refolded sample was then 
exchanged into fresh 50 mM NH4OAc buffer, pH 5.1 at 4 ºC using G25 Sephadex PD-10 
columns.  
Following concentration of the sample, the protein was titrated with Cu(II)SO4. 
Samples titrated with subequivalent additions of Cu(II) were titratated until saturation of 
the LMCT at 480 nm. The titrated samples were then purified separately using a 
Pharmacia Q HiTrap HP column (5 mL) which had been washed with 10 column 
volumes of 1 M NaCl in H2O and then equilibrated with 10 column volumes of 50 mM 
NH4OAc, pH 5.1. Following purification, proteins were concentrated and analyzed using 
MALDI-TOF-MS and ESI-MS. 
 
Electrochemical Measurements for Ester CuA Az, Lab Book 7, page 106. 
The reduction potential for the WT CuA was verified prior to taking any 
measurements for the ester CuA variant. All measurements were taken by cyclic 
voltammetry using a CH Instruments 617A potentiostat equipped with a picoamp booster 
and a faraday cag. A pyrolytic graphite edge (PGE) electrode was polished and soaked in 
the protein solution (200 µM). The voltage was cycled from 0.5 V to -0.3 V for 3-5 min. 
The electrode was removed from the protein solution and transferred into fresh 50 mM 
NH4OAc buffer, pH 5.1 at 4 °C that was degassed with Ar. The electrode was then 
cycled from 0.5 V to -0.3 V for 5-10 min or until loss of signal. The electrodes were used 
only a single time before cleaning by sonication and repeating the process.  
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The reduction potential was also determined by using a film of 
didodecyldimethylammonium bromide (DDAB) to facilitate protein binding to the 
electrode. A 20% solution of DDAB in CHCl3 (5 µL) was applied to the electrode and 
allowed to dry overnight. The electrode was then soaked in the protein solution and the 
voltage cycled from 0.5 V to -0.3 V for 5-10 min or until loss of signal. This method gave 
identical results to the previously described method. All reduction potentials were 
measured against Ag/AgCl and converted to NHE 
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